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Bundled payments have the opportunity to promote care standardization and 
coordination while incentivizing efficiency and value-based healthcare delivery. 
However, bundled payments have been scrutinized due to challenges with defining the 
bundled lengths (also known as the episode of care period), limited inclusion/exclusion 
criteria, the absence of IT systems to support new payment models, and the lack of 
federal support. The objective of this study was to develop a profile for head and neck 
cancer, including descriptive statistics, risk assessment and bundled payment pricing 
recommendations using a large national claims database. The ability to assess pricing 
risks associated with head and neck cancer bundled payments across the US from a 
large claims database can provide evidence to either support or discredit the feasibility 
of bundled payment reform.  
The results of the study highlighted the total episode costs for head and neck 
cancer from start of treatment and a transparent bundled payment methodology.  The 
results are as follows: 1) head and neck episode cancer costs on average $164,332 with 
 iii 
a standard deviation of $106,500, and median episode costs of $143,806; 2) bundled 
payments were developed using a complete-linked hierarchical clustering analysis of 2 
possible bundling approaches of either 3 bundled payment groups or 4 bundled 
payment groups; 3) a monte carlo simulation resulted in recommendations that pricing 
negotiations not start at the 50th percentile of the bundled payment group cost as 
suggested by previous studies but rather at the 75th percentile; 4) study aims were 
summarized and displayed in a visual framework to provide a practical ‘how-to guide’ 
for organizations looking to start modeling bundled payments.  
This analysis proves bundled payment grouping is feasible and viability, albeit 
dependent on an organization’s ability to control healthcare spending costs and 
negotiate bundled payment prices above costs.  The results of this work demonstrate 
the use of statistical and financial models to support price models and sensitivity 
analyses. Healthcare leaders can use these models to better understand their expected 
costs/ profits and leverage their negotiations; however, it should be noted that this 
research does not suggest all bundled payment methodologies are profitable. 
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IV. BACKGROUND 
Bundled Payments in the US  
In November 2018, US Secretary of Health and Human Services (HHS), Alex M. 
Azar II, identified value-based transformation as a top priority in Value Based Care and 
mandatory participation in episode-based bundling in radiation oncology (CMS, 2018). 
Several years prior, past former US Secretary of the HHS, Sylvia Burwell, launched an 
alternative payment initiative and set a goal of having 30% of all Medicare provider 
payments as alternative payments or bundled payments by 2016, and 50% of all  
Medicare payments in alternative payment models by 2018 (Burwell, 2015).  More 
recently, former US Secretary of the HHS, Tom Price, cancelled and delayed the 
previously proposed expansion of bundled payments program in an effort to test new 
innovative models across in-patient and acute care settings (Centers of Medicare and 
Medicaid, 2017). Bundled payments are supported by some patient advocacy groups 
which are urging the Centers of Medicare and Medicaid Services (CMS) to require 
bundled price transparency. This will reflect the total cost of care for proposed services 
rather than the price per unit or Diagnosis Related Group (DRG) price.  A bundled 
payment for the total episode of care – based on services or length of stay or time – will 
help patients determine their out of pocket financial responsibility.  For the purposes of 
this study, the definition of a bundled payment in cancer care is a single comprehensive 
payment made for all services during a pre-defined episode of care, regardless of the 
actual services utilized (Centers for Medicare and Medicaid Innovation, 2017).   
Bundled payments have the opportunity to promote care standardization and 
coordination while incentivizing efficiency and value-based healthcare delivery (Kaplan 
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& Porter, 2011; Porter & Lee, 2013). However, bundled payments have been scrutinized 
due to challenges with defining the bundled lengths (also known as the episode of care 
period), limited inclusion/exclusion criteria, and the absence of IT systems to support 
new payment models, and the lack of federal support. (Mechanic, 2011).  
Bundled payments have been proposed as a more viable (alternative) payment 
system to existing Accountable Care Organizations (ACOs), Medical Homes, and 
Population-based payment models like capitations, because bundled payments tie 
“reimbursement to predictable costs of an episode of care, resulting in gains to 
providers if costs are lower than predicted, and losses if they are higher” (Abecassis, 
Jackson, & Walsh, 2015).  Cost measurement and variability are essential for predicting 
the viability of bundled payments in oncology.  Medicare cancer costs variability has 
been attributed to factors unrelated to patient characteristics- provider, hospital, and 
region cost differences (Paravati et al., 2015).  These factors may be explained by 
inefficiencies in the system and may not be attributed to the patient.  To build a case for 
widespread adoption of bundled payments in oncology, it is necessary to assess cost 
variation and risk across geographic regions.   
 
Cancer Costs 
The cost of cancer care in the U.S. is estimated to increase by 39% from 2010 to 
2020 (Mariotto, Robin Yabroff, Shao, Feuer, & Brown, 2011).  Policy makers have 
suggested alternative payment methods as a strategy for reducing the cost of cancer in 
the US, given the estimation of $173 billion in health care costs attributable to cancer, in 
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2020.  CMS has several federal programs targeting alternative and bundled payments in 
cancer care.   
  Cancer care is expensive and costs related to the disease feature as high cost in 
healthcare spending categories in the US (Basch, 2017). The 10 dedicated cancer centers 
in the US, known as the Alliance of Dedicated Cancer Centers (ADCC), are specialty 
hospitals dedicated to cancer treatment only.  These hospitals provide multidisciplinary 
cancer care and champion access, advanced treatment discoveries, outcome 
measurement, and reimbursement models in cancer care.  The ADCC are CMS 
Prospective Payment System exempt as they do not bill based on DRGs like the majority 
of other cancer treating hospitals. These dedicated cancer hospitals are often excluded 
from other reimbursement programs based on the DRG system as well. Bundled 
payments has been identified as a reimbursement strategy agnostic to the current 
payment system, further supporting why bundled payments could be a viable 
alternative payment model in cancer care.   
The Oncology Care Model (OCM) and the Quality Payment Programs Alternative 
Payment Models (QPP- APMs) are CMS programs that are voluntary and small, localized 
efforts to test alternative payments and bundled payments in specific cancer disease 
sites. There are several bundled payment proposals being considered by the HHS.  To 
further support federal policy efforts to reduce cancer care costs, private payers are 
now testing bundled payments faster and with lower risk than CMS programs 
(Newcomer, 2014).   The literature review below provides a detailed description of the 
national and private payer bundled payment efforts across the US.  
 4 
 Literature Review 
 
 National Bundled Payment Efforts 
The Oncology Care Model 
The Oncology Care Model (OCM) was created by CMS to realign incentives and 
enforce value-driven oncology care; this model was authorized under Section 3021 of 
the Affordable Care Act (Centers for Medicare and Medicaid Innovation, 2017).  The 
initiative was charged with developing episode based chemotherapy price bundles and 
quality measurement accountability. OCM started with 196 physician practices and 17 
payer participants in 2016 and has since reduced to 176 physician practices and 11 
payer participants in 2019.  It aims to develop per-beneficiary-per-month and 
performance-based payments using clinical quality measures, communication and care 
coordination, patient centered experience and outcome measurement, and efficient 
and cost effective care transformations. Currently, one of the more notable activities, is 
the ongoing testing for price bundles for chemotherapy.  The bundled episodes start at 
first administration of chemotherapy and ended six months after the start of the 
treatment.  OCM has made headway in bundled payment development but  
participating institutions have expressed some opportunities for improvement (Thomas 
& Ward, 2016). Private payers have partnered with OCM to test bundled payments in 
the 65+ cancer population but no specific literature related to the program was found.  
Quality Payment Program- Alternative Payment Models 
The Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 outlined a 
new Quality Payment Program (QPP) that allows providers to participate in either of two 
programs: the Alternative Payment Models (QPP-APP) or Merit-based Incentive 
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Payment System (QPP-MIPS).  The QPP-APM has approximately 70,000 to 120,000 
projected clinicians since 2017. The program allows providers to participate in bundled 
payments or ACOs for specific clinical conditions, disease sites, and/ or chronic 
conditions. The bundled payment program under QPP-MIPS is called Bundled Payments 
for Care Improvement Advancement Models (BPCI).  BPCI consists of inpatient stay 
bundles, retrospective bundles, and comprehensive prospective bundles.  The first 
phase of BPCI resulted in 90-day clinical bundle periods for 29 inpatient clinical episodes 
and three outpatient clinical episodes with bundled payments tied to quality measures.  
At the end of the first phase, there were a total of 1100 participants in the QPP-APM 
BPCI program, with 226 being financially rewarded and 874 who initiated the 
program(Centers of Medicare and Medicaid, 2018; Curtin, Russell, & Odum, 2017).  
HHS Bundled Payment Proposals 
The HHS Physician Focused Payment Model Technical Advisory Committee 
(PTAC) have received proposals to develop 1) Oncology Bundled Payment Programs 
using Cota Nodal Address (CNA) system-guided care (Physician Focused Payment Model 
Technical Advisory Committee, 2017); 2) comprehensive colonoscopy for colorectal 
cancer screening, diagnosis, and surveillance (HHS Physician-Focused Payment Model 
Technical Advisory Committee, 2016); 3) episodic payment for radiation oncology (A. C. 
of R. Oncology, 2016); 4) radiation oncology total cost of care (A. S. for R. Oncology, 
2016); 5) and comprehensive cancer care delivery models (Alliance, 2017).    
The Oncology Bundled Payment Program Using Cota Nodal Address (CNA)-
Guided Care proposed a 12 month bundled payment episode based on historical 12 
month average cost per cancer type with quality reporting for all medical, surgical, and 
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radiation oncologists at Hackensack Meridian Health in New Jersey (Physician Focused 
Payment Model Technical Advisory Committee, 2017).  COTA Inc. developed and 
patented a CNA system to capture “digital expression of all attributes specific to the 
patient and their disease that affect clinical outcomes and total cost of care” (PFPMTAC, 
2017). Using big data analysis, this system promises to identify and understand clinical 
variation for patients with the same CNA and subsequently reduce unnecessary 
variation.  This proposal would further support CMS’ effort of value over volume and 
provide evidence for the feasibility of bundled payments in cancer care.   
The ‘Digestive Health Network for a Comprehensive Colonoscopy Advanced 
Alternative Payment Model for Colorectal Cancer Screening, Diagnosis and Surveillance’ 
proposed a 12 month bundle to include all outpatient services for colorectal screening, 
diagnosis or surveillance (HHS Physician-Focused Payment Model Technical Advisory 
Committee, 2016). The impact of this proposal, if expanded to scale, could impact  over 
11,500 gastroenterologists, 3,500 colorectal surgeons, 6,000 endoscopic surgeons, and 
thousands of other general surgeons, anesthesiologists, certified registered nurse 
anesthetists, pathologists, and primary care physicians.  The Comprehensive 
Colonoscopy proposal was adapted from a previous retrospective upside-only risk 
model by Horizon Blue Cross Blue Shield of New Jersey; it’s especially notable this model 
allows single providers and small practices to participate.  The proposal was later 
withdrawn.  
Two radiation oncology bundled payment proposals were submitted in 2016.  
The American College of Radiation Oncology (ACRO) letter of intent proposed three-
 7 
month radiation treatment bundles for 15 primary disease groups(A. C. of R. Oncology, 
2016). The American Society of Radiation Oncology (ASTRO) submitted the more 
comprehensive of the two bundles.  ASTRO proposed a radiation oncology total cost of 
care Physician Focused Payment Model. The episode starts from treatment planning 
and ends 90-days after the last radiation therapy treatment. (A. S. for R. Oncology, 
2016).  This comprehensive bundle was later referenced by HHS secretary Azar in 2018 
as a model for future mandatory models in radiation oncology. (CMS, 2018).  
The Community of Oncology Alliance (COA) proposed an End of Life bundled 
payment program in 2017 called The Comprehensive Cancer Care Delivery Model. The 
bundled payment program is initiated by treatment and is followed through survivorship 
and/or end-of-life care(Alliance, 2017).  To accelerate value-driven oncology care, 
further demonstrations of bundled payment methodologies and risk assessments need 
to be analyzed across payers, geographic regions and different types of cancers.   
A summary of all Medicare and HHS bundled payment proposals are summarized 
below in Table 1 with program overview, participants, and bundled definition. 
 
Table 1: CMS Bundled Payment Programs and HHS PTAC Bundled Payment Proposals 
 
Agency/ 
Organization/ 
Hospital 
Program Name Program Years 
No. of 
Participants Bundle Definition 
CMS Oncology Care model (OCM) 
2016-
2021 
196 
practices 
and 17 
payers 
Chemotherapy 6 month 
bundles starting on date of 
first chemo administration 
CMS 
Quality Payment 
Program- 
Alternative 
Payment 
2017-
2019 
1100 
participants, 
226 
awardees 
Model 1: Inpatient Stay in 
acute care hospitals 
Model 2 & 3: retrospective 
bundled payment  
 8 
Models (QPP-
APM) 
 
Bundled 
Payments for 
Care 
Improvement 
Advanced 
Models (BPCI) 
and 874 
episode 
initiators 
Model 4: Comprehensive 
prospective bundled 
payments 
 
COTA + 
Hackensack 
Meridian 
Health 
Oncology 
Bundled 
Payment 
Program Using 
CNA-Guided 
Care 
2017 
pilot 0 
Medical, surgical, and 
radiation oncologists at 
Hackensack Meridian 
Health; 12 month bundle 
period based on historical 
12 month average cost per 
cancer type with quality 
reporting 
Digestive 
Health 
Network 
Comprehensive 
Colonoscopy 
Advanced 
Alternative 
Payment Model 
for Colorectal 
Cancer 
Screening, 
Diagnosis and 
Surveillance 
Proposal 
Withdra
wn 
0 
12 month bundle including 
all outpatient services for 
colorectal screening, 
diagnosis or surveillance 
ACRO 
Episodic 
Payments for 
Radiation 
Oncology 
Letter of 
intent 
submitte
d 2016 
0 
3 month radiation 
treatment bundle for 15 
primary disease groups  
ASTRO 
Radiation 
Oncology Total 
Cost of Care 
Physician 
Focused 
Payment Model 
Letter of 
intent 
submitte
d 2016 
0 
Bundle starts at treatment 
planning and ends 90-days 
after last radiation therapy 
treatment 
COA 
Comprehensive 
Cancer Care 
Delivery Model 
Letter of 
intent 
submitte
d 2017 
0 
Starts with treatment 
followed through 
survivorship and/or end-of-
life care. 
 
Private Payer Bundled Payment Programs 
In an effort to support national policy efforts around bundled payments and to 
understand the financial risks associated with the same, private payers have launched 
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their own bundled payment programs in cancer care(Newcomer, Gould, Page, Donelan, 
& Perkins, 2014).  For example, Horizon Blue Cross Blue Shield of New Jersey, Anthem 
Blue Cross of California, and UnitedHealthcare have all launched oncology bundled 
payment programs before a Medicare mandate was released. Horizon Blue Cross Blue 
Shield of New Jersey started testing bundled payments under their Episode-of-Care 
Payment program in 2014 (Butcher, 2017). The program is designed to create an 
innovative care model that promotes multiple stakeholder care teams with high-quality 
care, outcomes driven, and cost transparent goals.  The program currently focuses on 
breast and prostate cancer. The breast program has 94 New Jersey providers while the 
prostate program has over 100 New Jersey providers participating in the 
program(Butcher, 2017).   All claims related to these two disease sites are being 
migrated from fee-for-service to alternative payments. No published data about the 
number of patients or results was found in the literature.  
In 2016, Anthem Blue Cross of California widely published its first bundled 
payment program in breast cancer treatment.  The bundled payment program included 
1 radiotherapy physician group (Castellucci, 2016).  Patients with Stage 1-3 breast 
cancer who required radiation therapy only were included in their first program. The 
bundled price varied based on treatment duration. The aims of the program were to 
create long-term pricing agreements and better predict the cost of breast cancer 
treatment.   
In 2009, UnitedHealthcare began its first bundled payment pilot program in medical 
oncology around lung, breast, and colon cancers (UnitedHealthcare, 2014).  The three-
 10 
year pilot program covered over 810 patients and resulted in a 34% reduction in 
healthcare costs. Five medical oncologist groups were paid a single payment for 
chemotherapy between October, 2009 and December, 2012. The predicted cost of care 
was much higher than the actual cost of care delivered with no difference between 
groups based on quality measures (Newcomer et al., 2014). This bundled payments pilot 
program of chemotherapy drugs was to eliminate financial incentives for increasing the 
use of high-cost, low-value chemotherapy drugs(Porter & Lee, 2013).  
Building upon UnitedHealthcare’s first bundled payment pilot in chemotherapy, 
The University of Texas MD Anderson Cancer Center and UnitedHealthcare developed a 
comprehensive cancer treatment bundled payment for head and neck cancer including 
chemotherapy, surgical and radiotherapy cancer treatments. MD Anderson and United 
Healthcare chose to focus on head and neck cancer care because head and neck cancer 
has well defined end points and requires multimodality treatment options (Spinks, 
Guzman, Lee, & et al, 2017). According to the National Cancer Institute, more than 
65,000 people were diagnosed with head and neck cancers in the US in 2017, 
accounting for approximately 4% of all cancers in the United States (The National Cancer 
Institute, 2017).  Head and neck cancer is the sixth most common cancer in the world 
with annual US healthcare costs of $71,151 per patient for commercially insured 
patients, $35,890 for Medicare patients, and $44,541 for Medicaid patients.  
By choosing to focus on a small cancer disease site like head and neck cancer, 
the protocol for MD Anderson’s proposed bundled payment program allowed for more 
manageable risk and administrative burden. The three-year MD Anderson bundled 
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payment program tested the feasibility of bundled prices for a 1-year of care from start 
of cancer treatment. Patients were grouped into 8 bundled payments based on a 
retrospective cost analysis.  The bundles were actually 4 different treatment modality 
clusters with a price modifier for patients with more than two co-morbidities based on 
the Charleston Co-Morbidity Index (Feeley, Spinks, & Guzman, 2015; Lee et al., 2016; 
Spinks et al., 2017).    Total enrollment equated to 88 patients over a two-year 
enrollment period, November 2014 to October 2016. Initial results concluded the need 
for more information technology to automate the bundled payment processes of 
identification, enrollment, billing and payment (Spinks et al., 2017).  
UnitedHealthcare’s third bundled payment program, in partnership with Moffitt 
Cancer Center, focused on early stage surgical and radiation therapy lung cancer 
only(Moffitt Cancer Center, 2016). This program aimed to reduce care variation through 
clinical pathway compliance. The pilot started on October 1, 2016 and there is no 
published data regarding this program.   
A Private Payor Bundled Payment Program Summary was provided below in 
Table 2 with program specific details, start date, and estimated number of impacted 
patients.  
Table 2: Private Payer Bundle Payment Program Summary 
 
Payer Provider(s) Disease Site(s) 
Tx 
Modalities Start Date 
Est. # 
Pts 
Horizon Blue Cross 
Blue Shield of New 
Jersey 
Regional 
Cancer Care 
Associates 
Breast & 
Prostate -- 10/2014 -- 
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Anthem Blue Cross 
of California 
Valley 
Radiotherap
y Associates 
Medical 
Group 
Stage 1-3 
breast 
cancer 
Radiation 
Therapy 05/2016 -- 
UnitedHealthcare 
5 Medical 
Oncology 
Groups 
Lung, breast, 
and colon 
cancers 
Medical 
Oncology 10/2009 810 
UT MD 
Anderson 
Cancer 
Center 
Head & Neck 
Surgery, 
Radiation 
Therapy, 
Medical 
Oncology 
11/2014 88 
Moffitt 
Cancer 
Center 
Early Stage 
Lung Cancer 
Surgery 
and 
Radiation 
Therapy 
10/2016 -- 
 
This dissertation will replicate The University of Texas MD Anderson Cancer 
Center and UnitedHealthcare’s bundled payment program, in that it will use the same 
disease site of head and neck, the same bundled payment episode period of 1 year from 
start of treatment, and will similarly bundle patients based on cancer treatment 
modalities (surgery, chemotherapy and radiation therapy). The objective of this study is 
to develop a profile for head and neck cancer, including descriptive statistics, risk 
assessment and bundled payment pricing recommendations using a large national 
claims database. The ability to assess pricing risks associated with head and neck cancer 
bundled payments across the US from a large claims database can provide evidence to 
either support or discredit the feasibility of bundled payment reform.  
 
Conceptual Model 
In theory, bundled payments create financial incentives to reduce healthcare costs 
by promoting efficient and effective care without compromising on quality.  Healthcare 
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providers have the discretion over the type and number of services to provide but are 
also held accountable for the outcomes and quality of the services rendered. The 
conceptual model builds upon the financial profit equation.  The profit equation simply 
states that all organizations quantify ‘profit’ from the total ‘revenue’ minus the total 
‘costs’ (Porter & Lee, 2013).   The revenue derived is based on the prices set by the 
organization and the costs are variable depending on the patient treatment modality 
utilization outlined by the patient’s cancer treatment plan.  These factors can be 
compared to the ‘market’ to benchmark pricing.  A graphical depiction of the conceptual 
model is presented as Figure 1. 
Figure 1: Profit Equation Conceptual Model  
 
 
This dissertation conceptually describes the bundled payment ‘market’ in Objective 
1.  Objective 1 describes the US head and neck cancer population by volume, cost, and 
treatment modality using privately insured allowable amounts for costs between 2011 
and 2017 from administrative in-network claims.  Objective 2 aims to create bundled 
payments by treatment modality to analyze the associated cost variation by treatment 
modality.  The ‘revenue’ component of the profit equation will be analyzed in Objective 
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3.  Objective 3 develops a methodology for organizations to use when determining 
financial feasibility of bundled payments, using a Monte Carlo pricing simulation.  
 
Public Health Significance 
This dissertation has the ability to validate a bundled payment pricing 
methodology and further impact the cancer payment reform in the US, subsequently 
affecting an estimated 18.2 million Americans (1 in 19) who will be cancer patients or 
survivors by 2020 (Butcher, 2008).  The Institute for Health Improvement (IHI) outlined a 
‘Triple Aim’ framework to help health care systems optimize their performance.  The 
triple aim consists of “improving the patient experience of care, improving the health of 
populations, and reducing the per capita cost of health care”(Institute for Healthcare 
Improvement, 2016).  The US healthcare system is presently unsustainable and accounts 
for 17% of the gross domestic product(Centers of Medicare and Medicaid, 2012), with 
this rate expected to rise by 2020.  Cancer care costs account for approximately 5% of 
total direct US health care cost. A study reported the financial burden of cancer as, “the 
direct costs of cancer diagnosis and treatment for the United States at $27.4 billion in 
1990, with an additional $9.9 billion in morbidity costs and $58.7 billion in mortality 
costs” (Brown & Fireman, 1995). Efforts in healthcare reform aim to transform the 
current healthcare payment system – which rewards volume and intensity of services – 
to a system where payment is rendered for value. (Porter, 2010).  The current strategies 
outlined to combat the cost crisis in the US are to create new delivery models, new 
reimbursement models, and to invest in comparable effectiveness research(Kaplan & 
Porter, 2011).  This dissertation will support the Triple Aim’s focus to reduce the cost of 
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healthcare in the US by studying a new reimbursement model promising to reduce the 
cost of cancer care.  
 
V. RESEARCH AIMS 
a. Aim 1: To describe US Head and Neck Cancer by volume, cost, and 
treatment modality using privately insured allowable amounts for costs 
from 2011- 2017 administrative claims for feasibility study.  
b. Aim 2:  To group patient-level treatment modalities by costs and describe 
the bundle-level volume and costs variation between bundles.  
c. Aim 3: To develop a methodology for organizations to use when 
determining financially feasible of bundled payments, using a Monte 
Carlo simulation of 10,000 trials of 100 annual patient costs based on 
statistics from Aim 1.   
d. Aim 4: To develop a recommendation for head and neck bundled 
payment groupings by treatment modality and pricing based on 
probabilistic results from Aims 1-3.  
 
 
 
VI. METHODOLOGY 
Administrative payor claims from the University of Texas (UT) Center for 
Healthcare Data was used in this study.  The claims database contains over 40 million 
patients, more than 4,000 hospitals, more than 750,000 physicians across the country as 
of 2013 with claim-specific clinical utilization level with data from inpatient, outpatient, 
 16 
drug, and other services included.  This data includes UnitedHealthcare Group claims 
from large employers, health plans and government and public organizations. Although 
this data does not include actual cost of care utilization, it does contain standardized 
allowable amounts that are more generalizable. This dissertation will define patient 
costs by total allowable amounts from administrative claims data.  
More specifically, only claims for patients with a primary diagnosis of head and 
neck cancer, specifically lip and oral cavity, larynx, oropharynx, and salivary gland 
disease sites, from 2011-2016 with no previous history of head and neck cancer in the 
preceding 12 months were requested, along with continuous insurance coverage 12 
months before and after the initial head and neck cancer diagnosis. The initial head and 
neck diagnosis was defined using a list of ICD 9 and ICD 10 codes and is outlined in 
Appendix A. All enrollment, procedure, inpatient, outpatient, and look-up data tables 
claims associated with the patient population of interest were requested.  
Once the data was received, the patient population was further limited to only 
patients greater than 18 years and less than 63 years of age at the time of initial head 
and neck diagnosis. Only patients with Preferred Provider Organization (PPO) or 
Provider Point of Service (POS) insurance coverage plan types were included, which 
ensures that the patients’ claims are in-network and are more comparable across 
different providers. The data was filtered to only include non-pediatric and non-
Medicare eligible ages (Age 18-63) due to the different payment structure of pediatric 
hospitals and patient possible eligible for Medicare.  Study subjects were also excluded 
if they had cancer treatment 3 months prior to the study period, based on the claims 
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information. Patients with concurrent cancer, recurrent cancer, or metastatic cancer 
disease were also excluded from the study due to variability of cancer treatment, use of 
off-label cancer treatment options, and sometime patient preference for additional 
treatment. This patient population is the same as The University of Texas MD Anderson 
Cancer Center and UnitedHealthcare’s bundled payment program (Feeley et al., 2015) 
patient inclusion criteria.   
For Aim 1, some of the variables of interest are treatment modality and total 
costs at the patient-level.  All of other variables are controls or covariates- age, sex, plan 
type, and geographic region.  Age was calculated by subtracting the patient’s birth year 
from the date of initial head and neck cancer diagnosis.  ‘Age’ was further summarized 
into 2 categories 18-44 or 45-63 years of age. As defined in the database, ‘Sex’ was 
categorized as male, female, or missing. The ‘plan types’ were summarized as either 
Preferred Provider Organization (PPO) or Point of Service (POS) insurance coverage plan 
types. Patients that received cancer treatment out of network, were excluded from the 
study.  The patient’s geographic region was categorized by using the provided 5-digit zip 
codes to categorize whether the patient was geographically located in a metropolitan 
statistical area (MSA) or other, non-metropolitan geographic region.  The US Census 
Bureau’s zip code to county code crosswalk and US Department of Economic Research’s 
MSA county crosswalk tables were utilized to identify if the patient is geographically 
located in a MSA based on their 5-digit zip code.  The patient’s ‘geographic location’ was 
further categorized into either ‘metropolitan’ or ‘other’ for statistical purposes. Lastly, 
the patient-level allowable amounts were summated to represent total ‘costs’ from 
 18 
cancer diagnosis through 1 year of total healthcare utilization- as seen below in Figure 2.   
A complete list of Aim 1 study variables are shown below in Table 3.  
Figure 2: Bundled Payment Grouping Methodology 
 
 
 
Table 3: Data Variable Matrix  
Variable Inclusion/ Exclusion Type Details 
Analytic patient 
identifier 
Exclude any claims with 
missing identifier 
Continuous 
Variable 
Used to link 
patient claims 
across data tables 
Birth Date Include patients >18  and 
<63 years of age at time of 
treatment start 
Continuous 
Variable 
Non- pediatric 
and Non-
Medicare eligible 
patients 
Sex Keep patients regardless if 
missing data exists 
Binary 
Variable 
Summarized in 
Aim #1 
Plan Type US Commercial- Preferred 
Provider Organization 
(PPO) or Provider Point of 
Service (POS) 
Categorical 
Variable 
Used to limit data 
Service Date Include patient service 
dates from first head & 
neck cancer diagnosis 
Continuous 
Variable 
Used to identify 
trigger event and 
all claims to 
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(January 1, 2011- 
December 31, 2016) and 
all service dates 1 year 
after diagnosis 
include in 
episode period  
Provider Place of 
Service 
Include only office visit, 
hospital inpatient, hospital 
outpatient, ambulatory 
surgical center, hospital 
outpatient department, 
and emergency center 
claim locations 
Categorical 
Variable 
Used to limit data 
Diagnosis Codes Include patient with a 
primary diagnosis of lip 
and oral cavity, larynx, 
oropharynx, or salivary 
gland ICD-9-CM & ICD-10 
Diagnosis Code in 
Appendix A; Exclude 
patients who develop a 
secondary cancer 
diagnosis during the 
treatment bundle period 
Categorical 
Variable 
Used to identify 
patient 
population of 
interest 
Procedure Codes Include patients with 
cancer treatment claims 
from 2011-2016 
Categorical 
Variable 
Used to assess 
patient’s cancer 
treatment 
modality 
Provider Zip Code Crosswalk to MSA 
geographic regions  
Binary 
Variable 
‘Metropolitan’ or 
‘Other’ 
Allowed Amounts Sum of 1-year of allowed 
amounts from start of 
cancer diagnosis  
Continuous 
Variable 
All costs inflated 
to 2017 values.  
 
All patient claims were evaluated to categorize the patient based on cancer 
treatment modality- surgery, chemotherapy, radiation therapy and/or a combination of 
more than one possibility.  The claim procedure codes were cross-walked using 
Appendices A, B, C to identify the patient’s cancer treatment modality by inpatient and 
outpatient procedure codes.  There were seven possible treatment modality categories 
for this population: surgery (S), chemotherapy (C ), radiation therapy (R ), surgery & 
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chemotherapy (SC), surgery & radiation therapy (SR) , chemotherapy & radiation 
therapy (CR), chemotherapy & radiation therapy & surgery (CRS).  Any patient who had 
a head and neck cancer diagnosis but had no treatment identified was excluded from 
the study. Also, patients with experimental cancer treatments, proton radiation therapy 
and immunotherapy were excluded due to the limited facilities providing this type of 
care and the high variability of costs amongst those who do provide this treatment. 
While this study did not following previous bundled payment methodology, it did mirror 
the patient inclusion criteria and bundling by treatment modality of the  University of 
Texas MD Anderson Cancer Center and UnitedHealthcare’s bundled payments for head 
and neck cancer by treatment modality is depicted in Figure 3. (Spinks et al., 2017).  
Figure 3: MD Anderson Cancer Center and UnitedHealthcare’s Head and Neck Bundled 
Payment Groupings 
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Treatment modalities are patient- dependent, provider-dependent, and often 
based on the patient’s tumort type.  Treatment modalities are an appropriate bundling 
characteristic because little has changed according to treatment modality guidelines. 
According to the National Comprehensive Cancer Network Guidelines (version 1.2016), 
there have been no new cancer treatment modality changes resulting in the need for 
the additional treatment modality groups (National Comprehensive Cancer Network, 
2016). Lastly, all data was cleaned and analyzed using SAS version 9.0 (SAS Institute Inc, 
2016) and STATA version 14.0 (StataCorp, 2011) for Windows.  Additional screening 
took place to evaluate outliers or extreme cases (Campbell, Sokal, & Rohlf, 2006; 
Rosner, 2011) . Extreme cases were manually reviewed and if the care provided was not 
associated with cancer or cancer toxicities, it was removed from the analysis. All 
variable categorization are further summarized below in Table 4.   
 
Table 4: Variable Categorization 
Variable Variable Type Categorization 
Age  Categorical  18-44 
45-63 
Sex Binary 0=female 
1=males 
Geographic 
Location 
Categorical Metropolitan 
Other 
Treatment 
Modality 
Categorical  C=Chemotherapy 
R=Radiation therapy 
S= Surgery 
CR= Chemotherapy & Radiation Therapy 
CS= Chemotherapy & Surgery 
RS= Radiation Therapy & Surgery 
CRS= Chemotherapy, Radiation Therapy & Surgery 
Costs Continuous  Allowed Amounts Inflated to CY 2017 dollars using 
The Bureau of Labor Statistics inflation rates 
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For Aim 2, the treatment modalities were categorized into the minimum number 
of bundled payments based on their mean costs similar to previous bundled payment 
programs (Lee et al., 2016).  The University of Texas MD Anderson Cancer Center and 
UnitedHealthcare head and neck bundled payment program used a proprietary bundling 
approach not published in the literature with  no statistical documentation published to 
support their bundled payment categorization (Feeley et al., 2015). This dissertation 
took a statistical approach to defining the minimum number of bundled payments 
groups for cost analysis and will further provide a guide to help others execute a 
bundled payment analysis across cancer populations.  
Bundled payment groups with similar mean costs were clustered using a 
hierarchical clustering method.  A hierarchical clustering approach measures the 
distance between treatment modality group means, also called the Euclidean distance.  
This approach standardizes the distance between group means then graphically 
represents the Euclidean distance using a dendrogram. A dendrogram is the easiest way 
to graph similarities amongst groups. The dendrogram branches identify similar groups 
and the height of the branches, also called ‘trees’, indicates the orders of the groups 
being joined.  The groupings are dependent on the algorithm used to measure distance 
(Heller & Ghahramani, 2006; Johnson, 1967).  A complex linkage cluster analyses 
calculated the maximum distance between the clusters and computes all pairwise 
dissimilarities between treatment modalities and only records the largest dissimilarity 
only (Ziegel, 2009). This test is most appropriate for this grouping because each 
treatment modality can only be clustered one time, giving each treatment modality a 
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unique cluster or bundled payment group.  The complex linkage algorithm calculates the 
Euclidean distance for each group on its own then combines the groups into larger 
clusters until all groups are clustered within one another(Kamvar, Klein, & Manning, 
2002; Ziegel, 2009).  This approaches supports the development of the minimum 
number of bundled payments groups.  The final number of bundled payments are 
determined by visually identifying a ‘cutoff’ point for cluster groups. The ‘cutoff’ points 
are naturally distinct groupings of clusters.  The minimum number of the bundles will be 
the bottom branches of the dendrogram. If the groupings are close, more than one 
bundled payment groupings with be analyzed.  
To validate the previous analysis,  a one-way analysis of variance test (ANOVA), 
with a Bonferroni Type Adjustment, was be used to identify the treatment modality 
groups that are statistically different, opposite of the clustering analysis. ANOVA is a 
level of measurement used to evaluate possible differences across more than two group 
means; the Bonferroni Adjustment Type (pair-wise t-test) corrects for additional 
possible Type I error from testing more than two groups. The Bonferroni Adjustment 
tests the error levels separately rather than all together at one time like other test 
adjustments(Judd, McClelland, & Ryan, 2018; Rosner, 2011).   
The ANOVA null hypothesis exams the population means, in this case the 
bundled payment groups, that are equal to one another (Ho: µ1=µ2=µ3=…µk where k is 
the number of bundled payment groups). The alternative hypothesis assumes the 
opposite, at least one of the population means differs from one of the others (Ha: 
µ1≠µ2≠µ3≠…µk where k is the number of bundled payment groups) (Rosner, 2011).  
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There are several statistical assumptions required to conclude the ANOVA test results 
are valid: 1) the populations must be independent from each other, 2) the dependent 
variable residuals must be normally distributed, the samples within the populations 
must be random samples across and within the populations, and 3) the population 
variances is assumed to be heteroskedastic – equal, homogenous variances across the 
groups(Agresti, 2002; Rosner, 2011).  An understanding of the claims and cost summary 
is essential to confirm the first ANOVA assumption.   
- Assumption 1: The total episode costs must be independent from one another, and in 
this case no patient can have more than 1 overlapping cost episode with one designated 
treatment modality categorization due to the patient population definition of no 
concurrent, no recurrent, nor metastatic cancer diagnoses.  If the costs were related a 
ANOVA test would not be appropriate and a repeated measures ANOVA test should be 
conducted instead(Rosner, 2011).  
- Assumption 2: The Shapiro-Wilk test was used to exam the second ANOVA assumption 
of normal data distribution.  The Shapiro-Wilk test exhibiting high power to account for 
the small number of observations in our episode bundled payment groupings and is the 
appropriate normality test in the study. The Shapiro-Wilk null hypothesis assumes the 
sample of (size n) comes from a normal distribution and the alternative hypothesis 
assumes the sample (of size n) does not come from a normal distribution (Rosner, 
2011).  The test probability value must be greater than the alpha of 0.05 error level to 
accept the null hypothesis and assume normal distribution. The acceptance of the null 
hypothesis would assume the second ANOVA assumption has been met.   
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The data was not normally distributed, therefore a square root data 
transformation was required.  Data transformations replaces a variable by the function 
of that same variable to change the shape of the variable distribution or 
relationship(Rosner, 2011). Data is often transformed to reduce skewness, equal the 
spread of the variance, to create a linear relationship, or create an additive relationship.  
In this case, roots or logarithms are necessary to reduce right skewness and squares or 
cubes can reduce left skewness(Judd et al., 2018; Ziegel, 2009).  
- Assumption 3: The third and last ANOVA assumption requires homogeneity of 
variances.  The Levene’s Test exams for homogeneity across the bundle payment cost 
variances.  The Levene’s null hypothesis assumes all bundled payment groups have 
similar population variances.  The alternative hypothesis assumes there is at least one 
bundled payment group has unequal variances.  If the null hypothesis is accepted, there 
is enough evidence to assume all assumptions are met to conduct the ANOVA test (Judd 
et al., 2018; Rosner, 2011; Ziegel, 2009).     
The Complete Linkage Hierarchical Clustering Analysis was used to assign and 
confirm the treatment modalities are grouped into similar, minimum number of 
bundled payment groups.  After confirming the grouping of bundled payment groups, an 
ANOVA will be retested with bundled payment groups rather than treatment modalities. 
Also, all ANOVA test assumptions will need to be confirmed before proceeding with 
bundled payment modeling and financial analyses in Aim 3.   
 
In Aim 3, a Monte Carlo simulation was used to analyze risk and sensitivity 
associated with bundled payment methodology.  The simulation summarized 10,000 
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trials of 100 randomly generated patient costs based on descriptive statistics from Aim 
1.  As noted from the literature, simulation modeling is used by healthcare payers to 
assess the risk exposure based on claim probability of distribution (Mao, 1997).   A 
report published by Zhirong Mao, data analyst from Blue Cross Blue Shield of California, 
stated that Monte Carlo simulation is “approach is extensible to risk management, 
insurance product pricing and provider network development” (Mao, 1997).   Claims risk 
management using simulated distributions can give a visual assessment of the 
probability distribution of risk under a new payment methodology such as bundled 
payments. This method of analysis estimates values using inferences, often called 
inferential statistics(Dimov, 2008).  Inferential statistics includes a known population 
and a random sample of the population with the same properties of the known 
population.  
A Monte Carlo risk simulation is a technique used in business and management to 
determine how independent variables impact dependent variables under certain 
assumptions; this technique is commonly called a simulation or what-if analysis (Zhu, 
Carlo, & Carlo, 2011). This business approach is often used in scenario analysis with 
projecting future financial states, such as bond prices or profit margin analyses. A Monte 
Carlo risk simulation defines the pricing risk associated with developing bundled 
payments with double sided risk sharing between providers and payers.  Monte Carlo 
simulation analysis is a robust, flexible computer generated risk simulation technique to 
model ‘real world’ situations with a desired degree of precision (Richter & Mauskopf, 
1998). This technique “accommodates complex relationships and depend less on 
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simplifying assumptions and standardized probability distributions” associated with 
option pricing (Zhu et al., 2011).  
Microsoft® Excel Random Number Generator Add-in Software was used to develop 
the random sample of 100 patients for each of the 10,000 trials statistical summaries 
(from Aim 1) for each bundled payment group (from Aim 2) (Microsoft Corporation, 
2018).  Because the original cost distribution was not normally distributed, a Poisson 
distribution was used to generate the random sample population.  The Poisson 
distribution used the average mean costs from the original cost data per bundle (from 
Aim 1). The random sample population was developed for the Monte Carlo simulation 
and pricing analysis.   
The mean expected loss per patient (Xij) was summarized and used to provide 
statistical probabilities for risk (loss) associated with bundled payments. and 
summarized below in Equation 1. 
  Equation 1: Average Expected Loss ($)Per Bundled Payment Group 
Xi * Xj =Xij 
Where i= the average episode cost per trial, j= the probability of patient incurring a 
cost greater than desired percentile 
Each trial was summarized at the patient-level and bundled payment levels. The 
mean episode cost per trial (Xi) and probability of a patient incurring a cost greater than 
the 50th percentile (from Aim 2), 75th percentile (from Aim 2), and 95th percentile (from 
Aim2) (Xj) was calculated to compute the probability the costs incurred will exceed the 
negotiated price levels at each percentile.   
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Last, the profitability of the bundled payment groupings A versus B were assessed by 
computing the expected net profit or loss.  The net revenue, or expected value E(V), is 
the difference from the expected bundled payment costs ($) per bundle group minus 
the expected revenue (Xij) from Monte Carlo simulation results.  The monte carlo 
simulation consisted of10,000 trials of 100 annual patients to estimate the expected net 
revenue profit or loss in each bundled payment grouping. .  The net revenue/loss per 
bundled payment group will provide evidence to either support or unsubstantiated the 
bundled payment methodology.  All summary findings from Aim 3 will be used to 
provide pricing negotiation recommendations in Aim 4.  
The final aim summarizes and provides organizations a guide for approaching 
bundled payment modeling based on results from Aims 1-3.  The ‘how-to’ guide 
provides high-level instructions on how to organize claims data for bundled payment 
analyses, instructions to group treatment modalities into bundled payment, and 
recommendations for financial and risk analyses for determining optimal bundled 
payment pricing for payor and provider negotiations.  The end result is a depiction of 
the methodology used in Aims 1-3.  A summary of all four aims are below in Table 5 with 
output, methodology and software for each aim.   
Table 5: Aim Summary 
 Output Methodology Software 
Aim 1 To describe US Head and 
Neck Cancer by volume, cost, 
and treatment modality using 
privately insured allowable 
amounts for costs for a 
feasibility study. 
Summary 
Tables 
Descriptive 
Statistics 
SAS 
Analytics 
Software & 
Solutions 
(SAS 
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Institute Inc, 
2016) 
Aim 2 To group patient-level 
treatment modalities by costs 
and describe the bundle-level 
volume and costs variation 
between bundles. 
Statistical 
Analysis 
and 
Summary 
Tables 
One-way 
ANOVA with 
Bonferroni 
Adjustment 
Type 
STATA 
Statistical 
Software 
Package 
(StataCorp, 
2011) 
Aim 3 To develop pricing scenarios 
for bundled payment groups, 
using a Monte Carlo 
simulation of 10,000 trials of 
100 annual patient costs 
based on statistics from Aim 
1.   
Summary 
Tables 
Monte Carlo 
Simulation 
Microsoft 
Excel 
Random 
Number 
Generator 
(Microsoft 
Corporation, 
2018) 
Aim 4 To develop a guide for 
approaching head and neck 
bundled payments based on 
results from Aims 1-3. 
Figure How-to-
Guide 
Microsoft 
Word  
 
VII. ANALYSIS 
 
As described in the methodology section, the first aim describes the newly 
diagnosed US Head and Neck Cancer by volume, cost, and treatment modality using 
privately insured allowable amounts for costs.  The frequencies and percentages were 
calculated for the categorical variables, such as gender and treatment modality.  Means, 
medians, quartiles, standard deviations, coefficient of variations, standard errors, and 
confidence intervals were calculated for costs  
There were a total of 220 newly diagnosed head and neck cancer patients 
identified according the criteria for eligibility outlines earlier. As noted above, the newly 
diagnosed head and neck patients had no cancer diagnosis in the prior 12 months, 
and/or no concurrent, recurrent, or metastatic disease during the bundled payment 
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episode. The majority of patients were between the age of 45 and 63 years at episode 
index or at first head and neck cancer diagnosis; there were 200 patients ages 45-63 
years (91%) of age and 20 patients ages 18-44 years of age (9%). There were 155 males 
(91%) and 65 females (9%) with 159 patients from metropolitan statistical areas (72%) 
and 61 patients from other non-metropolitan statistical areas, either micropolitan or 
rural areas. Most of the patient’s insurance plan types were Point of Service (POS) type 
plans; there were 213 patients with POS plan types (97%) and 7 patients with Preferred 
Provider Organization (PPO) (3%) plan types. Head and neck cancer patients were 
treated with Surgery (S), Chemotherapy (C), or Radiation Therapy (R) treatment 
modalities.  These three treatment types give a total of seven possible treatment 
modality combinations. In this case, 46 patients (21%) received surgery only; 44 patients 
received chemotherapy and radiation therapy (20%); 44 patients received 
chemotherapy, radiation therapy and surgery (20%); 37 patients received chemotherapy 
(16%); 19 patients received radiation therapy and surgery (9%); 17 patients received 
radiation therapy (8%); and 13 patients received chemotherapy and surgery treatment 
(6%).  The treatment modality categorization is the independent variable of interest in 
this analysis.   
The dependent variable in this analysis is the patient’s total bundled episode costs.  
The patients’ total bundled episode costs are the costs for 12 months after the initial 
primary head and neck diagnosis. The 220 patients had an average episode costs of 
$164,332 with a standard deviation of $106,500, median episode costs of $143,806, a 
confidence interval around the mean of $28,302, and the standardized measure of 
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dispersion of a probability distribution, also known as the co-efficient of variation (CV), 
of 0.65.  The CV for costs is greater than 0.50 indicating a larger dispersion of the 
standard deviation relative to the mean.  The costs of a head and neck cancer episode 
range from $5,547 (minimum value) to $548,201 (maximum value) with the 5th 
percentile at $19,137 and the 95th percentile at $504,797.  The interquartile range of 
episode costs is $429,102 (Q3-Q1). A summary of all variables are below in Table 6.  
Table 6: Descriptive Variable Summary  
 (N) (%) 
Age    
18-44 years 20 9% 
45-63 years 200 91% 
Gender   
Female (0) 65 30% 
Male (1) 155 70% 
Geographic Region   
Metropolitan Area 159 72% 
Other 61 28% 
Plan Type   
Preferred Provider Organization (PPO) 7 3% 
Point of Service (POS) 213 97% 
Treatment Modalities   
Surgery (S) 46 21% 
Radiation Therapy (R) 17 8% 
Chemotherapy (C) 37 16% 
Chemotherapy & Surgery (CS) 13 6% 
Radiation Therapy & Surgery(RS) 19 9% 
Chemotherapy & Radiation (CR) 44 20% 
Chemotherapy & Radiation Therapy & Surgery (CRS) 44 20% 
Total Patients 220 100% 
Costs   
Minimum Value (Min) $5,547 
5th Percentile (Lower Limit) $19,137 
25th Percentile (Q1) $24,065 
50th Percentile (median) $143,806 
75th Percentile (Q3) $453,167 
95th Percentile (Upper Limit) $504,797 
Maximum Value (Max) $548,201 
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Average (mean) $164,332 
Standard Deviation (SD) $106,500 
Coefficient of Variation (CV) 0.65 
 The average cost of an episode for patients treated with surgery is $107,971 
(SD= $93,376) with a median episode cost of $87,759.  The surgery treatment modality 
episode costs range from $5,548 to $453,167 with an interquartile range of $63,450 
(Q1= $55,178, Q3= $118,628). 
The average cost of an episode for patients treated with radiation therapy is 
$142,544 (SD= $78,410) with a median episode cost of $137,177.  The radiation therapy 
treatment modality episode costs range from $19,137 to $338,261 with interquartile 
range of $83,935 (Q1= $93,237, Q3= $177,172).  
The average cost of an episode for patients treated with chemotherapy is 
$145,872 (SD= $106,440) with a median episode cost of $115,742.  The chemotherapy 
treatment modality episode costs range from $24,065 to $425,383 with interquartile 
range of $112,702(Q1= $62,593, Q3= $175,295).   
The average cost of an episode for patients treated with chemotherapy and 
surgery is $148,965 (SD= $78,532) with a median episode cost of $149,308.  The 
chemotherapy and surgery treatment modality episode costs range from $24,065 to 
$253,471 with interquartile range of $139,677 (Q1= $100,362, Q3= $240,039). 
The average cost of an episode for patients treated with radiation therapy and 
surgery is $165,219 (SD= $67,778) with a median episode cost of $149,229.  The 
radiation therapy and surgery treatment modality episode costs range from $66,134 to 
$302,431 with interquartile range of $102,078 (Q1= $118,257, Q3= $220,335).  
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The average cost of an episode for patients treated with chemotherapy and 
radiation therapy is $181,855 (SD= $86,090) with a median episode cost of $167,227.  
The chemotherapy and radiation therapy treatment modality episode costs range from 
$21,695 to $413,352 with interquartile range of $97,389 (Q1= $124,058, Q3= $221,447).   
Chemotherapy, Radiation Therapy, and Surgery are the treatment modalities 
with the highest cost. The average cost of an episode for patients treated with all three 
treatment modalities is $233,829 (SD= $123,369) with a median episode cost of 
$223,453.  The chemotherapy and radiation therapy treatment modality episode costs 
range from $30,965 to $548,201 with interquartile range of $127,532 (Q1= $148,095, 
Q3= $275,627). A summary of all treatment modality categories by cost are below in 
Table 7.  
Table 7: Head and Neck Cancer Costs by Treatment Modality Summary Statistics 
Treatment 
Modality 
S R C CS RS CR CRS 
Number of 
Patients (N/%) 
46/ 21% 17/ 8% 37/ 16% 13/ 6% 19/ 9% 44/ 20% 44/ 20% 
Minimum Value 
(Min) 
$5,548 $19,137 $24,065 $28,843 $66,134 $21,695 $30,965 
5th Percentile  $27,252 $34,883 $34,392 $34,231 $75,670 $72,546 $62,719 
25th Percentile 
(Q1) 
$55,178 $93,237 $62,593 $100,362 $118,257 $124,058 $148,095 
50th Percentile 
(median) 
$87,759 $137,177 $115,742 $149,308 $149,229 $167,227 $223,453 
75th Percentile 
(Q3) 
$118,628 $177,172 $175,295 $240,039 $220,335 $221,447 $275,627 
95th Percentile  $308,900 $265,840 $407,949 $251,060 $276,021 $329,474 $449,518 
Maximum Value 
(Max) 
$453,167 $338,261 $425,383 $253,471 $302,431 $413,352 $548,201 
Average (Mean) $107,971 $142,544 $145,872 $148,965 $165,219 $181,855 $233,829 
Standard 
Deviation (SD) 
$93,376 $78,410 $106,440 $78,532 $67,778 $86,090 $123,369 
Coefficient of 
Variation (CV) 
0.86 0.55 0.73 0.53 0.41 0.47 0.53 
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 The treatment modality episode costs were graphed in a box and whisker plot 
shown below in Figure 4.  The lower and upper blue whiskers depict a Type I error rate 
of 0.05 (represented by the 5th to 95th percentiles) with outliers represented as blue 
dots. The average episode cost per treatment modality is represented by a gray dot with 
gray whiskers representing the confidence interval around the mean. All Aim 1 
descriptive summary statistics were conducted using SAS statistical software (SAS 
Institute Inc, 2016). 
Figure 4: Head and Neck Cancer Episode Costs by Treatment Modality Box & Whisker  
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 The first step in defining bundled payment groups is to define or confirm the 
normal distribution of the episode costs per patient.  A histogram was used to plot the 
head and neck cancer episode costs to visually depict a cost curve; the curve was not in 
a normally distributed shape further confirmed by the median ($143,806) not centered 
around the mean ($164,332, SD= $106,500) from Aim 1. Next, a Shapiro-Wilks Test was 
analyzed to validate the histogram output. The Shapiro-Wilk Test concluded a 
statistically significate p-value of less than the Type I error level and alpha level of 0.05 
(W= 0.94822, Z= 4.749, p<=0.05). There was sufficient evidence to reject the null 
hypothesis of normality and conclude the treatment modality costs are not normally 
distributed. The cost curve histography is found below in Figure 5 and the Shapiro-Wilk 
test results are found below in Table 8.  
Figure 5: Head and Neck Cancer Episode Costs Histogram 
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Table 8: Shapiro-Wilk Normality Test Results for Un-Transformed Cost Data  
Variable Obs. W V Z Prob>z 
Costs ($2017) 204 0.94822 7.860 4.749 <0.05 
 
 To correct the right skewness of the cost curve found in the Figure 5, a square 
root transformation was conducted to convert the data to a normal distribution. A 
square root transformation ( t= x2) has a moderate effect on distribution shape (Rosner, 
2011).  After the transformation, the histogram and Shapiro-Wilks normality test were 
re-tested.  The results are as follows: the histography curve was normally shaped and 
the Shapiro-Wilks Test found insufficient evidence to reject the null hypothesis.  The 
Shapiro-Wilks probability value was greater than the Type I error level of 0.05 to 
conclude the square root cost distribution is normally distributed (W= 0.99396, Z= -
0.199, P=value= 0.5788).   The transformed cost curve histography is found below in 
Figure 6 and the Shapiro-Wilk test results are found below in Table 9.  
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Figure 6: Transformed Head and Neck Cancer Episode Costs Histogram 
 
Table 9: Shapiro-Wilk Normality Test Results for Transformed Cost Data 
Variable Obs. W V Z Prob>z 
Sqrt Costs ($2017) 204 0.99396 0.917 -0.199 0.5788 
 
Next, a Complete-Linkage Hierarchical Clustering Analysis was conducted to 
identify bundled payment groupings of treatment modalities with similar mean costs 
(Ziegel, 2009). Theoretically, these bundled payment groups would be paid one price.  
Clustering analysis result in dendrograms with branches representing similar groups.  In 
this case, the Hierarchical Cluster dendrogram analyzed similar treatment modality 
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groups with similar square root transformed mean costs.  The results of the dendrogram 
are below in Figure 7 below. The dendrogram depicts 5 bundled payment groupings at 
the lowest branching level: Surgery only (1); Radiation Therapy (3) & Chemotherapy and 
Surgery (5); Chemotherapy only (2); Radiation Therapy and Surgery (6) & Chemotherapy 
and Radiation Therapy (4); and Chemotherapy, Radiation Therapy, and Surgery (7). As 
supported in the literature, a minimum number of bundled payments results in greater 
administrative efficiency.  Next, a next-highest grouping of bundled payment groups 
would result in a minimal bundled payment groups and less administrative burden. Two 
different groupings were used to analyze bundled payments.  
The bundled payment groups resulted as such: Group A Bundled Payment 
Groupings (A1) Surgery only, (A2) Radiation Therapy, Chemotherapy, Chemotherapy & 
Radiation Therapy, Chemotherapy & Surgery, and Radiation Therapy & Surgery, (A3) 
Chemotherapy, Radiation Therapy & Surgery; Group B Bundled Payment Groupings (B1) 
Surgery only, (B2) Radiation Therapy, Chemotherapy, Chemotherapy & Radiation 
Therapy, (B3) Chemotherapy & Surgery, and Radiation Therapy & Surgery, and (B4) 
Chemotherapy, Radiation Therapy & Surgery. The Bundled Payment Grouping results 
from the Hierarchical Clustering analysis are below in Table 10.  
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Figure 7: Complete-Linked Hierarchical Clustering Dendrogram 
 
 
Table 10: Bundled Payment Groupings from Hierarchical Clustering Analysis with Monte 
Carlo Simulation Results 
Bundle 
Group 
Bundle 
Number 
Treatment Modalities 
A 
 
A1 Surgery 
A2 
Radiation Therapy, 
Chemotherapy, 
Chemotherapy & Radiation Therapy, 
Chemotherapy & Surgery, 
Radiation Therapy & Surgery 
A3 Chemotherapy, Radiation Therapy & Surgery 
B 
 
B1 Surgery 
B2 
Radiation Therapy, 
Chemotherapy, 
Chemotherapy & Surgery 
B3 Radiation Therapy & Surgery, Chemotherapy & Radiation Therapy 
B4 Chemotherapy, Radiation Therapy & Surgery 
 
 40 
Subsequently, a One-way ANOVA was conducted to validate the results from the 
Hierarchical Clustering Analysis.  An ANOVA is a statistical test that generalizes a t-test 
for more than two groups by reducing the Type 1 errors (Judd et al., 2018; Rosner, 
2011).   The ANOVA null hypothesis  tests all treatment modality groups for equal means 
(H0: µ1=µ2=µ3=…=µn), where µ is the treatment modality group mean cost and n is the 
number of treatment modality groups or bundled payment groups. The analysis resulted 
in significant evidence to reject the null hypothesis and conclude there is a difference in 
mean costs between the treatment modality groups at p-value less than the Type I error 
level of 0.05 [F(6,197)=12.46, p=<0.05)], as seen in Appendix G. This result further 
validates that more than one bundled payment group is appropriate for all next steps.  If 
the ANOVA test had resulted in a failure to reject the null, then only one bundled 
payment would be appropriate for pricing.  Next, an ANOVA Bonferroni Adjustment 
Type was used to examine specific treatment modalities differences between one 
another to validate bundled payment groupings. Each of the treatment modalities are 
tested against one another and the probability values are displayed in a grid below in 
Appendix G.   Only three treatment modality combinations result in p-values less than 
0.05, concluding eighteen out of the twenty-one possible treatment combinations failed 
to reject the null hypothesis.  Therefore, further validating that statistically different 
population means.   It is with confidence, the results of the complete-linked Hierarchy 
Clustering Analysis are valid.  
In summary, there are two bundled payment groups: A and B. Bundled payment 
group A has 3 unique bundles while bundled payment group B has 4 unique bundles. 
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Bundled payment groups A1 and A3 are made up of single treatment modalities (S and 
SCR) already summarized above.  Bundled payment group A2 is made up of five 
treatment modalities (R, C, CR, CS, and RS) with a mean episode cost of $86,330 (SD= 
$73,079).  Bundle A2’s minimum value is $19,137, maximum value is $327,998 with IQR 
of $241,932.    Bundled payment group B2 is made up of three treatment modalities (R, 
C, and CS), making up 30% (N= 62) of the overall episode group, with mean episode cost 
of $127,758 (SD= $72,221).  Bundle payment group B2’s minimum value is $19,137, 
maximum value is $324,409 with IQR of $214,131.  Bundled payment group B3 is made 
up of three treatment modalities (RS and CR), making up 29% (N= 59) of the overall 
episode group, with mean episode cost of $165,027 (SD= $69,567).  Bundle B3’s 
minimum value is $21,695, maximum value is $327,998 with IQR of $220,437.  Bundled 
payment groups A and B are summarized in Tables 11 and 12 and visually depicted in 
box and whisker plots in Figures 8 and 9.  
Table 11: Bundled group A Descriptive Summary  
Bundled payment group A 1 S 
2 
R, C, CR,CS,RS 
3 
SCR 
Number of Patients (N/%) 43/ 21% 121/ 59% 40/ 20% 
Minimum Value (Min) $5,548 $19,137 $54,884 
5th Percentile (Lower Bound) $26,722 $34,589 $67,408 
25th Percentile (Q1) $50,741 $88,843 $147,636 
50th Percentile (median) $82,885 $141,012 $209,539 
75th Percentile (Q3) $113,809 $203,889 $268,832 
95th Percentile (Upper Bound) $164,311 $276,521 $418,891 
Maximum Value (Max) $191,208 $327,998 $437,037 
Average (mean) $86,330 $145,931 $218,819 
Standard Deviation (SD) $44,971 $73,079 $101,246 
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Figure 8: Bundled group A Box and Whisker Plot 
 
  
 
Table 12: Bundled group B Descriptive Summary  
Bundled payment group B 1 
S 
2 
R, C, CS 
3 
RS, CR 
4 
SCR 
Number of Patients (N/%) 43/ 21% 62/ 30% 59/ 29% 40/ 20% 
Minimum Value (Min) $5,548 $19,137 $21,695 $54,884 
5th Percentile (Lower Bound) $26,722 $33,603 $66,134 $67,408 
25th Percentile (Q1) $50,741 $73,318 $109,760 $147,636 
50th Percentile (median) $82,885 $116,848 $157,150 $209,539 
75th Percentile (Q3) $113,809 $173,606 $215,728 $268,832 
95th Percentile (Upper Bound) $164,311 $247,734 $286,571 $418,891 
Maximum Value (Max) $191,208 $324,409 $327,998 $437,037 
Average (mean) $86,330 $127,758 $165,027 $218,819 
Standard Deviation (SD) $44,971 $72,221 $69,567 $101,246 
 
Figure 9: Bundled group B Box and Whisker Plot  
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Bundled payment group A and B was re-tested using a One-way ANOVA with 
Bonferroni Adjustment Type. The results further confirmed the initial treatment 
modality bundling tests.  Bundled payment group A and B resulted in all bundled 
payment groups statistically different from one another with probability values less than 
Type I error level 0.05.  The ANOVA with Bonferroni adjustment type test results are in 
Appendix H (Group A) and Appendix I (Group B).   
The Levene’s homogeneity tests the null hypothesis that all bundled payment 
groups have equal population variances.  The alternative hypothesis assumes there is at 
least one bundled payment group has unequal variances. The results of bundled 
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payment groups A and B found insufficient evidence (p=value > 0.05) to reject the null 
hypothesis.  All One-Way ANOVA assumptions were confirmed and both Levene’s test 
summary tables are in Appendix J.  
 
A Monte Carlo simulation was created to quantify the risk associated with 
bundled payment methodology.  The simulation measures the probability of a bundled 
payment group cost above the 50th, 75th, and 95th cost percentile per bundle.  The 100 
patients per 10,000 trials were simulated using the Microsoft Excel Random Number 
Generator Add-in Application(Microsoft Corporation, 2018).  The random numbers were 
generated using a Poisson distribution with lambda equal to the bundled payment 
groups average cost per bundle. Each trial was summarized at the trial-level and per 
bundled payment group.  A sample of Bundled Payment Group A’s summary sheet per 
trial are below in Appendix K.  Each trial’s minimum value, average value, median value, 
maximum value and standard deviation were calculated per trials.  A summary of the 
total average value, standard deviation, and range of values are below in Table 13.  
Table 13: Bundled Payment Groupings with Monte Carlo Simulation Results 
Bundle Group Bundle Number Treatment 
Modalities 
Average (SD) Range 
A 
 
A1 Surgery $86,251 ($10,029) 
$63,417- 
$114,191 
A2 
Radiation 
Therapy, 
Chemotherapy
, 
Chemotherapy 
& Radiation 
Therapy, 
Chemotherapy 
& Surgery, 
$146,315 
($14,877) 
$111,546 -
$186,912 
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Radiation 
Therapy & 
Surgery 
A3 
Chemotherapy
, Radiation 
Therapy & 
Surgery 
$219,294 
($20,176) 
$171,845 - 
$274,228 
B 
 
B1 Surgery $86,251 ($10,029) 
$63,417- 
$114,191 
B2 
Radiation 
Therapy, 
Chemotherapy
, 
Chemotherapy 
& Surgery 
$128,123 
($13,443) 
$96,735- 
$164,718 
B3 
Radiation 
Therapy & 
Surgery, 
Chemotherapy 
& Radiation 
Therapy 
$165,429 
($16,301) 
$127,234- 
$209,747 
B4 
Chemotherapy
, Radiation 
Therapy & 
Surgery 
$219,294 
($20,176) 
$171,845 - 
$274,228 
 
 Negotiating bundled payment prices to cover expenses or costs will determine 
the success or failure of bundled payments in a particular disease site or modality. The 
financial risk associated with pricing at the 50th, 75th, or 95th percentile of each bundled 
payment group A and B was calculated below in Appendix L and M.  The results are as 
follows: If each Group A bundles were price at the 50th percentile of its bundled average 
cost, about 49-50% of each bundle would result in a financial loss.  More specifically, if 
the price were at 50% percentile of the bundled average, 50% of the patients in Bundle 
A1 would result in an average of $8,281 loss over all patients with pricing at the 50th 
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percentile.  Bundled payment A2 and A3 would realize a financial loss of $12,647 or 
$16,578 per patient with approximately 49 or 50% of its patient population greater than 
the 50th percentile.    
If bundles A1-A3 were priced at the 75th percentile, the financial risk of this type 
of bundled payment arrangement reduces by approximately 50 percent.  In bundle 
simulation A1, if pricing was set at the 75th percentile, about 0.85% would have cost 
greater than the price.  For the 0.85% above the 75th percentile price, there would be an 
approximate $4,087 loss for each patient.  For bundles A2 and A3 priced at the 75th 
percentile, approximately 2.6-6.1% would lose about $6,894- $9,486 for each patient.  
In an ideal world, if pricing were at the 95th percentile of the average bundle 
cost, the financial risk would be minimal.  The simulation modeled found approximately 
0.0003-0.0004% patients in bundles A1-A3 would realize a financial loss. A summary of 
all Group A Monte Carlo pricing financial risk analyses are below in Appendix L.  
The same analysis was conducted for bundled payment group B with the 4 
bundled payment groups. Bundles A1 and A4 were similar to the previous analysis 
findings for the corresponding treatment modality bundled payment groups.  If the 
Bundles A2 and A3 were priced at the 50th percentile of each bundle payment group, 
approximately 80% of Bundle A2 and 68% of Bundle A3 costs would be greater than the 
price resulting in a financial loss of approximately $15,871 to $16,699 per all patients.   
The financial risk reduces dramatically when the bundled price is set at the 75th 
percentile of the bundled price. For bundle A2, only 0.115% of the patients simulated a 
cost greater than the price and would incur a financial loss of approximately $4,799 for 
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each patient. Bundle 3A has a similar financial profile for pricing at the 75th percentile; 
approximately 0.237% of patient would have a cost higher than the price and result in a 
financial loss of approximately $6,277 per all patients.  There is minimal risk associated 
with the bundles A2 and A3 priced at the 95th percentile; approximately 0.0004% of 
patients would incur a financial loss of $57,384 and $122,825 for all patients.   
 A comprehensive financial summary of the average expected loss per patient for 
pricing at the 50th, 75th, and 95th percentile based on the probability of each bundle 
occurring per 10,000 trials are summarized below in Appendix N. If the bundled 
payment groups were priced at the 50th percentile, there are approximately $6,171 (A) 
or $9,642 (B) per patient at financial risk.  The risk decreases as the price increases.  At 
the 75th percentile, $229 (A) or $129 (B) per patient was potentially at risk. In an ideal 
pricing scenario, at the 95th percentile, only about $6 per patient is at financial risk.  
 Lastly, the average expected profitability for 100 Head and Neck Cancer patients 
per bundled group at the 50th, 75th, and 95th pricing percentiles was analyzed to provide 
an overall estimate of financial viability.  The expected revenue by bundled group for 
100 Head and Neck patients was calculated based on the average cost and probability of 
bundled occurrence from the Monte Carlo analysis in Aim 3.  The expected cost was 
calculated from the bundled payment mean costs summary from the data analysis in 
Aim1. The profit or loss is the difference of the revenue minus costs.  The net profit/loss 
was calculated for the 100 patient population and per patient in Table 14.   
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Table 14: Expected Profitability at Pricing Percentiles for 100 Head and Neck Cancer 
Patients By Bundled Payment Group 
Bundle 
Group 
Pricing 
Percentiles Revenue Costs Profit/Loss 
Profit/Loss 
Per Patient 
A 
50% $14,251,073 $14,799,241 ($548,168) ($5,482) 
75% $19,796,080 $14,799,241 $4,996,839  $49,968  
95% $28,143,090 $14,799,241 $13,343,849  $133,438  
B 
50% $13,994,155 $14,807,833 ($813,678) ($8,137) 
75% $19,230,921 $14,807,833 $4,423,088  $44,231  
95% $27,570,930 $14,807,833 $12,763,097  $127,631  
 
 The expected profitability analysis concluded that pricing at the 50th percentile of 
the bundled payment group costs is not profitable and resulted in a net loss of $548,168 
for Bundle Group A ($5,482 loss per patient) and $813,678 for Bundle Group B ($8,137 
per patient). The expected profitability analysis concluded that pricing at the 75th 
percentile of the bundled payment group costs is profitable and resulted in a net 
revenue of $4,996,839 for Bundle Group A ($49,968 profit per patient) and $4,423,088 
for Bundle Group B $44,231 profit per patient). The expected profitability analysis 
concluded that pricing at the 95th percentile of the bundled payment group costs is very 
profitable and resulted in a net revenue of $13,343,849 for Bundle Group A ($133,438 
profit per patient) and $12,763,097 for Bundle Group B ($127,631 profit per patient). 
 In conclusion, the financial risk of bundled payment is dependent on pricing 
negotiations and manageable if sufficient simulation modeling is conducted prior to 
pricing negotiations.  Price modeling can provide expected financial resulted based on 
previous patient data.  In this analysis, the number of bundled payment groups does 
impact the expected profitability. As supported by previous studies(Feeley et al., 2015),  
a minimum number of bundled payments helps diversify risk as long as the price point 
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cover the expected costs per bundled payment treatment group.  Furthermore, risk can 
be more strictly managed by increasing the number of bundled payment groups and 
minimizing the variation within groups.  More importantly, grouping the treatment 
modalities in the correct bundled payments reduces the variability between groups and 
further provide a transparent model for bundled payments and future price 
negotiations.  
 
Finally, the last aim is a summary of all the previous aims in figure form. This 
figure is a 5-step visual framework to help organizations develop a bundled payment in 
cancer care. This aim will fill a gap in the current literature by providing a simplified 
approach for organizing the data, defining bundled payment groups, and 
recommendations for financial analyses.  
The first step in the bundled payment framework is to ‘define cancer patient 
criteria’ of interest. The patient criteria defined in Aim 1 is for newly diagnosed head 
and neck cancer patients.  This framework could be used for other non- head and neck 
cancer disease sites, concurrent, recurrent, or metastatic cancer patients.  This 
framework can be used by other cancer populations as long the treatment modalities 
are within a pre-defined period of time.  
The second step in the bundled payment framework is to ‘prepare the data for 
analyses. The statistical tests in the analyses require the observations, in this case, the 
bundled payment 1-year episodes to be independent and unique.  They must not be 
influenced or affected by other observations.  If these assumptions are met, then it is 
acceptable to identify the independent and dependent variables for all analyses.  The 
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dependent variables are the total episode costs per patient calculated in Aim 1.  In this 
analyses, each newly diagnosed patient will have only one episode.  For other scenarios, 
it is possible for patients to have more than one episode.  Next, the independent 
variables are the defined treatment modalities per episode.  Patients cannot have more 
than 1 treatment modality combination or it will not meet the above assumption of 
unique observations.  Steps 1 and 2 describe Aim 1 and are essential before proceeding 
forward.  
The third step in the bundled payment framework is to confirm the normal 
distribution of the curve.  There are 2 possible ways to confirm the data is normally 
distributed: 1) create a histogram of the dependent variable, the episode costs, and 
visually confirm the cost curve is normally distributed; and/or 2) conduct a Shapiro-
Wilks Normality Tests.  The null hypothesis and outcome instructions are described 
above.  If the cost curve is not normally distributed, a data transformation will be 
required to convert the cost curve to a normal distribution. In this analysis, a square 
root transformation was used.  The last phase of the third step is to remove all outliers 
from the data before proceeding forward with step four. Step Three is a description of 
Aim 2 above. 
The fourth step in the bundled payment framework is to define, bundle, and 
confirm the bundled payments by treatment modality.  A Complete-Linked Hierarchical 
Clustering analysis is required to identify the treatment modalities with similar mean 
costs.  The output of the clustering is a dendrogram that will provide a visual branching 
diagram of the treatment modality bundled groups.  To confirm the bundled groupings 
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are correctly bundled, a One-Way ANOVA with Bonferroni Adjustment Type tests can be 
conducted to determine with bundled payment groups are statistically different.  This 
test will help identify that statistically significant treatment modalities are not bundled 
together.  
The fifth and final step in the ‘how-to’ guide includes recommendations for 
financial analyses.  These recommendations include a simulation and pricing profitability 
analyses with stop-loss modeling if appropriate.  These types of analyses will provide 
insights on how many bundles to create and where pricing negotiations should be 
targeted to be profitable for either the payor or provider.  Although stop-loss modeling 
was not conducted in this study, it has been recommended in previous bundled 
payment methodologies(Feeley et al., 2015). The fourth and fifth steps reflect the 
previous analyses in Aim 3.  The visual cancer bundled payment guide is below in Figure 
10.  
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Figure 10: Cancer Bundled Payment Guide 
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VIII. DISCUSSION  
The continuous expansion of bundled payment programs amongst the private 
payors and CMS suggests this alternative payment model is viable and profitable.  
Comprehensive cancer bundling methodology is absent from the literature.  This missing 
literature is giving rise to single cancer treatment modality bundles.  This analysis 
provides and supports transparent comprehensive bundled payment methodology.  
Furthermore, the proposed framework can help organizations and the government 
develop treatment modality based bundled payment methods.   
This research introduced one dependent and one independent variables; however, 
this framework would still be applicable if future studies introduced more than one 
independent variable.  The changes necessary would be the use an alternative analysis 
to confirm the differences between bundled payments. For example, hospitals or 
provider organizations may want to include cancer tumor registry data if available, 
bundles could be clustered by tumor stage with or without treatment modality 
combinations.  As long as tumor stages were independent and unique, the bundling 
framework is still applicable to guide bundled payment modeling. 
The bundled payment episode period is not consistent in the literature.  Bundled 
payment programs with single treatment modality bundles have implemented shorter-
term bundled payment episode of 90-180 days from start of treatment.  Larger multi-
modality treatment bundles have implemented 180 day to 1 year episodes.  As 
suggested by the literature, a 12-month bundled payment episode is sufficient time for 
completion of all cancer treatment with appropriate time to assess immediate quality 
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outcomes. The OCM has implemented 6 month chemotherapy bundled payments 
(Thomas & Ward, 2016).  Further research is necessary the financial risk and non-cancer 
utilization between 6 and 12-month past single cancer treatment modality.  
Additionally, further research is needed to evaluate the administrative burden of 
implementing and managing bundled payments with different bundled episodes.   
An important recommendation highlighted in step five of the bundled payment 
framework is the modeling of a stop-loss agreement during pricing negotiations. As 
defined by the Health Care Administrators Association, “a specific stop-loss is a form of 
excess risk coverage that provides protection for the employer against a high claim on 
any one individual. This is protection against abnormal severity of a single claim rather 
than abnormal frequency of claims in total” (Health Care Administrators Association, 
2019). A stop loss coverage can further protect against unforeseen financial loss.  The 
MD Anderson head and neck bundled payment program negotiated a stop loss(Feeley 
et al., 2015). A stop loss analysis coupled with pricing analyses can further enhanced the 
profitability of this type of payment arrangement.   
As CMS moves forward with mandatory single treatment modality bundles, 
researchers have speculated other, more complex, bundles are projected for the future.  
This analysis provides a transparent approach for CMS and other payors and providers 
to develop more comprehensive multi-modality treatment bundles.  CMS’s rationale for 
their proposed mandatory radiation therapy bundles is to incentivize value-based 
cancer treatment delivery.  Radiation therapy is expensive and research would suggest 
more radiation treatment is not necessary efficient in some cancers (Paravati et al., 
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2015). This type of alternative payment model creates incentives for providers to 
provide the highest quality care without the incremental disincentive of paying for 
volume that exists in current payment systems.  In the current payment system, the fee-
for-service system, providers would be paid more for additional cycles of radiation 
treatments and could be financially incentivized to provide more cycles with disregard 
for the quality implications of radiation toxicities.    
CMS QPP-MIPS program introduced new episode-based cost measures.  The 
approach is similar to bundled payments.  QPP-MIPS episode-based cost measurers 
calculate the national total cost of care for a specific procedure and sets provider cost 
benchmarks with financial incentives or penalties. This program incentives decreases in 
cost of care delivery.  There is currently only one cancer diagnostic procedure in the 
2019 QPP-MIPS episode cost measure program.  There is a surgical breast cancer 
episode based cost measure proposed for 2020.  This bundled payment approach can be 
used to assess and model an organizations QPP-MIPS episode based cost category.  
It’s important to note there is strong opposition against bundled payments in the 
literature. Critics suggest bundled payments is only viable amongst providers who 
practice in integrated practice units (Deloitte Center for Health Solutions, 2017), where 
providers and hospital service lines are able to appropriately allocate costs and disperse 
bundled payment savings (Porter & Teisberg, 2006).  The majority of the cancer 
delivered in the US is not within a comprehensive cancer center organized in this 
fashion.  The second opposition against bundled payments is the unpredictability of 
new, high cost cancer drugs and treatment technologies (Deloitte Center for Health 
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Solutions, 2017).  Under a bundled payment arrangement, providers would be dis-
incentivized to provide new treatment innovations. Critics have stated that the shorter 
term bundled payment incentives do not reflect the real long-term incentives needed to 
reduce costs of treatment modalities in cancer care.  Lastly,  bundled payments does not 
address other cost drivers of cancer care spending (Basch, 2017; Thomas & Ward, 2016).  
This type of alternative payments does not solve the inaccuracy and misdiagnosis 
problem that currently exists.  Future research is encouraged to address each of these 
critiques to help reduce the cost of cancer care delivery through alternative payments, 
like bundled payments.  
IX. LIMITATIONS 
Administrative claims bundled payment research can provide evidence to support or 
dismiss alternative payment models in healthcare.  Due to the nature and limitation of 
the data, there are several limitations.  The data validity and reliability is as accurate as 
the contractual payment audit processes and provider documentation currently used by 
hospitals and providers. All claims have undergone the typical billing audit and are 
deemed reliable but limitations may exist if the documentation errors or medical billing 
errors were present and not caught by the medical billing audit process. The 
administrative claims databased used in this research does not have unique provider or 
hospital information.  This limits the ability to analyze data by provider therefore the 
data was summarized at the patient, treatment-modality, and bundled payment group 
level only.   
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The ‘costs’ analyzed in this study are actually payor allowed amounts and 
geographically standardized across regions.  This limitation does not allow for 
geographic costs comparison analyses nor longitudinal studies by provider.  It’s also 
important to note the allowed amounts are not correlated nor do they reflect actual 
provider costs.  The allowed amounts are contractual limits negotiated between 
provider and payors.  This study assumes provider costs are below allowed amounts.  
Therefore only those providers who can make a profit will stay sustainable in the long 
run under bundled payment methodology.    
This study will not examine the head and neck cancer cost drivers nor the cost of 
cancer care for other non-newly diagnosed patients. This research is proposing a 
bundled payment methodology for newly diagnosed payment.  Future is necessary to 
validate this bundled payment approach under bundled payment scenarios and patient 
populations.  
Next, the use of a Monte Carlo simulation introduces several limitations.  A Monte 
Carlo simulation is a type of analysis that provides a distribution of results to allow 
organizations to assess risk on their own behalf (Dimov, 2008; Gao, 1999; Mao, 1997; 
Perrott, 2004; Richter & Mauskopf, 1998; Rodina-Theocharaki, Bliznakova, & 
Pallikarakis, 2012; Zhu et al., 2011). A Monte Carlo simulation requires a Random 
number generator to create data based on data statistics.  The simulations are 
dependent on the validity and reliability of the administrative claims data and the 
bundled payment grouping approach. Depending on the distribution of future studies, 
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the random number generator may need to use a different algorithm than the one used 
in this study.  
Lastly, the bundling of treatment modalities into payment groups based on historical 
costs may not be appropriate for all future bundled payment analyses.  Treatment 
modalities are usually depending on the cancer patient’s disease status (cancer tumor 
and stage), patient preference, or access to appropriate treatment types.  This research 
does not attempt to access appropriate access to care or scarcity of treatment options.  
In the future, if patient level tumor registry data were available with administrative 
claims,  a better appropriate to bundling would be by tumor stage or clinical pathways.   
X. HUMAN SUBJECTS AND DATA VALIDITY 
 The University of Texas School of Public Health (UTSPH) has access to Optum® 
Life Sciences Database administrative claims data; no clinical data is available for 
members in their database. Administrative claims data are contractual agreements 
between the provider and payors (insurance carriers) that require the collection of data 
for business and reporting purposes only. There are patient sensitive data (date of birth, 
gender, and zip code) available in the member claims database.  No persons were 
harmed in the collection of this data.  Providers initiated the data collection in an effort 
to request of payment for services rendered by patients.  Payors collect and store data 
upon receipt for transaction business purposes. It is presumed data in this database are 
validate and acceptable for costs analyses.  
 Both parties conduct claim audits to ensure that the validity of the information in 
the claims reported is accurate; audits help protect the legal and financial obligations 
 59 
under the contract. Many providers perform independent, internal audits to catch 
errors in the reporting process to ensure that the claims submitted to insurance carriers 
are accurate; errors claims submissions could trigger additional audits from external 
agents and dismissal of reimbursement for such claims. Errors can also jeopardize 
business affairs and potentially result in termination of contractual agreements.  The 
University Of Texas School Of Public Health has also taken measures to protect 
administrative claims data. No security breaches or compromises have been reported. In 
conclusion, the data is assumed to be valid and reliable.  
A formal data request will be submitted in January 2019 to gain access to head 
and neck patient claims for 2011- 2017. All data extracted was stored on a UTSPH 
secured servers and only accessed using a secure VPN and under password protection.   
The study was reviewed by the ‘Committee of the Protection of Human Subjects’ to 
ensure the methods and measures described above protect the privacy and safety of 
patient’s data. No data extraction or analyses were conducted until exempt study 
approval letter were submitted to the UTSPH Data Center.  A copy of the approved 
letter are available in Appendix G and H.   
XI. CONCLUSION 
Bundled payments, along with other alternative payments, have the ability to curb the 
healthcare cost curve in the US.  There is evidence to suggest bundled payments can 
reduce the cost of care by incentivizing quality cancer care delivery and penalizing 
inefficiencies in the delivery systems.  Currently, there are no transparent, multi-cancer 
treatment modality bundled payment methodologies to support comprehensive 
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bundled payments in the US.  This research fills a gap in the literature by providing a 
transparent, feasible approach to bundling chemotherapy, radiation therapy, and 
surgery cancer treatment modalities.   Additionally, this research provides a framework 
for approaching cancer bundles which is currently missing in the literature.  While, this 
analysis focused on newly diagnosed cancer treatment bundles, the framework can be 
used to model all other treatment modality bundles; for example, concurrent, recurrent, 
and metastatic are proposed future bundles using this same framework. Lastly, this 
analysis proves bundled payment grouping  is feasible and viability, albeit dependent on 
an organization’s ability to control healthcare spending costs and negotiate bundled 
payment prices above costs.  The results of this work demonstrate the use of statistical 
and financial models to support price models and sensitivity analyses. Healthcare 
leaders can use these models to better understand their expected costs/ profits and 
leverage their negotiations; however, it should be noted that  this research does not 
suggest all bundled payment methodologies are profitable. Future studies, using this 
framework and institutional level costs, are needed to validate and potentially improve 
the proposed methodology.  
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XIII. APPENDICES 
Appendix A: Head & Neck Primary Cancer Diagnosis Codes 
Code Type Code Diagnosis Description 
ICD-9 CM 140.0 Malignant neoplasm of upper lip, vermilion border 
ICD-9 CM 140.1 Malignant neoplasm of lower lip, vermilion border 
ICD-9 CM 140.3 Malignant neoplasm of upper lip, inner aspect 
ICD-9 CM 140.4 Malignant neoplasm of lower lip, inner aspect 
ICD-9 CM 140.5 Malignant neoplasm of lip, unspecified, inner aspect 
ICD-9 CM 140.6 Malignant neoplasm of commissure of lip 
ICD-9 CM 140.8 Malignant neoplasm of other sites of lip 
ICD-9 CM 140.9 Malignant neoplasm of lip, unspecified, vermilion border 
ICD-9 CM 141.0 Malignant neoplasm of base of tongue 
ICD-9 CM 141.1 Malignant neoplasm of dorsal surface of tongue 
ICD-9 CM 141.2 Malignant neoplasm of tip and lateral border of tongue 
ICD-9 CM 141.3 Malignant neoplasm of ventral surface of tongue 
ICD-9 CM 141.4 Malignant neoplasm of anterior two-thirds of tongue, part unspecified 
ICD-9 CM 141.5 Malignant neoplasm of junctional zone of tongue 
ICD-9 CM 141.6 Malignant neoplasm of lingual tonsil 
ICD-9 CM 141.8 Malignant neoplasm of other sites of tongue 
ICD-9 CM 141.9 Malignant neoplasm of tongue, unspecified 
ICD-9 CM 142.0 Malignant neoplasm of parotid gland 
ICD-9 CM 142.1 Malignant neoplasm of submandibular gland 
ICD-9 CM 142.2 Malignant neoplasm of sublingual gland 
ICD-9 CM 142.8 Malignant neoplasm of other major salivary glands 
ICD-9 CM 142.9 Malignant neoplasm of salivary gland, unspecified 
ICD-9 CM 143.0 Malignant neoplasm of upper gum 
ICD-9 CM 143.1 Malignant neoplasm of lower gum 
ICD-9 CM 143.8 Malignant neoplasm of other sites of gum 
ICD-9 CM 143.9 Malignant neoplasm of gum, unspecified 
ICD-9 CM 144.0 Malignant neoplasm of anterior portion of floor of mouth 
ICD-9 CM 144.1 Malignant neoplasm of lateral portion of floor of mouth 
ICD-9 CM 144.8 Malignant neoplasm of other sites of floor of mouth 
 66 
ICD-9 CM 144.9 Malignant neoplasm of floor of mouth, part unspecified 
ICD-9 CM 145.0 Malignant neoplasm of cheek mucosa 
ICD-9 CM 145.1 Malignant neoplasm of vestibule of mouth 
ICD-9 CM 145.2 Malignant neoplasm of hard palate 
ICD-9 CM 145.3 Malignant neoplasm of soft palate 
ICD-9 CM 145.4 Malignant neoplasm of uvula 
ICD-9 CM 145.5 Malignant neoplasm of palate, unspecified 
ICD-9 CM 145.6 Malignant neoplasm of retromolar area 
ICD-9 CM 145.8 Malignant neoplasm of other specified parts of mouth 
ICD-9 CM 145.9 Malignant neoplasm of mouth, unspecified 
ICD-9 CM 146.0 Malignant neoplasm of tonsil 
ICD-9 CM 146.1 Malignant neoplasm of tonsillar fossa 
ICD-9 CM 146.2 Malignant neoplasm of tonsillar pillars (anterior) (posterior) 
ICD-9 CM 146.3 Malignant neoplasm of vallecula epiglottica 
ICD-9 CM 146.4 Malignant neoplasm of anterior aspect of epiglottis 
ICD-9 CM 146.5 Malignant neoplasm of junctional region of oropharynx 
ICD-9 CM 146.6 Malignant neoplasm of lateral wall of oropharynx 
ICD-9 CM 146.7 Malignant neoplasm of posterior wall of oropharynx 
ICD-9 CM 146.8 Malignant neoplasm of other specified sites of oropharynx 
ICD-9 CM 146.9 Malignant neoplasm of oropharynx, unspecified site 
ICD-9 CM 149.0 Malignant neoplasm of pharynx, unspecified 
ICD-9 CM 149.1 Malignant neoplasm of waldeyer's ring 
ICD-9 CM 149.8 Malignant neoplasm of other sites within the lip and oral cavity 
ICD-9 CM 149.9 Malignant neoplasm of ill-defined sites within the lip and oral cavity 
ICD-9 CM 161.0 Malignant neoplasm of glottis 
ICD-9 CM 161.1 Malignant neoplasm of supraglottis 
ICD-9 CM 161.2 Malignant neoplasm of subglottis 
ICD-9 CM 161.3 Malignant neoplasm of laryngeal cartilages 
ICD-9 CM 161.8 Malignant neoplasm of other specified sites of larynx 
ICD-9 CM 161.9 Malignant neoplasm of larynx, unspecified 
ICD-10 CM C00.0 Malignant neoplasm of external upper lip 
ICD-10 CM C00.1 Malignant neoplasm of external lower lip 
ICD-10 CM C00.2 Malignant neoplasm of external lip, unspecified 
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ICD-10 CM C00.3 Malignant neoplasm of upper lip, inner aspect 
ICD-10 CM C00.4 Malignant neoplasm of lower lip, inner aspect 
ICD-10 CM C00.5 Malignant neoplasm of lip, unspecified, inner aspect 
ICD-10 CM C00.6 Malignant neoplasm of commissure of lip, unspecified 
ICD-10 CM C00.8 Malignant neoplasm of overlapping sites of lip 
ICD-10 CM C00.9 Malignant neoplasm of lip, unspecified 
ICD-10 CM C01 Malignant neoplasm of base of tongue 
ICD-10 CM C02.0 Malignant neoplasm of dorsal surface of tongue 
ICD-10 CM C02.1 Malignant neoplasm of border of tongue 
ICD-10 CM C02.2 Malignant neoplasm of ventral surface of tongue 
ICD-10 CM C02.3 Malignant neoplasm of anterior two-thirds of tongue, part unspecified 
ICD-10 CM C02.4 Malignant neoplasm of lingual tonsil 
ICD-10 CM C02.8 Malignant neoplasm of overlapping sites of tongue 
ICD-10 CM C02.9 Malignant neoplasm of tongue, unspecified 
ICD-10 CM C03.0 Malignant neoplasm of upper gum 
ICD-10 CM C03.1 Malignant neoplasm of lower gum 
ICD-10 CM C03.9 Malignant neoplasm of gum, unspecified 
ICD-10 CM C04.0 Malignant neoplasm of anterior floor of mouth 
ICD-10 CM C04.1 Malignant neoplasm of lateral floor of mouth 
ICD-10 CM C04.8 Malignant neoplasm of overlapping sites of floor of mouth 
ICD-10 CM C04.9 Malignant neoplasm of floor of mouth, unspecified 
ICD-10 CM C05.0 Malignant neoplasm of hard palate 
ICD-10 CM C05.1 Malignant neoplasm of soft palate 
ICD-10 CM C05.2 Malignant neoplasm of uvula 
ICD-10 CM C05.8 Malignant neoplasm of overlapping sites of palate 
ICD-10 CM C05.9 Malignant neoplasm of palate, unspecified 
ICD-10 CM C06.0 Malignant neoplasm of cheek mucosa 
ICD-10 CM C06.1 Malignant neoplasm of vestibule of mouth 
ICD-10 CM C06.2 Malignant neoplasm of retromolar area 
ICD-10 CM C06.80 Malignant neoplasm of overlapping sites of unspecified parts of mouth 
ICD-10 CM C06.89 Malignant neoplasm of overlapping sites of other parts of mouth 
ICD-10 CM C06.9 Malignant neoplasm of mouth, unspecified 
ICD-10 CM C07 Malignant neoplasm of parotid gland 
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ICD-10 CM C08.0 Malignant neoplasm of submandibular gland 
ICD-10 CM C08.1 Malignant neoplasm of sublingual gland 
ICD-10 CM C08.9 Malignant neoplasm of major salivary gland, unspecified 
ICD-10 CM C09.0 Malignant neoplasm of tonsillar fossa 
ICD-10 CM C09.1 Malignant neoplasm of tonsillar pillar (anterior) (posterior) 
ICD-10 CM C09.8 Malignant neoplasm of overlapping sites of tonsil 
ICD-10 CM C09.9 Malignant neoplasm of tonsil, unspecified 
ICD-10 CM C10.0 Malignant neoplasm of vallecula 
ICD-10 CM C10.1 Malignant neoplasm of anterior surface of epiglottis 
ICD-10 CM C10.2 Malignant neoplasm of lateral wall of oropharynx 
ICD-10 CM C10.3 Malignant neoplasm of posterior wall of oropharynx 
ICD-10 CM C10.4 Malignant neoplasm of branchial cleft 
ICD-10 CM C10.8 Malignant neoplasm of overlapping sites of oropharynx 
ICD-10 CM C10.9 Malignant neoplasm of oropharynx, unspecified 
ICD-10 CM C14.0 Malignant neoplasm of pharynx, unspecified 
ICD-10 CM C14.2 Malignant neoplasm of Waldeyer's ring 
ICD-10 CM C14.8 Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx 
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Appendix B: Surgery Procedure Codes 
CODE PROCEDURE DESCRIPTION 
CODE 
TYPE SERVICE CATEGORY DESCRIPTION 
31300 
LARYNGOTOMY W/RMVL TUMOR/LARYNGOCELE 
CORDECTOMY CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31320 LARYNGOTOMY THYROTOMY LARYNGOFISSURE DX CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31360 
LARYNGECTOMY TOTAL W/O RADICAL NECK 
DISSECTION CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31364 
BRONCHOSCOPY, RIGID OR FLEXIBLE, INCLUDING 
FLUOR CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31365 LARYNGECTOMY TOTAL W/RADICAL NECK DISSECTION CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31367 
LARYNGECTOMY STOT SUPRAGLOTTIC W/O RAD NECK 
DSJ CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31368 
LARYNGECTOMY STOT SUPRAGLOTTIC W/RAD NCK 
DSJ CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31370 
PARTIAL LARYNGECTOMY HEMILARYGECTOMY 
HORIZONTAL CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31375 
PARTIAL LARYNGECTOMY HEMILARYNG 
LATEROVERTICAL CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31380 
PARTIAL LARYNGECTOMY HEMILARYNG 
ANTEROVERTICAL CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31382 
PARTIAL LARYNG HEMILARYNG ANTERO-LATERO-
VERTICAL CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31390 
PHARYNGOLARYNGECTOMY W/RAD NECK DSJ W/O 
RCNSTJ CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31395 
PHARYNGOLARYNGECTOMY W/RAD NECK DSJ 
W/RCNSTJ CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31400 
ARYTENOIDECTOMY/ARYTENOIDOPEXY XTRNL 
APPROACH CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31420 EPIGLOTTIDECTOMY CPT-4 RESPIRATORY SYSTEM - LARYNX - EXCISION 
31500 
INTUBATION ENDOTRACHEAL EMERGENCY 
PROCEDURE CPT-4 RESPIRATORY SYSTEM - LARYNX - INTRODUCTION 
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31502 
TRACHEOTOMY TUBE CHANGE PRIOR TO FISTULA 
TRACT CPT-4 RESPIRATORY SYSTEM - LARYNX - INTRODUCTION 
31505 LARYNGOSCOPY INDIRECT DIAGNOSTIC SPX CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31510 LARYNGOSCOPY INDIRECT W/BIOPSY CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31511 
LARYNGOSCOPY INDIRECT W/REMOVAL FOREIGN 
BODY CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31512 LARYNGOSCOPY INDIRECT W/REMOVAL LESION CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31513 LARYNGOSCOPY INDIRECT W/VOCAL CORD INJECTION CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31515 LARYNGOSCOPY W/WO TRACHEOSCOPY ASPIRATION CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31525 
LARYNGOSCOPY W/WO TRACHEOSCOPY DX EXCEPT 
NEWBORN CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31526 
LARYNGOSCOPY W/WO TRACHEOSCOPY 
W/MICRO/TELESCOPE CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31527 
LARYNGOSCOPY W/WO TRACHEOSCOPY INSERT 
OBTURATOR CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31528 
LARYNGOSCOPY W/WO TRACHEOSCOPY W/DILATION 
IN CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31529 
LARYNGOSCOPY W/WO TRACHEOSCOPY DILATION 
SUBSQ CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31530 LARYNGOSCOPY W/FOREIGN BODY REMOVAL CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31531 
LARYNGOSCOPY FOREIGN BODY RMVL 
MICRO/TELESCOPE CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31535 LARYNGOSCOPY DIRECT OPERATIVE W/BIOPSY CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31536 LARYNGOSCOPY W/BIOPSY MICROSCOPE/TELESCOPE CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31540 
LARYNGOSCOPY EXC TUM&/STRIPPING 
CORDS/EPIGLOTT CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31541 
LARGSC EXC TUM&/STRPG CORDS/EPIGL 
MCRSCP/TLSCP CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31545 
LARGSC MICRO/TELESCOPE RMVL LES VOCAL CORD 
FLAP CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31546 
LARGSC MICRO/TELESCOPE RMVL LES VOCAL CORD 
GRAFT CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
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31551 
LARYNGOPLASTY LARYNGEAL STEN W/O STENT < 12 
YRS CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31552 
LARYNGOPLASTY LARYNGEAL STEN W/O STENT 12 YRS 
> CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31553 LARYNGOPLASTY LARYNGEAL STEN W/STENT < 12 YRS CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31554 LARYNGOPLASTY LARYNGEAL STEN W/STENT 12 YRS > CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31560 
LARYNGOSCOPY DIRECT OPERATIVE 
W/ARYTENOIDECTOMY CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31561 LARGSC ARYTENOIDECTOMY MICROSCOPE/TELESCOPE CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31570 
LARYNGOSCOPE INJECTION VOCAL CORD 
THERAPEUTIC CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31571 
LARGSC W/NJX VOCAL CORD THER 
W/MICRO/TELESCOPE CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31572 LARYNGOSCOPY FLEXIBLE ABLATJ DESTJ LESION(S) UNI CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31573 
LARYNGOSCOPY FLEXIBLE THERAPEUTIC INJECTION 
UNI CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31574 LARYNGOSCOPY FLEXIBLE W/INJECTION AGMNTJ UNI CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31575 LARYNGOSCOPY FLEXIBLE DIAGNOSTIC CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31576 LARYNGOSCOPY FLEXIBLE W/BIOPSY(IES) CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31577 LARYNGOSCOPY FLX RMVL FOREIGN BODY(S) CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31578 LARYNGOSCOPY FLEXIBLE RMVL LESION(S) NON-LASER CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31579 
LARYNGOSCOPY FLX/RGD TELESCOPIC 
W/STROBOSCOPY CPT-4 RESPIRATORY SYSTEM - LARYNX - ENDOSCOPY 
31580 
LARYNGOPLASTY LARYN WEB W/KEEL STENT 
INSERTION CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31582 
LARYNGP LARYN STENOSIS GRF/CORE MOLD 
W/TRACHT CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31584 
LARYNGOPLASTY W/OPEN REDUCTION FRACTURE 
W/TRACHS CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31587 
LARYNGOPLASTY CRICOID SPLIT W/O GRAFT 
PLACEMENT CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31588 LARYNGOPLASTY NOT OTHERWISE SPECIFIED CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
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31590 
LARYNGEAL REINNERVATION NEUROMUSCULAR 
PEDICLE CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31591 LARYNGOPLASTY MEDIALIZATION UNLIATERAL CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31592 CRICOTRACHEAL RESECTION CPT-4 RESPIRATORY SYSTEM - LARYNX - REPAIR 
31595 
SECTION RECURRENT LARYNGEAL NERVE THER UNI 
SPX CPT-4 RESPIRATORY SYSTEM - LARYNX - DESTRUCTION 
31599 UNLISTED PROCEDURE LARYNX CPT-4 RESPIRATORY SYSTEM - LARYNX - OTHER PROCEDURES 
40500 VERMILIONECTOMY LIP SHV W/MUCOSAL ADVMNT CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
40510 EXC LIP TRANSVRS WEDGE EXC W/PRIM CLSR CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
40520 EXC LIP V-EXC W/PRIM DIR LINR CLSR CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
40525 EXC LIP FULL THKNS RCNSTJ W/LOCAL FLAP CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
40527 EXC LIP FULL THKNS RCNSTJ W/CROSS LIP FLAP CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
40530 RESCJ LIP > ONE-FOURTH W/O RCNSTJ CPT-4 DIGESTIVE SYSTEM - LIPS - EXCISION 
41100 BIOPSY TONGUE ANTERIOR TWO-THIRDS CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41105 BIOPSY TONGUE POSTERIOR ONE-THIRD CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41108 BIOPSY FLOOR MOUTH CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41110 EXCISION LESION TONGUE W/O CLOSURE CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41112 EXC LESION TONGUE W/CLSR ANTERIOR TWO-THIRDS CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41113 EXC LESION TONGUE W/CLSR POSTERIOR ONE-THIRD CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41114 EXC LESION TONGUE W/CLSR W/LOCAL TONGUE FLAP CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41115 EXCISION LINGUAL FRENUM FRENECTOMY CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41116 EXCISION LESION FLOOR MOUTH CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41120 GLOSSECTOMY <ONE-HALF TONGUE CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
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41130 GLOSSECTOMY HEMIGLOSSECTOMY CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41135 GLOSSECTOMY PRTL W/UNI RADICAL NECK DSJ CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41140 GLSSC COMPL/TOT W/WOTRACHS W/O RAD NECK DSJ CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41145 
GLSSC COMPL/TOT W/WO TRACHS W/UNI RAD NECK 
DSJ CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
41150 
GLSSC COMPOSIT W/RESCJ FLOOR & MANDIBULAR 
RESCJ CPT-4 
DIGESTIVE SYSTEM - TONGUE  FLOOR OF MOUTH - 
EXCISION 
42100 BIOPSY PALATE UVULA CPT-4 
DIGESTIVE SYSTEM - PALATE  UVULA - EXCISION  
DESTRUCTION 
42104 EXC LESION PALATE UVULA W/O CLOSURE CPT-4 
DIGESTIVE SYSTEM - PALATE  UVULA - EXCISION  
DESTRUCTION 
42106 EXC LESION PALATE UVULA W/SMPL PRIM CLOSURE CPT-4 
DIGESTIVE SYSTEM - PALATE  UVULA - EXCISION  
DESTRUCTION 
42107 EXC LESION PALATE UVULA W/LOCAL FLAP CLOSURE CPT-4 
DIGESTIVE SYSTEM - PALATE  UVULA - EXCISION  
DESTRUCTION 
42120 RESCJ PALATE/EXTENSIVE RESCJ LESION CPT-4 
DIGESTIVE SYSTEM - PALATE  UVULA - EXCISION  
DESTRUCTION 
42400 BIOPSY SALIVARY GLAND NEEDLE CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42405 BIOPSY SALIVARY GLAND INCISIONAL CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42408 EXC SUBLINGUAL SALIVARY CYST RANULA CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42409 MARSUPIALIZATION SUBLNGL SALIVARY CST RANULA CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42410 EXC PRTD TUM/PRTD GLND LAT LOBE W/O NRV DSJ CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42415 EXC PRTD TUM/PRTD GLND LAT DSJ&PRSRV FACIAL NR CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42420 
EXC PRTD TUM/PRTD GLND TOT DSJ&PRSRV FACIAL 
NR CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42425 
EXCISION PAROTID TUMOR/GLAND TOTAL EN BLOC 
RMVL CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42426 EXC PRTD TUM/PRTD GLND TOT W/UNI RAD NCK DSJ CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42440 EXCISION SUBMANDIBULAR SUBMAXILLARY GLAND CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
42450 EXISION OF SUBLINGUAL GLAND CPT-4 DIGESTIVE SYSTEM - SALIVARY GLAND/DUCTS - EXCISION 
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42700 I&D ABSCESS PERITONSILLAR CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- INCISION 
42720 I&D ABSC RTRPHRNGL/PARAPHARYNGEAL INTRAORAL CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- INCISION 
42725 
I&D ABSC RTRPHRNGL/PARAPHARYNGEAL XTRNL 
APPR CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- INCISION 
42800 BIOPSY OROPHARYNX CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42802 BX HYPOPHARYNX CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42808 
EXCISION/DESTRUCTION LESION PHARYNX ANY 
METHOD CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42809 REMOVAL FOREIGN BODY PHARYNX CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42810 EXC BRANCHIAL CLEFT CYST CONFINED SKN&SUBQ TIS CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42815 
EXC BRANCHIAL CLEFT CYST BELOW SUBQ 
TISS&/PHRYNX CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
42821 TONSILLECTOMY&ADENOIDECTOMY AGE 12/> CPT-4 
TONSILLECTOMY AND ADENOIDECTOMY; AGE 12 OR 
OVER 
42826 TONSILLECTOMY PRIMARY/SECONDARY AGE 12/> CPT-4 
TONSILLECTOMY  PRIMARY OR SECONDARY; AGE 12 OR 
OVER 
42831 ADENOIDECTOMY PRIMARY AGE 12/> CPT-4 ADENOIDECTOMY  PRIMARY; AGE 12 OR OVER 
42836 ADENOIDECTOMY SECONDARY AGE 12/> CPT-4 ADENOIDECTOMY  SECONDARY; AGE 12 OR OVER 
42870 EXC/DSTRJ LINGUAL TONSIL ANY METHOD SPX CPT-4 
DIGESTIVE SYSTEM - PHARYNX  ADENOIDS  AND TONSILS 
- EXCISION  DESTRUCTION - OTHER 
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Appendix C: Radiation Therapy Procedure Codes  
 
CODE PROCEDURE DESCRIPTION 
CODE 
TYPE 
0073T COMPNSTR-BASED BEAM MODLJ TX DLVR INVERSE 3> FLD CPT-4 
0182T HDR ELECTRONIC BRACHYTHERAPY PER FRACTION CPT-4 
0190T INTRAOCULAR RADIATION SRC APPLICATOR PLACEMENT CPT-4 
0197T LOCLZJ&TRACKING TARGET/PT MOTION DEL RADJ THER CPT-4 
0301T DEST/REDUC MALIG BRST TUMR W/US THRMORX GUIDANCE CPT-4 
0394T HDR ELECTRONIC BRACHYTHERAPY SKIN SURFACE CPT-4 
0395T HDR ELECTRONIC BRACHYTHERAPY NTRSTL/INTRCAV CPT-4 
19296 PLMT EXPANDABLE CATH BRST FOLLOWING PRTL MAST CPT-4 
19297 PLMT EXPANDABLE CATH BRST CONCURRENT PRTL MAST CPT-4 
19298 PLMT RADTHX BRACHYTX BRST FOLLOWING PRTL MAST CPT-4 
32553 PLMT NTRSTL DEV RADJ THX GID PRQ INTRATHRC 1/MLT CPT-4 
32701 THORAX STEREOTACTIC RADIATION TARGET W/TX COURSE CPT-4 
41019 PLACEMENT NEEDLE HEAD/NECK RADIOELEMENT APPLICAT CPT-4 
49327 LAPS W/INSERTION NTRSTL DEV W/IMG GUID 1/MLT CPT-4 
49411 INTERSTITIAL DEV PLMT RADIATION THERAPY 1/MLT CPT-4 
49412 PLACEMENT INTRSTL DEV OPN W/IMG GUID 1/MLT CPT-4 
55875 TRANSPERINEAL PLMT NDL/CATHS PROSTATE RADJ INSJ CPT-4 
55876 PLMT INTERSTITIAL DEV RADIAT TX PROSTATE 1/MULT CPT-4 
55920 PLACEMENT NEEDLE PELVIC ORGAN RADIOELEMENT APPL CPT-4 
57155 INSERTION UTERINE TANDEM&/VAGINAL OVOIDS CPT-4 
57156 INSERTION VAGINAL RADIATION DEVICE CPT-4 
58346 INSERTION HEYMAN CAPSULES CLINICAL BRACHYTHERAPY CPT-4 
61770 STRTCTC LOCLZJ INSJ CATH/PRB PLMT RADJ SRC CPT-4 
67218 DSTRJ LESION RETINA 1/> SESS RADJ IMPLTJ CPT-4 
76873 US TRANSRCT PRSTATE VOL BRACHYTX PLNNING SPX CPT-4 
76950 US PLMT RADJ THER FLDS CPT-4 
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76965 US GUIDANCE INTERSTITIAL RADIOELMENT APPLICATION CPT-4 
77014 CT GUIDANCE RADIATION THERAPY FLDS PLACEMENT CPT-4 
77261 THERAPEUTIC RADIOLOGY TX PLANNING SIMPLE CPT-4 
77262 THERAPEUTIC RADIOLOGY TX PLANNING INTERMEDIATE CPT-4 
77263 THERAPEUTIC RADIOLOGY TX PLANNING COMPLEX CPT-4 
77280 THER RAD SIMULAJ-AIDED FIELD SETTING SIMPLE CPT-4 
77285 THER RAD SIMULAJ-AIDED FIELD SETTING INTERMED CPT-4 
77290 THER RAD SIMULAJ-AIDED FIELD SETTING COMPLEX CPT-4 
77295 3-D RADIOTHERAPY PLAN DOSE-VOLUME HISTOGRAMS CPT-4 
77300 BASIC RADIATION DOSIMETRY CALCULATION CPT-4 
77301 NTSTY MODUL RADTHX PLN DOSE-VOL HISTOS CPT-4 
77306 TELETHX ISODOSE PLN SMPL W/DOSIMETRY CALCULATION CPT-4 
77307 TELETHX ISODOSE PLN CPLX W/BASIC DOSIMETRY CPT-4 
77316 BRACHYTX ISODOSE PLN SMPL W/DOSIMETRY CAL CPT-4 
77317 BRACHYTX ISODOSE PLN INTERMED W/DOSIMETRY CAL CPT-4 
77318 BRACHYTX ISODOSE PLN CPLX W/DOSIMETRY CAL CPT-4 
77321 SPEC TELETHX PORT PLN PARTS HEMIBDY TOT BDY CPT-4 
77326 BRACHYTX ISODOSE PLN SMPL CPT-4 
77327 BRACHYTX ISODOSE PLN INTRM CPT-4 
77328 BRACHYTX ISODOSE PLN CPLX CPT-4 
77331 SPEC DOSIM ONLY PRESCRIBED TREATING PHYS CPT-4 
77332 TX DEVICES DESIGN & CONSTRUCTION SIMPLE CPT-4 
77333 TX DEVICES DESIGN & CONSTRUCTION INTERMEDIATE CPT-4 
77336 CONTINUING MEDICAL PHYSICS CONSLTJ PR WK CPT-4 
77338 MLC IMRT DESIGN & CONSTRUCTION PER IMRT PLAN CPT-4 
77370 SPEC MEDICAL RADJ PHYSICS CONSLTJ CPT-4 
77371 RADIATION DELIVERY STEREOTACTIC CRANIAL COBALT CPT-4 
77372 RADIATION DELIVERY STEREOTACTIC CRANIAL LINEAR CPT-4 
77373 STEREOTACTIC BODY RADIATION DELIVERY CPT-4 
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77385 INTENSITY MODULATED RADIATION TX DLVR SIMPLE CPT-4 
77386 INTENSITY MODULATED RADIATION TX DLVR COMPLEX CPT-4 
77387 GUIDANCE FOR LOC OF TARGET VOL RADIAJ TX DLVR CPT-4 
77399 UNLIS MEDICAL RADJ DOSIM TX DEV SPEC SVCS CPT-4 
77401 RADIATION TX DELIVERY SUPERFICIAL&/ORTHO VOLTA CPT-4 
77402 RADIATION TREATMENT DELIVERY 1 MEV+ SIMPLE CPT-4 
77403 RADJ DLVR 1 AREA 1/PRLL OPSD PORTS SMPL 6-10MEV CPT-4 
77404 RADJ DLVR 1 AREA 1/PRLL OPSD PORTS SMPL 11-19MEV CPT-4 
77405 UNKNOWN PROCEDURE UNKN 
77406 RADJ DLVR 1 AREA 1/PRLL OPSD PORTS SMPL 20MEV/< CPT-4 
77407 RADIATION TX DELIVERY 1 MEV => INTERMEDIATE CPT-4 
77408 RADJ DLVR 2 AREAS 3/>PORTS 1 MLT BLKS 6-1MEV CPT-4 
77409 RADJ DLVR 2 AREAS 3/>PORTS 1 MLT BLKS 11-19MEV CPT-4 
77411 RADJ DLVR 2 AREAS 3/> PORTS 1 TX AREA 20 MEV/< CPT-4 
77412 RADIATION TREATMENT DELIVERY 1 MEV => COMPLEX CPT-4 
77413 RADJ DLVR 3/> AREAS CUSTOM BLKING 6-10MEV CPT-4 
77414 RADJ DLVR 3/> AREAS CUSTOM BLKING 11-19MEV CPT-4 
77416 RADJ DLVR 3/> AREAS CUSTOM BLKING 20MEV/< CPT-4 
77417 THERAPEUTIC RADIOLOGY PORT IMAGES(S) CPT-4 
77418 NTSTY MODUL DLVR 1/MLT FLDS/ARCS PR TX SESSION CPT-4 
77421 STRSC X-RAY GDN LOCLZJ TARGET VOL DLVR RADJ THER CPT-4 
77422 HIGH ENERGY NEUTRON RADJ TX DLVR 1 TX AREA CPT-4 
77423 HIGH ENERGY NEUTRON RADJ TX DLVR 1/> ISOCENTER CPT-4 
77424 INTRAOP RADIAJ TX DELIVER XRAY SINGLE TX SESSION CPT-4 
77425 INTRAOP RADIAJ TX DELIVER ELECTRONS SNGL TX SESS CPT-4 
77427 RADIATION TREATMENT MANAGEMENT 5 TREATMENTS CPT-4 
77431 RADIATION THERAPY MGMT 1/2 FRACTIONS ONLY CPT-4 
77432 STERETCTC RADIATION TX MANAGEMENT CRANIAL LESION CPT-4 
77435 STEREOTACTIC BODY RADIATION MANAGEMENT CPT-4 
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77469 INTRAOPERATIVE RADIATION TREATMENT MANAGEMENT CPT-4 
77470 SPECIAL TREATMENT PROCEDURE CPT-4 
77499 UNLISTED PROCEDURE THERAPEUTIC RADIOLOGY TX MGMT CPT-4 
77520 PROTON TX DELIVERY SIMPLE W/O COMPENSATION CPT-4 
77522 PROTON TX DELIVERY SIMPLE W/COMPENSATION CPT-4 
77523 PROTON TX DELIVERY INTERMEDIATE CPT-4 
77525 PROTON TX DELIVERY COMPLEX CPT-4 
77600 HYPERTHERMIA EXTERNAL GENERATED SUPERFICIAL CPT-4 
77605 HYPERTHERMIA EXTERNAL GENERATED DEEP CPT-4 
77610 HYPERTHERMIA INTERSTITIAL PROBE 5/< APPLICATORS CPT-4 
77615 HYPERTHERMIA INTERSTIAL PROBE 5/> APPLICATORS CPT-4 
77620 HYPERTHERMIA INTRACAVITARY PROBES CPT-4 
77750 NFS/INSTLJ RADIOELMNT SLN 3 MO FOLLOW-UP CARE CPT-4 
77761 INTRACAVITARY RADIATION SOURCE APPLIC SIMPLE CPT-4 
77762 INTRACAVITARY RADIATION SOURCE APPLIC INTERMED CPT-4 
77763 INTRACAVITARY RADIATION SOURCE APPLIC COMPLEX CPT-4 
77767 HDR RDNCL SKN SURF BRACHYTX LES </2CM/1 CHAN CPT-4 
77768 HDR RDNCL SK SRF BRCHYTX LES >2CM&2CHAN/MLT LES CPT-4 
77770 HDR RDNCL NTRSTL/INTRCAV BRACHYTX 1 CHANNEL CPT-4 
77771 HDR RDNCL NTRSTL/INTRCAV BRACHYTX 2-12 CHANNEL CPT-4 
77772 HDR RDNCL NTRSTL/INTRCAV BRACHYTX >12 CHANNELS CPT-4 
77776 INTERSTITIAL RADIATION SOURCE APPLIC SIMPLE CPT-4 
77777 INTERSTITIAL RADIATION SOURCE APPLIC INTERMED CPT-4 
77778 INTERSTITIAL RADIATION SOURCE APPLIC COMPLEX CPT-4 
77785 REMOTE AFTLD RADIONUCLIDE BRACHYTX  1 CHANNEL CPT-4 
77786 REMOTE AFTLD RADIONUCLIDE BRACHYTX  2-12 CHANNEL CPT-4 
77789 SURFACE APPLIC LOW DOSE RATE RADIONUCLIDE SOURCE CPT-4 
77790 SUPERVISION HANDLING LOADING RADIATION SOURCE CPT-4 
77799 UNLISTED PROCEDURE CLINICAL BRACHYTHERAPY CPT-4 
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G6001 ULTRASONIC GUID PLACEMENT RADIATION TX FIELDS HCPCS 
G6002 STEREOSCOPIC X-RAY GUID LOCALIZ TRG VOL DEL RT HCPCS 
G6003 RAD TX DEL 2 TX AREA PORT/PL OPP PORTS:TO 5 MEV HCPCS 
G6004 RAD TX DEL 1 TX AREA PORT/PL OPP PORTS: 6-10 MEV HCPCS 
G6005 RAD TX DEL 1 TX AREA PORT/PL OPP PORTS: 11-19 ME HCPCS 
G6006 RAD TX DEL 1 TX AREA PORT/PL OPP PORTS: 20 ME/> HCPCS 
G6007 RT DEL 2 SEP AR 3/> PT 1 TX AR MX BLKS:TO 5 MEV HCPCS 
G6008 RT DEL 2 SEP AR 3/> PT 1 TX AR MX BLKS:6-10 MEV HCPCS 
G6009 RT DEL 2 SEP AR 3/> PT 1 TX AR MX BLKS:11-19 MEV HCPCS 
G6010 RT DEL 2 SEP AR 3/> PT 1 TX AR MX BLKS:20 MEV/> HCPCS 
G6011 RAD TX DEL 3/> SEP TX AR CSTM BLOCKING; TO 5 MEV HCPCS 
G6012 RAD TX DEL 3/> SEP TX AR CSTM BLOCKING; 6-10 MEV HCPCS 
G6013 RAD TX DEL 3/> SEP TX AR CSTM BLOCKING;11-19 MEV HCPCS 
G6014 RAD TX DEL 3/> SEP TX AR CSTM BLOCKING;20 MEV/> HCPCS 
G6015 INTENSITY MODULATED TX DEL 1/MX FLDS PER TX SESS HCPCS 
G6016 COMP-BASED BEAM MOD TX DEL I PLND TX 3 > HR SESS HCPCS 
G6017 INTRA-FRAC LOC & TRACKING TARGET/PT M EA FRAC TX HCPCS 
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Appendix D: Chemotherapy Procedure Codes 
 
CODE PROCEDURE DESCRIPTION 
Code 
Type 
96413 CHEMO, IV INFUSION, 1 HR CPT-4 
96415 CHEMO, IV INFUSION, ADDL HR CPT-4 
96416 CHEMO PROLONG INFUSE W/PUMP CPT-4 
96417 CHEMO IV INFUS EACH ADDL SEQ CPT-4 
96409 INFUSION OF CHEMOTHERAPY INTO VEIN CPT-4 
96411 INFUSION OF DIFFERENT CHEMOTHERAPY DRUG OR SUBSTANCE INTO 
VEIN 
CPT-4 
96420 INJECTION OF CHEMOTHERAPY USING PUSH TECHNIQUE CPT-4 
96422 INFUSION OF CHEMOTHERAPY INTO ARTERY UP TO 1 HR CPT-4 
96423 INFUSION OF CHEMOTERHAPY INTO ARTERY CPT-4 
J2405 INJECTION ONDANSETRON HCL PER 1 MG CPT-4 
J2765 INJ METOCLOPRAMIDE HCL TO 10 MG CPT-4 
J9045 INJECTION CARBOPLATIN 50 MG CPT-4 
J9055 INJECTION CETUXIMAB 10 MG CPT-4 
J9190 INJECTION FLUOROURACIL 500 MG CPT-4 
J9267 INJECTION PACLITAXEL 1 MG CPT-4 
J9355 INJECTION TRASTUZUMAB 10 MG CPT-4 
96425 PROLONGED CHEMOTHERAPY INFUSION INTO ARTERY BY PORTABLE OR 
IMPLANTABLE PUMP, MORE THAN 8 HRS 
CPT-4 
96549 CHEMOTHERAPY PROCEDURE CPT-4 
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Appendix E: Other Oncology Procedure Codes 
 
CODE TYPE CODE DIAGNOSIS DESCRIPTION 
ICD-9 CM 147.0 Malignant neoplasm of superior wall of nasopharynx 
ICD-9 CM 147.1 Malignant neoplasm of posterior wall of nasopharynx 
ICD-9 CM 147.2 Malignant neoplasm of lateral wall of nasopharynx 
ICD-9 CM 147.3 Malignant neoplasm of anterior wall of nasopharynx 
ICD-9 CM 147.8 Malignant neoplasm of other specified sites of nasopharynx 
ICD-9 CM 147.9 Malignant neoplasm of nasopharynx, unspecified site 
ICD-9 CM 148.0 Malignant neoplasm of postcricoid region of hypopharynx 
ICD-9 CM 148.1 Malignant neoplasm of pyriform sinus 
ICD-9 CM 148.2 Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect 
ICD-9 CM 148.3 Malignant neoplasm of posterior hypopharyngeal wall 
ICD-9 CM 148.8 Malignant neoplasm of other specified sites of hypopharynx 
ICD-9 CM 148.9 Malignant neoplasm of hypopharynx, unspecified site 
ICD-9 CM 149.0 Malignant neoplasm of pharynx, unspecified 
ICD-9 CM 149.1 Malignant neoplasm of waldeyer's ring 
ICD-9 CM 149.8 Malignant neoplasm of other sites within the lip and oral cavity 
ICD-9 CM 149.9 Malignant neoplasm of ill-defined sites within the lip and oral cavity 
ICD-9 CM 150.0 Malignant neoplasm of cervical esophagus 
ICD-9 CM 150.1 Malignant neoplasm of thoracic esophagus 
ICD-9 CM 150.2 Malignant neoplasm of abdominal esophagus 
ICD-9 CM 150.3 Malignant neoplasm of upper third of esophagus 
ICD-9 CM 150.4 Malignant neoplasm of middle third of esophagus 
ICD-9 CM 150.5 Malignant neoplasm of lower third of esophagus 
ICD-9 CM 150.8 Malignant neoplasm of other specified part of esophagus 
ICD-9 CM 150.9 Malignant neoplasm of esophagus, unspecified site 
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ICD-9 CM 151.0 Malignant neoplasm of cardia 
ICD-9 CM 151.1 Malignant neoplasm of pylorus 
ICD-9 CM 151.2 Malignant neoplasm of pyloric antrum 
ICD-9 CM 151.3 Malignant neoplasm of fundus of stomach 
ICD-9 CM 151.4 Malignant neoplasm of body of stomach 
ICD-9 CM 151.5 Malignant neoplasm of lesser curvature of stomach, unspecified 
ICD-9 CM 151.6 Malignant neoplasm of greater curvature of stomach, unspecified 
ICD-9 CM 151.8 Malignant neoplasm of other specified sites of stomach 
ICD-9 CM 151.9 Malignant neoplasm of stomach, unspecified site 
ICD-9 CM 152.0 Malignant neoplasm of duodenum 
ICD-9 CM 152.1 Malignant neoplasm of jejunum 
ICD-9 CM 152.2 Malignant neoplasm of ileum 
ICD-9 CM 152.3 Malignant neoplasm of Meckel's diverticulum 
ICD-9 CM 152.8 Malignant neoplasm of other specified sites of small intestine 
ICD-9 CM 152.9 Malignant neoplasm of small intestine, unspecified site 
ICD-9 CM 153.0 Malignant neoplasm of hepatic flexure 
ICD-9 CM 153.1 Malignant neoplasm of transverse colon 
ICD-9 CM 153.2 Malignant neoplasm of descending colon 
ICD-9 CM 153.3 Malignant neoplasm of sigmoid colon 
ICD-9 CM 153.4 Malignant neoplasm of cecum 
ICD-9 CM 153.5 Malignant neoplasm of appendix vermiformis 
ICD-9 CM 153.6 Malignant neoplasm of ascending colon 
ICD-9 CM 153.7 Malignant neoplasm of splenic flexure 
ICD-9 CM 153.8 Malignant neoplasm of other specified sites of large intestine 
ICD-9 CM 153.9 Malignant neoplasm of colon, unspecified site 
ICD-9 CM 154.0 Malignant neoplasm of rectosigmoid junction 
ICD-9 CM 154.1 Malignant neoplasm of rectum 
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ICD-9 CM 154.2 Malignant neoplasm of anal canal 
ICD-9 CM 154.3 Malignant neoplasm of anus, unspecified site 
ICD-9 CM 154.8 
Malignant neoplasm of other sites of rectum, rectosigmoid junction, and 
anus 
ICD-9 CM 155.0 Malignant neoplasm of liver, primary 
ICD-9 CM 155.1 Malignant neoplasm of intrahepatic bile ducts 
ICD-9 CM 155.2 Malignant neoplasm of liver, not specified as primary or secondary 
ICD-9 CM 156.0 Malignant neoplasm of gallbladder 
ICD-9 CM 156.1 Malignant neoplasm of extrahepatic bile ducts 
ICD-9 CM 156.2 Malignant neoplasm of ampulla of vater 
ICD-9 CM 156.8 
Malignant neoplasm of other specified sites of gallbladder and extrahepatic 
bile ducts 
ICD-9 CM 156.9 Malignant neoplasm of biliary tract, part unspecified site 
ICD-9 CM 157.0 Malignant neoplasm of head of pancreas 
ICD-9 CM 157.1 Malignant neoplasm of body of pancreas 
ICD-9 CM 157.2 Malignant neoplasm of tail of pancreas 
ICD-9 CM 157.3 Malignant neoplasm of pancreatic duct 
ICD-9 CM 157.4 Malignant neoplasm of islets of langerhans 
ICD-9 CM 157.8 Malignant neoplasm of other specified sites of pancreas 
ICD-9 CM 157.9 Malignant neoplasm of pancreas, part unspecified 
ICD-9 CM 158.0 Malignant neoplasm of retroperitoneum 
ICD-9 CM 158.8 Malignant neoplasm of specified parts of peritoneum 
ICD-9 CM 158.9 Malignant neoplasm of peritoneum, unspecified 
ICD-9 CM 159.0 Malignant neoplasm of intestinal tract, part unspecified 
ICD-9 CM 159.1 Malignant neoplasm of spleen, not elsewhere classified 
ICD-9 CM 159.8 
Malignant neoplasm of other sites of digestive system and intra-abdominal 
organs 
ICD-9 CM 159.9 
Malignant neoplasm of ill-defined sites within the digestive organs and 
peritoneum 
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ICD-9 CM 160.0 Malignant neoplasm of nasal cavities 
ICD-9 CM 160.1 Malignant neoplasm of auditory tube, middle ear, and mastoid air cells 
ICD-9 CM 160.2 Malignant neoplasm of maxillary sinus 
ICD-9 CM 160.3 Malignant neoplasm of ethmoidal sinus 
ICD-9 CM 160.4 Malignant neoplasm of frontal sinus 
ICD-9 CM 160.5 Malignant neoplasm of sphenoidal sinus 
ICD-9 CM 160.8 Malignant neoplasm of other accessory sinuses 
ICD-9 CM 160.9 Malignant neoplasm of accessory sinus, unspecified 
ICD-9 CM 161.0 Malignant neoplasm of glottis 
ICD-9 CM 161.1 Malignant neoplasm of supraglottis 
ICD-9 CM 161.2 Malignant neoplasm of subglottis 
ICD-9 CM 162.0 Malignant neoplasm of trachea 
ICD-9 CM 162.2 Malignant neoplasm of main bronchus 
ICD-9 CM 162.3 Malignant neoplasm of upper lobe, bronchus or lung 
ICD-9 CM 162.4 Malignant neoplasm of middle lobe, bronchus or lung 
ICD-9 CM 162.5 Malignant neoplasm of lower lobe, bronchus or lung 
ICD-9 CM 162.8 Malignant neoplasm of other parts of bronchus or lung 
ICD-9 CM 162.9 Malignant neoplasm of bronchus and lung, unspecified 
ICD-9 CM 163.0 Malignant neoplasm of parietal pleura 
ICD-9 CM 163.1 Malignant neoplasm of visceral pleura 
ICD-9 CM 163.8 Malignant neoplasm of other specified sites of pleura 
ICD-9 CM 163.9 Malignant neoplasm of pleura, unspecified 
ICD-9 CM 164.0 Malignant neoplasm of thymus 
ICD-9 CM 164.1 Malignant neoplasm of heart 
ICD-9 CM 164.2 Malignant neoplasm of anterior mediastinum 
ICD-9 CM 164.3 Malignant neoplasm of posterior mediastinum 
ICD-9 CM 164.8 Malignant neoplasm of other parts of mediastinum 
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ICD-9 CM 164.9 Malignant neoplasm of mediastinum, part unspecified 
ICD-9 CM 165.0 Malignant neoplasm of upper respiratory tract, part unspecified 
ICD-9 CM 165.8 
Malignant neoplasm of other sites within the respiratory system and 
intrathoracic organs 
ICD-9 CM 165.9 Malignant neoplasm of ill-defined sites within the respiratory system 
ICD-9 CM 170.0 Malignant neoplasm of bones of skull and face, except mandible 
ICD-9 CM 170.1 Malignant neoplasm of mandible 
ICD-9 CM 170.2 Malignant neoplasm of vertebral column, excluding sacrum and coccyx 
ICD-9 CM 170.3 Malignant neoplasm of ribs, sternum, and clavicle 
ICD-9 CM 170.4 Malignant neoplasm of scapula and long bones of upper limb 
ICD-9 CM 170.5 Malignant neoplasm of short bones of upper limb 
ICD-9 CM 170.6 Malignant neoplasm of pelvic bones, sacrum, and coccyx 
ICD-9 CM 170.7 Malignant neoplasm of long bones of lower limb 
ICD-9 CM 170.8 Malignant neoplasm of short bones of lower limb 
ICD-9 CM 170.9 Malignant neoplasm of bone and articular cartilage, site unspecified 
ICD-9 CM 171.0 
Malignant neoplasm of connective and other soft tissue of head, face, and 
neck 
ICD-9 CM 171.2 
Malignant neoplasm of connective and other soft tissue of upper limb, 
including shoulder 
ICD-9 CM 171.3 
Malignant neoplasm of connective and other soft tissue of lower limb, 
including hip 
ICD-9 CM 171.4 Malignant neoplasm of connective and other soft tissue of thorax 
ICD-9 CM 171.5 Malignant neoplasm of connective and other soft tissue of abdomen 
ICD-9 CM 171.6 Malignant neoplasm of connective and other soft tissue of pelvis 
ICD-9 CM 171.7 Malignant neoplasm of connective and other soft tissue of trunk, unspecified 
ICD-9 CM 171.8 
Malignant neoplasm of other specified sites of connective and other soft 
tissue 
ICD-9 CM 171.9 Malignant neoplasm of connective and other soft tissue, site unspecified 
ICD-9 CM 173.00 Unspecified malignant neoplasm of skin of lip 
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ICD-9 CM 173.01 Basal cell carcinoma of skin of lip 
ICD-9 CM 173.02 Squamous cell carcinoma of skin of lip 
ICD-9 CM 173.09 Other specified malignant neoplasm of skin of lip 
ICD-9 CM 173.10 Unspecified malignant neoplasm of eyelid, including canthus 
ICD-9 CM 173.11 Basal cell carcinoma of eyelid, including canthus 
ICD-9 CM 173.12 Squamous cell carcinoma of eyelid, including canthus 
ICD-9 CM 173.19 Other specified malignant neoplasm of eyelid, including canthus 
ICD-9 CM 173.20 Unspecified malignant neoplasm of skin of ear and external auditory canal 
ICD-9 CM 173.21 Basal cell carcinoma of skin of ear and external auditory canal 
ICD-9 CM 173.22 Squamous cell carcinoma of skin of ear and external auditory canal 
ICD-9 CM 173.29 
Other specified malignant neoplasm of skin of ear and external auditory 
canal 
ICD-9 CM 173.30 
Unspecified malignant neoplasm of skin of other and unspecified parts of 
face 
ICD-9 CM 173.31 Basal cell carcinoma of skin of other and unspecified parts of face 
ICD-9 CM 173.32 Squamous cell carcinoma of skin of other and unspecified parts of face 
ICD-9 CM 173.39 
Other specified malignant neoplasm of skin of other and unspecified parts of 
face 
ICD-9 CM 173.40 Unspecified malignant neoplasm of scalp and skin of neck 
ICD-9 CM 173.41 Basal cell carcinoma of scalp and skin of neck 
ICD-9 CM 173.42 Squamous cell carcinoma of scalp and skin of neck 
ICD-9 CM 173.49 Other specified malignant neoplasm of scalp and skin of neck 
ICD-9 CM 173.50 Unspecified malignant neoplasm of skin of trunk, except scrotum 
ICD-9 CM 173.51 Basal cell carcinoma of skin of trunk, except scrotum 
ICD-9 CM 173.52 Squamous cell carcinoma of skin of trunk, except scrotum 
ICD-9 CM 173.59 Other specified malignant neoplasm of skin of trunk, except scrotum 
ICD-9 CM 173.60 Unspecified malignant neoplasm of skin of upper limb, including shoulder 
ICD-9 CM 173.61 Basal cell carcinoma of skin of upper limb, including shoulder 
ICD-9 CM 173.62 Squamous cell carcinoma of skin of upper limb, including shoulder 
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ICD-9 CM 173.69 Other specified malignant neoplasm of skin of upper limb, including shoulder 
ICD-9 CM 173.70 Unspecified malignant neoplasm of skin of lower limb, including hip 
ICD-9 CM 173.71 Basal cell carcinoma of skin of lower limb, including hip 
ICD-9 CM 173.72 Squamous cell carcinoma of skin of lower limb, including hip 
ICD-9 CM 173.79 Other specified malignant neoplasm of skin of lower limb, including hip 
ICD-9 CM 173.80 Unspecified malignant neoplasm of other specified sites of skin 
ICD-9 CM 173.81 Basal cell carcinoma of other specified sites of skin 
ICD-9 CM 173.82 Squamous cell carcinoma of other specified sites of skin 
ICD-9 CM 173.89 Other specified malignant neoplasm of other specified sites of skin 
ICD-9 CM 173.90 Unspecified malignant neoplasm of skin, site unspecified 
ICD-9 CM 173.91 Basal cell carcinoma of skin, site unspecified 
ICD-9 CM 173.92 Squamous cell carcinoma of skin, site unspecified 
ICD-9 CM 173.99 Other specified malignant neoplasm of skin, site unspecified 
ICD-9 CM 174.0 Malignant neoplasm of nipple and areola of female breast 
ICD-9 CM 174.1 Malignant neoplasm of central portion of female breast 
ICD-9 CM 174.2 Malignant neoplasm of upper-inner quadrant of female breast 
ICD-9 CM 174.3 Malignant neoplasm of lower-inner quadrant of female breast 
ICD-9 CM 174.4 Malignant neoplasm of upper-outer quadrant of female breast 
ICD-9 CM 174.5 Malignant neoplasm of lower-outer quadrant of female breast 
ICD-9 CM 174.6 Malignant neoplasm of axillary tail of female breast 
ICD-9 CM 174.8 Malignant neoplasm of other specified sites of female breast 
ICD-9 CM 174.9 Malignant neoplasm of breast (female), unspecified 
ICD-9 CM 175.0 Malignant neoplasm of nipple and areola of male breast 
ICD-9 CM 175.9 Malignant neoplasm of other and unspecified sites of male breast 
ICD-9 CM 179 Malignant neoplasm of uterus, part unspecified 
ICD-9 CM 180.0 Malignant neoplasm of endocervix 
ICD-9 CM 180.1 Malignant neoplasm of exocervix 
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ICD-9 CM 180.8 Malignant neoplasm of other specified sites of cervix 
ICD-9 CM 180.9 Malignant neoplasm of cervix uteri, unspecified site 
ICD-9 CM 181 Malignant neoplasm of placenta 
ICD-9 CM 182.0 Malignant neoplasm of corpus uteri, except isthmus 
ICD-9 CM 182.1 Malignant neoplasm of isthmus 
ICD-9 CM 182.8 Malignant neoplasm of other specified sites of body of uterus 
ICD-9 CM 183.0 Malignant neoplasm of ovary 
ICD-9 CM 183.2 Malignant neoplasm of fallopian tube 
ICD-9 CM 183.3 Malignant neoplasm of broad ligament of uterus 
ICD-9 CM 183.4 Malignant neoplasm of parametrium 
ICD-9 CM 183.5 Malignant neoplasm of round ligament of uterus 
ICD-9 CM 183.8 Malignant neoplasm of other specified sites of uterine adnexa 
ICD-9 CM 183.9 Malignant neoplasm of uterine adnexa, unspecified site 
ICD-9 CM 184.0 Malignant neoplasm of vagina 
ICD-9 CM 184.1 Malignant neoplasm of labia majora 
ICD-9 CM 184.2 Malignant neoplasm of labia minora 
ICD-9 CM 184.3 Malignant neoplasm of clitoris 
ICD-9 CM 184.4 Malignant neoplasm of vulva, unspecified site 
ICD-9 CM 184.8 Malignant neoplasm of other specified sites of female genital organs 
ICD-9 CM 184.9 Malignant neoplasm of female genital organ, site unspecified 
ICD-9 CM 185 Malignant neoplasm of prostate 
ICD-9 CM 186.0 Malignant neoplasm of undescended testis 
ICD-9 CM 186.9 Malignant neoplasm of other and unspecified testis 
ICD-9 CM 187.1 Malignant neoplasm of prepuce 
ICD-9 CM 187.2 Malignant neoplasm of glans penis 
ICD-9 CM 187.3 Malignant neoplasm of body of penis 
ICD-9 CM 187.4 Malignant neoplasm of penis, part unspecified 
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ICD-9 CM 187.5 Malignant neoplasm of epididymis 
ICD-9 CM 187.6 Malignant neoplasm of spermatic cord 
ICD-9 CM 187.7 Malignant neoplasm of scrotum 
ICD-9 CM 187.8 Malignant neoplasm of other specified sites of male genital organs 
ICD-9 CM 187.9 Malignant neoplasm of male genital organ, site unspecified 
ICD-9 CM 188.0 Malignant neoplasm of trigone of urinary bladder 
ICD-9 CM 188.1 Malignant neoplasm of dome of urinary bladder 
ICD-9 CM 188.2 Malignant neoplasm of lateral wall of urinary bladder 
ICD-9 CM 188.3 Malignant neoplasm of anterior wall of urinary bladder 
ICD-9 CM 188.4 Malignant neoplasm of posterior wall of urinary bladder 
ICD-9 CM 188.5 Malignant neoplasm of bladder neck 
ICD-9 CM 188.6 Malignant neoplasm of ureteric orifice 
ICD-9 CM 188.7 Malignant neoplasm of urachus 
ICD-9 CM 188.8 Malignant neoplasm of other specified sites of bladder 
ICD-9 CM 188.9 Malignant neoplasm of bladder, part unspecified 
ICD-9 CM 189.0 Malignant neoplasm of kidney, except pelvis 
ICD-9 CM 189.1 Malignant neoplasm of renal pelvis 
ICD-9 CM 189.2 Malignant neoplasm of ureter 
ICD-9 CM 189.3 Malignant neoplasm of urethra 
ICD-9 CM 189.4 Malignant neoplasm of paraurethral glands 
ICD-9 CM 189.8 Malignant neoplasm of other specified sites of urinary organs 
ICD-9 CM 189.9 Malignant neoplasm of urinary organ, site unspecified 
ICD-9 CM 190.0 
Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and 
choroid 
ICD-9 CM 190.1 Malignant neoplasm of orbit 
ICD-9 CM 190.2 Malignant neoplasm of lacrimal gland 
ICD-9 CM 190.3 Malignant neoplasm of conjunctiva 
ICD-9 CM 190.4 Malignant neoplasm of cornea 
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ICD-9 CM 190.5 Malignant neoplasm of retina 
ICD-9 CM 190.6 Malignant neoplasm of choroid 
ICD-9 CM 190.7 Malignant neoplasm of lacrimal duct 
ICD-9 CM 190.8 Malignant neoplasm of other specified sites of eye 
ICD-9 CM 190.9 Malignant neoplasm of eye, part unspecified 
ICD-9 CM 191.0 Malignant neoplasm of cerebrum, except lobes and ventricles 
ICD-9 CM 191.1 Malignant neoplasm of frontal lobe 
ICD-9 CM 191.2 Malignant neoplasm of temporal lobe 
ICD-9 CM 191.3 Malignant neoplasm of parietal lobe 
ICD-9 CM 191.4 Malignant neoplasm of occipital lobe 
ICD-9 CM 191.5 Malignant neoplasm of ventricles 
ICD-9 CM 191.6 Malignant neoplasm of cerebellum nos 
ICD-9 CM 191.7 Malignant neoplasm of brain stem 
ICD-9 CM 191.8 Malignant neoplasm of other parts of brain 
ICD-9 CM 191.9 Malignant neoplasm of brain, unspecified 
ICD-9 CM 192.0 Malignant neoplasm of cranial nerves 
ICD-9 CM 192.1 Malignant neoplasm of cerebral meninges 
ICD-9 CM 192.2 Malignant neoplasm of spinal cord 
ICD-9 CM 192.3 Malignant neoplasm of spinal meninges 
ICD-9 CM 192.8 Malignant neoplasm of other specified sites of nervous system 
ICD-9 CM 192.9 Malignant neoplasm of nervous system, part unspecified 
ICD-9 CM 193 Malignant neoplasm of thyroid gland 
ICD-9 CM 194.0 Malignant neoplasm of adrenal gland 
ICD-9 CM 194.1 Malignant neoplasm of parathyroid gland 
ICD-9 CM 194.3 Malignant neoplasm of pituitary gland and craniopharyngeal duct 
ICD-9 CM 194.4 Malignant neoplasm of pineal gland 
ICD-9 CM 194.5 Malignant neoplasm of carotid body 
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ICD-9 CM 194.6 Malignant neoplasm of aortic body and other paraganglia 
ICD-9 CM 194.8 Malignant neoplasm of other endocrine glands and related structures 
ICD-9 CM 194.9 Malignant neoplasm of endocrine gland, site unspecified 
ICD-9 CM 195.0 Malignant neoplasm of head, face, and neck 
ICD-9 CM 195.1 Malignant neoplasm of thorax 
ICD-9 CM 195.2 Malignant neoplasm of abdomen 
ICD-9 CM 195.3 Malignant neoplasm of pelvis 
ICD-9 CM 195.4 Malignant neoplasm of upper limb 
ICD-9 CM 195.5 Malignant neoplasm of lower limb 
ICD-9 CM 195.8 Malignant neoplasm of other specified sites 
ICD-9 CM 196.0 
Secondary and unspecified malignant neoplasm of lymph nodes of head, 
face, and neck 
ICD-9 CM 196.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes 
ICD-9 CM 196.2 
Secondary and unspecified malignant neoplasm of intra-abdominal lymph 
nodes 
ICD-9 CM 196.3 
Secondary and unspecified malignant neoplasm of lymph nodes of axilla and 
upper limb 
ICD-9 CM 196.5 
Secondary and unspecified malignant neoplasm of lymph nodes of inguinal 
region and lower limb 
ICD-9 CM 196.6 Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes 
ICD-9 CM 196.8 
Secondary and unspecified malignant neoplasm of lymph nodes of multiple 
sites 
ICD-9 CM 196.9 
Secondary and unspecified malignant neoplasm of lymph nodes, site 
unspecified 
ICD-9 CM 197.0 Secondary malignant neoplasm of lung 
ICD-9 CM 197.1 Secondary malignant neoplasm of mediastinum 
ICD-9 CM 197.2 Secondary malignant neoplasm of pleura 
ICD-9 CM 197.3 Secondary malignant neoplasm of other respiratory organs 
ICD-9 CM 197.4 Secondary malignant neoplasm of small intestine including duodenum 
ICD-9 CM 197.5 Secondary malignant neoplasm of large intestine and rectum 
 92 
ICD-9 CM 197.6 Secondary malignant neoplasm of retroperitoneum and peritoneum 
ICD-9 CM 197.7 Malignant neoplasm of liver, secondary 
ICD-9 CM 197.8 Secondary malignant neoplasm of other digestive organs and spleen 
ICD-9 CM 198.0 Secondary malignant neoplasm of kidney 
ICD-9 CM 198.1 Secondary malignant neoplasm of other urinary organs 
ICD-9 CM 198.2 Secondary malignant neoplasm of skin 
ICD-9 CM 198.3 Secondary malignant neoplasm of brain and spinal cord 
ICD-9 CM 198.4 Secondary malignant neoplasm of other parts of nervous system 
ICD-9 CM 198.5 Secondary malignant neoplasm of bone and bone marrow 
ICD-9 CM 198.6 Secondary malignant neoplasm of ovary 
ICD-9 CM 198.7 Secondary malignant neoplasm of adrenal gland 
ICD-9 CM 198.81 Secondary malignant neoplasm of breast 
ICD-9 CM 198.82 Secondary malignant neoplasm of genital organs 
ICD-9 CM 198.89 Secondary malignant neoplasm of other specified sites 
ICD-9 CM 199.0 Disseminated malignant neoplasm without specification of site 
ICD-9 CM 199.1 Other malignant neoplasm without specification of site 
ICD-9 CM 199.2 Malignant neoplasm associated with transplant organ 
ICD-9 CM 202.80 
Other malignant lymphomas, unspecified site, extranodal and solid organ 
sites 
ICD-9 CM 202.81 Other malignant lymphomas, lymph nodes of head, face, and neck 
ICD-9 CM 202.82 Other malignant lymphomas, intrathoracic lymph nodes 
ICD-9 CM 202.83 Other malignant lymphomas, intra-abdominal lymph nodes 
ICD-9 CM 202.84 Other malignant lymphomas, lymph nodes of axilla and upper limb 
ICD-9 CM 202.85 Other malignant lymphomas, lymph nodes of inguinal region and lower limb 
ICD-9 CM 202.86 Other malignant lymphomas, intrapelvic lymph nodes 
ICD-9 CM 202.87 Other malignant lymphomas, spleen 
ICD-9 CM 202.88 Other malignant lymphomas, lymph nodes of multiple sites 
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ICD-9 CM 202.90 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, unspecified site, extranodal and solid organ sites 
ICD-9 CM 202.91 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, lymph nodes of head, face, and neck 
ICD-9 CM 202.92 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, intrathoracic lymph nodes 
ICD-9 CM 202.93 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, intra-abdominal lymph nodes 
ICD-9 CM 202.94 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, lymph nodes of axilla and upper limb 
ICD-9 CM 202.95 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, lymph nodes of inguinal region and lower limb 
ICD-9 CM 202.96 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, intrapelvic lymph nodes 
ICD-9 CM 202.97 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, spleen 
ICD-9 CM 202.98 
Other and unspecified malignant neoplasms of lymphoid and histiocytic 
tissue, lymph nodes of multiple sites 
ICD-9 CM 203.80 
Other immunoproliferative neoplasms, without mention of having achieved 
remission 
ICD-9 CM 203.81 Other immunoproliferative neoplasms, in remission 
ICD-9 CM 203.82 Other immunoproliferative neoplasms, in relapse 
ICD-10 CM C11.0 Malignant neoplasm of superior wall of nasopharynx 
ICD-10 CM C11.1 Malignant neoplasm of posterior wall of nasopharynx 
ICD-10 CM C11.2 Malignant neoplasm of lateral wall of nasopharynx 
ICD-10 CM C11.3 Malignant neoplasm of anterior wall of nasopharynx 
ICD-10 CM C11.8 Malignant neoplasm of overlapping sites of nasopharynx 
ICD-10 CM C11.9 Malignant neoplasm of nasopharynx, unspecified 
ICD-10 CM C12 Malignant neoplasm of pyriform sinus 
ICD-10 CM C13.0 Malignant neoplasm of postcricoid region 
ICD-10 CM C13.1 Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect 
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ICD-10 CM C13.2 Malignant neoplasm of posterior wall of hypopharynx 
ICD-10 CM C13.8 Malignant neoplasm of overlapping sites of hypopharynx 
ICD-10 CM C13.9 Malignant neoplasm of hypopharynx, unspecified 
ICD-10 CM C15.3 Malignant neoplasm of upper third of esophagus 
ICD-10 CM C15.4 Malignant neoplasm of middle third of esophagus 
ICD-10 CM C15.5 Malignant neoplasm of lower third of esophagus 
ICD-10 CM C15.8 Malignant neoplasm of overlapping sites of esophagus 
ICD-10 CM C15.9 Malignant neoplasm of esophagus, unspecified 
ICD-10 CM C16.0 Malignant neoplasm of cardia 
ICD-10 CM C16.1 Malignant neoplasm of fundus of stomach 
ICD-10 CM C16.2 Malignant neoplasm of body of stomach 
ICD-10 CM C16.3 Malignant neoplasm of pyloric antrum 
ICD-10 CM C16.4 Malignant neoplasm of pylorus 
ICD-10 CM C16.5 Malignant neoplasm of lesser curvature of stomach, unspecified 
ICD-10 CM C16.6 Malignant neoplasm of greater curvature of stomach, unspecified 
ICD-10 CM C16.8 Malignant neoplasm of overlapping sites of stomach 
ICD-10 CM C16.9 Malignant neoplasm of stomach, unspecified 
ICD-10 CM C17.0 Malignant neoplasm of duodenum 
ICD-10 CM C17.1 Malignant neoplasm of jejunum 
ICD-10 CM C17.2 Malignant neoplasm of ileum 
ICD-10 CM C17.3 Meckel's diverticulum, malignant 
ICD-10 CM C17.8 Malignant neoplasm of overlapping sites of small intestine 
ICD-10 CM C17.9 Malignant neoplasm of small intestine, unspecified 
ICD-10 CM C18.0 Malignant neoplasm of cecum 
ICD-10 CM C18.1 Malignant neoplasm of appendix 
ICD-10 CM C18.2 Malignant neoplasm of ascending colon 
ICD-10 CM C18.3 Malignant neoplasm of hepatic flexure 
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ICD-10 CM C18.4 Malignant neoplasm of transverse colon 
ICD-10 CM C18.5 Malignant neoplasm of splenic flexure 
ICD-10 CM C18.6 Malignant neoplasm of descending colon 
ICD-10 CM C18.7 Malignant neoplasm of sigmoid colon 
ICD-10 CM C18.8 Malignant neoplasm of overlapping sites of colon 
ICD-10 CM C18.9 Malignant neoplasm of colon, unspecified 
ICD-10 CM C19 Malignant neoplasm of rectosigmoid junction 
ICD-10 CM C20 Malignant neoplasm of rectum 
ICD-10 CM C21.0 Malignant neoplasm of anus, unspecified 
ICD-10 CM C21.1 Malignant neoplasm of anal canal 
ICD-10 CM C21.2 Malignant neoplasm of cloacogenic zone 
ICD-10 CM C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal 
ICD-10 CM C22.0 Liver cell carcinoma 
ICD-10 CM C22.1 Intrahepatic bile duct carcinoma 
ICD-10 CM C22.2 Hepatoblastoma 
ICD-10 CM C22.3 Angiosarcoma of liver 
ICD-10 CM C22.4 Other sarcomas of liver 
ICD-10 CM C22.7 Other specified carcinomas of liver 
ICD-10 CM C22.8 Malignant neoplasm of liver, primary, unspecified as to type 
ICD-10 CM C22.9 Malignant neoplasm of liver, not specified as primary or secondary 
ICD-10 CM C23 Malignant neoplasm of gallbladder 
ICD-10 CM C24.0 Malignant neoplasm of extrahepatic bile duct 
ICD-10 CM C24.1 Malignant neoplasm of ampulla of Vater 
ICD-10 CM C24.8 Malignant neoplasm of overlapping sites of biliary tract 
ICD-10 CM C24.9 Malignant neoplasm of biliary tract, unspecified 
ICD-10 CM C25.0 Malignant neoplasm of head of pancreas 
ICD-10 CM C25.1 Malignant neoplasm of body of pancreas 
 96 
ICD-10 CM C25.2 Malignant neoplasm of tail of pancreas 
ICD-10 CM C25.3 Malignant neoplasm of pancreatic duct 
ICD-10 CM C25.4 Malignant neoplasm of endocrine pancreas 
ICD-10 CM C25.7 Malignant neoplasm of other parts of pancreas 
ICD-10 CM C25.8 Malignant neoplasm of overlapping sites of pancreas 
ICD-10 CM C25.9 Malignant neoplasm of pancreas, unspecified 
ICD-10 CM C26.0 Malignant neoplasm of intestinal tract, part unspecified 
ICD-10 CM C26.1 Malignant neoplasm of spleen 
ICD-10 CM C26.9 Malignant neoplasm of ill-defined sites within the digestive system 
ICD-10 CM C30.0 Malignant neoplasm of nasal cavity 
ICD-10 CM C30.1 Malignant neoplasm of middle ear 
ICD-10 CM C31.0 Malignant neoplasm of maxillary sinus 
ICD-10 CM C31.1 Malignant neoplasm of ethmoidal sinus 
ICD-10 CM C31.2 Malignant neoplasm of frontal sinus 
ICD-10 CM C31.3 Malignant neoplasm of sphenoid sinus 
ICD-10 CM C31.8 Malignant neoplasm of overlapping sites of accessory sinuses 
ICD-10 CM C31.9 Malignant neoplasm of accessory sinus, unspecified 
ICD-10 CM C32.0 Malignant neoplasm of glottis 
ICD-10 CM C32.1 Malignant neoplasm of supraglottis 
ICD-10 CM C32.2 Malignant neoplasm of subglottis 
ICD-10 CM C32.3 Malignant neoplasm of laryngeal cartilage 
ICD-10 CM C33 Malignant neoplasm of trachea 
ICD-10 CM C34.00 Malignant neoplasm of unspecified main bronchus 
ICD-10 CM C34.01 Malignant neoplasm of right main bronchus 
ICD-10 CM C34.02 Malignant neoplasm of left main bronchus 
ICD-10 CM C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung 
ICD-10 CM C34.11 Malignant neoplasm of upper lobe, right bronchus or lung 
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ICD-10 CM C34.12 Malignant neoplasm of upper lobe, left bronchus or lung 
ICD-10 CM C34.2 Malignant neoplasm of middle lobe, bronchus or lung 
ICD-10 CM C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung 
ICD-10 CM C34.31 Malignant neoplasm of lower lobe, right bronchus or lung 
ICD-10 CM C34.32 Malignant neoplasm of lower lobe, left bronchus or lung 
ICD-10 CM C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung 
ICD-10 CM C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung 
ICD-10 CM C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung 
ICD-10 CM C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung 
ICD-10 CM C34.91 Malignant neoplasm of unspecified part of right bronchus or lung 
ICD-10 CM C34.92 Malignant neoplasm of unspecified part of left bronchus or lung 
ICD-10 CM C37 Malignant neoplasm of thymus 
ICD-10 CM C38.0 Malignant neoplasm of heart 
ICD-10 CM C38.1 Malignant neoplasm of anterior mediastinum 
ICD-10 CM C38.2 Malignant neoplasm of posterior mediastinum 
ICD-10 CM C38.3 Malignant neoplasm of mediastinum, part unspecified 
ICD-10 CM C38.4 Malignant neoplasm of pleura 
ICD-10 CM C38.8 Malignant neoplasm of overlapping sites of heart, mediastinum and pleura 
ICD-10 CM C39.0 Malignant neoplasm of upper respiratory tract, part unspecified 
ICD-10 CM C39.9 Malignant neoplasm of lower respiratory tract, part unspecified 
ICD-10 CM C40.00 Malignant neoplasm of scapula and long bones of unspecified upper limb 
ICD-10 CM C40.01 Malignant neoplasm of scapula and long bones of right upper limb 
ICD-10 CM C40.02 Malignant neoplasm of scapula and long bones of left upper limb 
ICD-10 CM C40.10 Malignant neoplasm of short bones of unspecified upper limb 
ICD-10 CM C40.11 Malignant neoplasm of short bones of right upper limb 
ICD-10 CM C40.12 Malignant neoplasm of short bones of left upper limb 
ICD-10 CM C40.20 Malignant neoplasm of long bones of unspecified lower limb 
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ICD-10 CM C40.21 Malignant neoplasm of long bones of right lower limb 
ICD-10 CM C40.22 Malignant neoplasm of long bones of left lower limb 
ICD-10 CM C40.30 Malignant neoplasm of short bones of unspecified lower limb 
ICD-10 CM C40.31 Malignant neoplasm of short bones of right lower limb 
ICD-10 CM C40.32 Malignant neoplasm of short bones of left lower limb 
ICD-10 CM C40.80 
Malignant neoplasm of overlapping sites of bone and articular cartilage of 
unspecified limb 
ICD-10 CM C40.81 
Malignant neoplasm of overlapping sites of bone and articular cartilage of 
right limb 
ICD-10 CM C40.82 
Malignant neoplasm of overlapping sites of bone and articular cartilage of 
left limb 
ICD-10 CM C40.90 
Malignant neoplasm of unspecified bones and articular cartilage of 
unspecified limb 
ICD-10 CM C40.91 Malignant neoplasm of unspecified bones and articular cartilage of right limb 
ICD-10 CM C40.92 Malignant neoplasm of unspecified bones and articular cartilage of left limb 
ICD-10 CM C41.0 Malignant neoplasm of bones of skull and face 
ICD-10 CM C41.1 Malignant neoplasm of mandible 
ICD-10 CM C41.2 Malignant neoplasm of vertebral column 
ICD-10 CM C41.3 Malignant neoplasm of ribs, sternum and clavicle 
ICD-10 CM C41.4 Malignant neoplasm of pelvic bones, sacrum and coccyx 
ICD-10 CM C41.9 Malignant neoplasm of bone and articular cartilage, unspecified 
ICD-10 CM C44.00 Unspecified malignant neoplasm of skin of lip 
ICD-10 CM C44.01 Basal cell carcinoma of skin of lip 
ICD-10 CM C44.02 Squamous cell carcinoma of skin of lip 
ICD-10 CM C44.09 Other specified malignant neoplasm of skin of lip 
ICD-10 CM C44.101 
Unspecified malignant neoplasm of skin of unspecified eyelid, including 
canthus 
ICD-10 CM C44.102 Unspecified malignant neoplasm of skin of right eyelid, including canthus 
ICD-10 CM C44.109 Unspecified malignant neoplasm of skin of left eyelid, including canthus 
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ICD-10 CM C44.111 Basal cell carcinoma of skin of unspecified eyelid, including canthus 
ICD-10 CM C44.112 Basal cell carcinoma of skin of right eyelid, including canthus 
ICD-10 CM C44.119 Basal cell carcinoma of skin of left eyelid, including canthus 
ICD-10 CM C44.121 Squamous cell carcinoma of skin of unspecified eyelid, including canthus 
ICD-10 CM C44.122 Squamous cell carcinoma of skin of right eyelid, including canthus 
ICD-10 CM C44.129 Squamous cell carcinoma of skin of left eyelid, including canthus 
ICD-10 CM C44.191 
Other specified malignant neoplasm of skin of unspecified eyelid, including 
canthus 
ICD-10 CM C44.192 Other specified malignant neoplasm of skin of right eyelid, including canthus 
ICD-10 CM C44.199 Other specified malignant neoplasm of skin of left eyelid, including canthus 
ICD-10 CM C44.201 
Unspecified malignant neoplasm of skin of unspecified ear and external 
auricular canal 
ICD-10 CM C44.202 
Unspecified malignant neoplasm of skin of right ear and external auricular 
canal 
ICD-10 CM C44.209 
Unspecified malignant neoplasm of skin of left ear and external auricular 
canal 
ICD-10 CM C44.211 Basal cell carcinoma of skin of unspecified ear and external auricular canal 
ICD-10 CM C44.212 Basal cell carcinoma of skin of right ear and external auricular canal 
ICD-10 CM C44.219 Basal cell carcinoma of skin of left ear and external auricular canal 
ICD-10 CM C44.221 
Squamous cell carcinoma of skin of unspecified ear and external auricular 
canal 
ICD-10 CM C44.222 Squamous cell carcinoma of skin of right ear and external auricular canal 
ICD-10 CM C44.229 Squamous cell carcinoma of skin of left ear and external auricular canal 
ICD-10 CM C44.291 
Other specified malignant neoplasm of skin of unspecified ear and external 
auricular canal 
ICD-10 CM C44.292 
Other specified malignant neoplasm of skin of right ear and external 
auricular canal 
ICD-10 CM C44.299 
Other specified malignant neoplasm of skin of left ear and external auricular 
canal 
ICD-10 CM C44.300 Unspecified malignant neoplasm of skin of unspecified part of face 
 100 
ICD-10 CM C44.301 Unspecified malignant neoplasm of skin of nose 
ICD-10 CM C44.309 Unspecified malignant neoplasm of skin of other parts of face 
ICD-10 CM C44.310 Basal cell carcinoma of skin of unspecified parts of face 
ICD-10 CM C44.311 Basal cell carcinoma of skin of nose 
ICD-10 CM C44.319 Basal cell carcinoma of skin of other parts of face 
ICD-10 CM C44.320 Squamous cell carcinoma of skin of unspecified parts of face 
ICD-10 CM C44.321 Squamous cell carcinoma of skin of nose 
ICD-10 CM C44.329 Squamous cell carcinoma of skin of other parts of face 
ICD-10 CM C44.390 Other specified malignant neoplasm of skin of unspecified parts of face 
ICD-10 CM C44.391 Other specified malignant neoplasm of skin of nose 
ICD-10 CM C44.399 Other specified malignant neoplasm of skin of other parts of face 
ICD-10 CM C44.40 Unspecified malignant neoplasm of skin of scalp and neck 
ICD-10 CM C44.41 Basal cell carcinoma of skin of scalp and neck 
ICD-10 CM C44.42 Squamous cell carcinoma of skin of scalp and neck 
ICD-10 CM C44.49 Other specified malignant neoplasm of skin of scalp and neck 
ICD-10 CM C44.500 Unspecified malignant neoplasm of anal skin 
ICD-10 CM C44.501 Unspecified malignant neoplasm of skin of breast 
ICD-10 CM C44.509 Unspecified malignant neoplasm of skin of other part of trunk 
ICD-10 CM C44.510 Basal cell carcinoma of anal skin 
ICD-10 CM C44.511 Basal cell carcinoma of skin of breast 
ICD-10 CM C44.519 Basal cell carcinoma of skin of other part of trunk 
ICD-10 CM C44.520 Squamous cell carcinoma of anal skin 
ICD-10 CM C44.521 Squamous cell carcinoma of skin of breast 
ICD-10 CM C44.529 Squamous cell carcinoma of skin of other part of trunk 
ICD-10 CM C44.590 Other specified malignant neoplasm of anal skin 
ICD-10 CM C44.591 Other specified malignant neoplasm of skin of breast 
ICD-10 CM C44.599 Other specified malignant neoplasm of skin of other part of trunk 
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ICD-10 CM C44.601 
Unspecified malignant neoplasm of skin of unspecified upper limb, including 
shoulder 
ICD-10 CM C44.602 
Unspecified malignant neoplasm of skin of right upper limb, including 
shoulder 
ICD-10 CM C44.609 
Unspecified malignant neoplasm of skin of left upper limb, including 
shoulder 
ICD-10 CM C44.611 Basal cell carcinoma of skin of unspecified upper limb, including shoulder 
ICD-10 CM C44.612 Basal cell carcinoma of skin of right upper limb, including shoulder 
ICD-10 CM C44.619 Basal cell carcinoma of skin of left upper limb, including shoulder 
ICD-10 CM C44.621 
Squamous cell carcinoma of skin of unspecified upper limb, including 
shoulder 
ICD-10 CM C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder 
ICD-10 CM C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder 
ICD-10 CM C44.691 
Other specified malignant neoplasm of skin of unspecified upper limb, 
including shoulder 
ICD-10 CM C44.692 
Other specified malignant neoplasm of skin of right upper limb, including 
shoulder 
ICD-10 CM C44.699 
Other specified malignant neoplasm of skin of left upper limb, including 
shoulder 
ICD-10 CM C44.701 
Unspecified malignant neoplasm of skin of unspecified lower limb, including 
hip 
ICD-10 CM C44.702 Unspecified malignant neoplasm of skin of right lower limb, including hip 
ICD-10 CM C44.709 Unspecified malignant neoplasm of skin of left lower limb, including hip 
ICD-10 CM C44.711 Basal cell carcinoma of skin of unspecified lower limb, including hip 
ICD-10 CM C44.712 Basal cell carcinoma of skin of right lower limb, including hip 
ICD-10 CM C44.719 Basal cell carcinoma of skin of left lower limb, including hip 
ICD-10 CM C44.721 Squamous cell carcinoma of skin of unspecified lower limb, including hip 
ICD-10 CM C44.722 Squamous cell carcinoma of skin of right lower limb, including hip 
ICD-10 CM C44.729 Squamous cell carcinoma of skin of left lower limb, including hip 
ICD-10 CM C44.791 
Other specified malignant neoplasm of skin of unspecified lower limb, 
including hip 
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ICD-10 CM C44.792 Other specified malignant neoplasm of skin of right lower limb, including hip 
ICD-10 CM C44.799 Other specified malignant neoplasm of skin of left lower limb, including hip 
ICD-10 CM C44.80 Unspecified malignant neoplasm of overlapping sites of skin 
ICD-10 CM C44.81 Basal cell carcinoma of overlapping sites of skin 
ICD-10 CM C44.82 Squamous cell carcinoma of overlapping sites of skin 
ICD-10 CM C44.89 Other specified malignant neoplasm of overlapping sites of skin 
ICD-10 CM C44.90 Unspecified malignant neoplasm of skin, unspecified 
ICD-10 CM C44.91 Basal cell carcinoma of skin, unspecified 
ICD-10 CM C44.92 Squamous cell carcinoma of skin, unspecified 
ICD-10 CM C44.99 Other specified malignant neoplasm of skin, unspecified 
ICD-10 CM C45.0 Mesothelioma of pleura 
ICD-10 CM C45.1 Mesothelioma of peritoneum 
ICD-10 CM C45.2 Mesothelioma of pericardium 
ICD-10 CM C45.7 Mesothelioma of other sites 
ICD-10 CM C45.9 Mesothelioma, unspecified 
ICD-10 CM C47.0 Malignant neoplasm of peripheral nerves of head, face and neck 
ICD-10 CM C47.10 
Malignant neoplasm of peripheral nerves of unspecified upper limb, 
including shoulder 
ICD-10 CM C47.11 
Malignant neoplasm of peripheral nerves of right upper limb, including 
shoulder 
ICD-10 CM C47.12 
Malignant neoplasm of peripheral nerves of left upper limb, including 
shoulder 
ICD-10 CM C47.20 
Malignant neoplasm of peripheral nerves of unspecified lower limb, 
including hip 
ICD-10 CM C47.21 Malignant neoplasm of peripheral nerves of right lower limb, including hip 
ICD-10 CM C47.22 Malignant neoplasm of peripheral nerves of left lower limb, including hip 
ICD-10 CM C47.3 Malignant neoplasm of peripheral nerves of thorax 
ICD-10 CM C47.4 Malignant neoplasm of peripheral nerves of abdomen 
ICD-10 CM C47.5 Malignant neoplasm of peripheral nerves of pelvis 
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ICD-10 CM C47.6 Malignant neoplasm of peripheral nerves of trunk, unspecified 
ICD-10 CM C47.8 
Malignant neoplasm of overlapping sites of peripheral nerves and autonomic 
nervous system 
ICD-10 CM C47.9 
Malignant neoplasm of peripheral nerves and autonomic nervous system, 
unspecified 
ICD-10 CM C48.0 Malignant neoplasm of retroperitoneum 
ICD-10 CM C48.1 Malignant neoplasm of specified parts of peritoneum 
ICD-10 CM C48.2 Malignant neoplasm of peritoneum, unspecified 
ICD-10 CM C48.8 
Malignant neoplasm of overlapping sites of retroperitoneum and 
peritoneum 
ICD-10 CM C49.0 Malignant neoplasm of connective and soft tissue of head, face and neck 
ICD-10 CM C49.10 
Malignant neoplasm of connective and soft tissue of unspecified upper limb, 
including shoulder 
ICD-10 CM C49.11 
Malignant neoplasm of connective and soft tissue of right upper limb, 
including shoulder 
ICD-10 CM C49.12 
Malignant neoplasm of connective and soft tissue of left upper limb, 
including shoulder 
ICD-10 CM C49.20 
Malignant neoplasm of connective and soft tissue of unspecified lower limb, 
including hip 
ICD-10 CM C49.21 
Malignant neoplasm of connective and soft tissue of right lower limb, 
including hip 
ICD-10 CM C49.22 
Malignant neoplasm of connective and soft tissue of left lower limb, 
including hip 
ICD-10 CM C49.3 Malignant neoplasm of connective and soft tissue of thorax 
ICD-10 CM C49.4 Malignant neoplasm of connective and soft tissue of abdomen 
ICD-10 CM C49.5 Malignant neoplasm of connective and soft tissue of pelvis 
ICD-10 CM C49.6 Malignant neoplasm of connective and soft tissue of trunk, unspecified 
ICD-10 CM C49.8 Malignant neoplasm of overlapping sites of connective and soft tissue 
ICD-10 CM C49.9 Malignant neoplasm of connective and soft tissue, unspecified 
ICD-10 CM C50.011 Malignant neoplasm of nipple and areola, right female breast 
ICD-10 CM C50.012 Malignant neoplasm of nipple and areola, left female breast 
 104 
ICD-10 CM C50.019 Malignant neoplasm of nipple and areola, unspecified female breast 
ICD-10 CM C50.021 Malignant neoplasm of nipple and areola, right male breast 
ICD-10 CM C50.022 Malignant neoplasm of nipple and areola, left male breast 
ICD-10 CM C50.029 Malignant neoplasm of nipple and areola, unspecified male breast 
ICD-10 CM C50.111 Malignant neoplasm of central portion of right female breast 
ICD-10 CM C50.112 Malignant neoplasm of central portion of left female breast 
ICD-10 CM C50.119 Malignant neoplasm of central portion of unspecified female breast 
ICD-10 CM C50.121 Malignant neoplasm of central portion of right male breast 
ICD-10 CM C50.122 Malignant neoplasm of central portion of left male breast 
ICD-10 CM C50.129 Malignant neoplasm of central portion of unspecified male breast 
ICD-10 CM C50.211 Malignant neoplasm of upper-inner quadrant of right female breast 
ICD-10 CM C50.212 Malignant neoplasm of upper-inner quadrant of left female breast 
ICD-10 CM C50.219 Malignant neoplasm of upper-inner quadrant of unspecified female breast 
ICD-10 CM C50.221 Malignant neoplasm of upper-inner quadrant of right male breast 
ICD-10 CM C50.222 Malignant neoplasm of upper-inner quadrant of left male breast 
ICD-10 CM C50.229 Malignant neoplasm of upper-inner quadrant of unspecified male breast 
ICD-10 CM C50.311 Malignant neoplasm of lower-inner quadrant of right female breast 
ICD-10 CM C50.312 Malignant neoplasm of lower-inner quadrant of left female breast 
ICD-10 CM C50.319 Malignant neoplasm of lower-inner quadrant of unspecified female breast 
ICD-10 CM C50.321 Malignant neoplasm of lower-inner quadrant of right male breast 
ICD-10 CM C50.322 Malignant neoplasm of lower-inner quadrant of left male breast 
ICD-10 CM C50.329 Malignant neoplasm of lower-inner quadrant of unspecified male breast 
ICD-10 CM C50.411 Malignant neoplasm of upper-outer quadrant of right female breast 
ICD-10 CM C50.412 Malignant neoplasm of upper-outer quadrant of left female breast 
ICD-10 CM C50.419 Malignant neoplasm of upper-outer quadrant of unspecified female breast 
ICD-10 CM C50.421 Malignant neoplasm of upper-outer quadrant of right male breast 
ICD-10 CM C50.422 Malignant neoplasm of upper-outer quadrant of left male breast 
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ICD-10 CM C50.429 Malignant neoplasm of upper-outer quadrant of unspecified male breast 
ICD-10 CM C50.511 Malignant neoplasm of lower-outer quadrant of right female breast 
ICD-10 CM C50.512 Malignant neoplasm of lower-outer quadrant of left female breast 
ICD-10 CM C50.519 Malignant neoplasm of lower-outer quadrant of unspecified female breast 
ICD-10 CM C50.521 Malignant neoplasm of lower-outer quadrant of right male breast 
ICD-10 CM C50.522 Malignant neoplasm of lower-outer quadrant of left male breast 
ICD-10 CM C50.529 Malignant neoplasm of lower-outer quadrant of unspecified male breast 
ICD-10 CM C50.611 Malignant neoplasm of axillary tail of right female breast 
ICD-10 CM C50.612 Malignant neoplasm of axillary tail of left female breast 
ICD-10 CM C50.619 Malignant neoplasm of axillary tail of unspecified female breast 
ICD-10 CM C50.621 Malignant neoplasm of axillary tail of right male breast 
ICD-10 CM C50.622 Malignant neoplasm of axillary tail of left male breast 
ICD-10 CM C50.629 Malignant neoplasm of axillary tail of unspecified male breast 
ICD-10 CM C50.811 Malignant neoplasm of overlapping sites of right female breast 
ICD-10 CM C50.812 Malignant neoplasm of overlapping sites of left female breast 
ICD-10 CM C50.819 Malignant neoplasm of overlapping sites of unspecified female breast 
ICD-10 CM C50.821 Malignant neoplasm of overlapping sites of right male breast 
ICD-10 CM C50.822 Malignant neoplasm of overlapping sites of left male breast 
ICD-10 CM C50.829 Malignant neoplasm of overlapping sites of unspecified male breast 
ICD-10 CM C50.911 Malignant neoplasm of unspecified site of right female breast 
ICD-10 CM C50.912 Malignant neoplasm of unspecified site of left female breast 
ICD-10 CM C50.919 Malignant neoplasm of unspecified site of unspecified female breast 
ICD-10 CM C50.921 Malignant neoplasm of unspecified site of right male breast 
ICD-10 CM C50.922 Malignant neoplasm of unspecified site of left male breast 
ICD-10 CM C50.929 Malignant neoplasm of unspecified site of unspecified male breast 
ICD-10 CM C51.0 Malignant neoplasm of labium majus 
ICD-10 CM C51.1 Malignant neoplasm of labium minus 
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ICD-10 CM C51.2 Malignant neoplasm of clitoris 
ICD-10 CM C51.8 Malignant neoplasm of overlapping sites of vulva 
ICD-10 CM C51.9 Malignant neoplasm of vulva, unspecified 
ICD-10 CM C52 Malignant neoplasm of vagina 
ICD-10 CM C53.0 Malignant neoplasm of endocervix 
ICD-10 CM C53.1 Malignant neoplasm of exocervix 
ICD-10 CM C53.8 Malignant neoplasm of overlapping sites of cervix uteri 
ICD-10 CM C53.9 Malignant neoplasm of cervix uteri, unspecified 
ICD-10 CM C54.0 Malignant neoplasm of isthmus uteri 
ICD-10 CM C54.1 Malignant neoplasm of endometrium 
ICD-10 CM C54.2 Malignant neoplasm of myometrium 
ICD-10 CM C54.3 Malignant neoplasm of fundus uteri 
ICD-10 CM C54.8 Malignant neoplasm of overlapping sites of corpus uteri 
ICD-10 CM C54.9 Malignant neoplasm of corpus uteri, unspecified 
ICD-10 CM C55 Malignant neoplasm of uterus, part unspecified 
ICD-10 CM C56.1 Malignant neoplasm of right ovary 
ICD-10 CM C56.2 Malignant neoplasm of left ovary 
ICD-10 CM C56.9 Malignant neoplasm of unspecified ovary 
ICD-10 CM C57.00 Malignant neoplasm of unspecified fallopian tube 
ICD-10 CM C57.01 Malignant neoplasm of right fallopian tube 
ICD-10 CM C57.02 Malignant neoplasm of left fallopian tube 
ICD-10 CM C57.10 Malignant neoplasm of unspecified broad ligament 
ICD-10 CM C57.11 Malignant neoplasm of right broad ligament 
ICD-10 CM C57.12 Malignant neoplasm of left broad ligament 
ICD-10 CM C57.20 Malignant neoplasm of unspecified round ligament 
ICD-10 CM C57.21 Malignant neoplasm of right round ligament 
ICD-10 CM C57.22 Malignant neoplasm of left round ligament 
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ICD-10 CM C57.3 Malignant neoplasm of parametrium 
ICD-10 CM C57.4 Malignant neoplasm of uterine adnexa, unspecified 
ICD-10 CM C57.7 Malignant neoplasm of other specified female genital organs 
ICD-10 CM C57.8 Malignant neoplasm of overlapping sites of female genital organs 
ICD-10 CM C57.9 Malignant neoplasm of female genital organ, unspecified 
ICD-10 CM C58 Malignant neoplasm of placenta 
ICD-10 CM C60.0 Malignant neoplasm of prepuce 
ICD-10 CM C60.1 Malignant neoplasm of glans penis 
ICD-10 CM C60.2 Malignant neoplasm of body of penis 
ICD-10 CM C60.8 Malignant neoplasm of overlapping sites of penis 
ICD-10 CM C60.9 Malignant neoplasm of penis, unspecified 
ICD-10 CM C61 Malignant neoplasm of prostate 
ICD-10 CM C62.00 Malignant neoplasm of unspecified undescended testis 
ICD-10 CM C62.01 Malignant neoplasm of undescended right testis 
ICD-10 CM C62.02 Malignant neoplasm of undescended left testis 
ICD-10 CM C62.10 Malignant neoplasm of unspecified descended testis 
ICD-10 CM C62.11 Malignant neoplasm of descended right testis 
ICD-10 CM C62.12 Malignant neoplasm of descended left testis 
ICD-10 CM C62.90 
Malignant neoplasm of unspecified testis, unspecified whether descended or 
undescended 
ICD-10 CM C62.91 
Malignant neoplasm of right testis, unspecified whether descended or 
undescended 
ICD-10 CM C62.92 
Malignant neoplasm of left testis, unspecified whether descended or 
undescended 
ICD-10 CM C63.00 Malignant neoplasm of unspecified epididymis 
ICD-10 CM C63.01 Malignant neoplasm of right epididymis 
ICD-10 CM C63.02 Malignant neoplasm of left epididymis 
ICD-10 CM C63.10 Malignant neoplasm of unspecified spermatic cord 
ICD-10 CM C63.11 Malignant neoplasm of right spermatic cord 
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ICD-10 CM C63.12 Malignant neoplasm of left spermatic cord 
ICD-10 CM C63.2 Malignant neoplasm of scrotum 
ICD-10 CM C63.7 Malignant neoplasm of other specified male genital organs 
ICD-10 CM C63.8 Malignant neoplasm of overlapping sites of male genital organs 
ICD-10 CM C63.9 Malignant neoplasm of male genital organ, unspecified 
ICD-10 CM C64.1 Malignant neoplasm of right kidney, except renal pelvis 
ICD-10 CM C64.2 Malignant neoplasm of left kidney, except renal pelvis 
ICD-10 CM C64.9 Malignant neoplasm of unspecified kidney, except renal pelvis 
ICD-10 CM C65.1 Malignant neoplasm of right renal pelvis 
ICD-10 CM C65.2 Malignant neoplasm of left renal pelvis 
ICD-10 CM C65.9 Malignant neoplasm of unspecified renal pelvis 
ICD-10 CM C66.1 Malignant neoplasm of right ureter 
ICD-10 CM C66.2 Malignant neoplasm of left ureter 
ICD-10 CM C66.9 Malignant neoplasm of unspecified ureter 
ICD-10 CM C67.0 Malignant neoplasm of trigone of bladder 
ICD-10 CM C67.1 Malignant neoplasm of dome of bladder 
ICD-10 CM C67.2 Malignant neoplasm of lateral wall of bladder 
ICD-10 CM C67.3 Malignant neoplasm of anterior wall of bladder 
ICD-10 CM C67.4 Malignant neoplasm of posterior wall of bladder 
ICD-10 CM C67.5 Malignant neoplasm of bladder neck 
ICD-10 CM C67.6 Malignant neoplasm of ureteric orifice 
ICD-10 CM C67.7 Malignant neoplasm of urachus 
ICD-10 CM C67.8 Malignant neoplasm of overlapping sites of bladder 
ICD-10 CM C67.9 Malignant neoplasm of bladder, unspecified 
ICD-10 CM C68.0 Malignant neoplasm of urethra 
ICD-10 CM C68.1 Malignant neoplasm of paraurethral glands 
ICD-10 CM C68.8 Malignant neoplasm of overlapping sites of urinary organs 
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ICD-10 CM C68.9 Malignant neoplasm of urinary organ, unspecified 
ICD-10 CM C69.00 Malignant neoplasm of unspecified conjunctiva 
ICD-10 CM C69.01 Malignant neoplasm of right conjunctiva 
ICD-10 CM C69.02 Malignant neoplasm of left conjunctiva 
ICD-10 CM C69.10 Malignant neoplasm of unspecified cornea 
ICD-10 CM C69.11 Malignant neoplasm of right cornea 
ICD-10 CM C69.12 Malignant neoplasm of left cornea 
ICD-10 CM C69.20 Malignant neoplasm of unspecified retina 
ICD-10 CM C69.21 Malignant neoplasm of right retina 
ICD-10 CM C69.22 Malignant neoplasm of left retina 
ICD-10 CM C69.30 Malignant neoplasm of unspecified choroid 
ICD-10 CM C69.31 Malignant neoplasm of right choroid 
ICD-10 CM C69.32 Malignant neoplasm of left choroid 
ICD-10 CM C69.40 Malignant neoplasm of unspecified ciliary body 
ICD-10 CM C69.41 Malignant neoplasm of right ciliary body 
ICD-10 CM C69.42 Malignant neoplasm of left ciliary body 
ICD-10 CM C69.50 Malignant neoplasm of unspecified lacrimal gland and duct 
ICD-10 CM C69.51 Malignant neoplasm of right lacrimal gland and duct 
ICD-10 CM C69.52 Malignant neoplasm of left lacrimal gland and duct 
ICD-10 CM C69.60 Malignant neoplasm of unspecified orbit 
ICD-10 CM C69.61 Malignant neoplasm of right orbit 
ICD-10 CM C69.62 Malignant neoplasm of left orbit 
ICD-10 CM C69.80 Malignant neoplasm of overlapping sites of unspecified eye and adnexa 
ICD-10 CM C69.81 Malignant neoplasm of overlapping sites of right eye and adnexa 
ICD-10 CM C69.82 Malignant neoplasm of overlapping sites of left eye and adnexa 
ICD-10 CM C69.90 Malignant neoplasm of unspecified site of unspecified eye 
ICD-10 CM C69.91 Malignant neoplasm of unspecified site of right eye 
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ICD-10 CM C69.92 Malignant neoplasm of unspecified site of left eye 
ICD-10 CM C70.0 Malignant neoplasm of cerebral meninges 
ICD-10 CM C70.1 Malignant neoplasm of spinal meninges 
ICD-10 CM C70.9 Malignant neoplasm of meninges, unspecified 
ICD-10 CM C71.0 Malignant neoplasm of cerebrum, except lobes and ventricles 
ICD-10 CM C71.1 Malignant neoplasm of frontal lobe 
ICD-10 CM C71.2 Malignant neoplasm of temporal lobe 
ICD-10 CM C71.3 Malignant neoplasm of parietal lobe 
ICD-10 CM C71.4 Malignant neoplasm of occipital lobe 
ICD-10 CM C71.5 Malignant neoplasm of cerebral ventricle 
ICD-10 CM C71.6 Malignant neoplasm of cerebellum 
ICD-10 CM C71.7 Malignant neoplasm of brain stem 
ICD-10 CM C71.8 Malignant neoplasm of overlapping sites of brain 
ICD-10 CM C71.9 Malignant neoplasm of brain, unspecified 
ICD-10 CM C72.0 Malignant neoplasm of spinal cord 
ICD-10 CM C72.1 Malignant neoplasm of cauda equina 
ICD-10 CM C72.20 Malignant neoplasm of unspecified olfactory nerve 
ICD-10 CM C72.21 Malignant neoplasm of right olfactory nerve 
ICD-10 CM C72.22 Malignant neoplasm of left olfactory nerve 
ICD-10 CM C72.30 Malignant neoplasm of unspecified optic nerve 
ICD-10 CM C72.31 Malignant neoplasm of right optic nerve 
ICD-10 CM C72.32 Malignant neoplasm of left optic nerve 
ICD-10 CM C72.40 Malignant neoplasm of unspecified acoustic nerve 
ICD-10 CM C72.41 Malignant neoplasm of right acoustic nerve 
ICD-10 CM C72.42 Malignant neoplasm of left acoustic nerve 
ICD-10 CM C72.50 Malignant neoplasm of unspecified cranial nerve 
ICD-10 CM C72.59 Malignant neoplasm of other cranial nerves 
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ICD-10 CM C72.9 Malignant neoplasm of central nervous system, unspecified 
ICD-10 CM C73 Malignant neoplasm of thyroid gland 
ICD-10 CM C74.00 Malignant neoplasm of cortex of unspecified adrenal gland 
ICD-10 CM C74.01 Malignant neoplasm of cortex of right adrenal gland 
ICD-10 CM C74.02 Malignant neoplasm of cortex of left adrenal gland 
ICD-10 CM C74.10 Malignant neoplasm of medulla of unspecified adrenal gland 
ICD-10 CM C74.11 Malignant neoplasm of medulla of right adrenal gland 
ICD-10 CM C74.12 Malignant neoplasm of medulla of left adrenal gland 
ICD-10 CM C74.90 Malignant neoplasm of unspecified part of unspecified adrenal gland 
ICD-10 CM C74.91 Malignant neoplasm of unspecified part of right adrenal gland 
ICD-10 CM C74.92 Malignant neoplasm of unspecified part of left adrenal gland 
ICD-10 CM C75.0 Malignant neoplasm of parathyroid gland 
ICD-10 CM C75.1 Malignant neoplasm of pituitary gland 
ICD-10 CM C75.2 Malignant neoplasm of craniopharyngeal duct 
ICD-10 CM C75.3 Malignant neoplasm of pineal gland 
ICD-10 CM C75.4 Malignant neoplasm of carotid body 
ICD-10 CM C75.5 Malignant neoplasm of aortic body and other paraganglia 
ICD-10 CM C75.8 Malignant neoplasm with pluriglandular involvement, unspecified 
ICD-10 CM C75.9 Malignant neoplasm of endocrine gland, unspecified 
ICD-10 CM C76.0 Malignant neoplasm of head, face and neck 
ICD-10 CM C76.1 Malignant neoplasm of thorax 
ICD-10 CM C76.2 Malignant neoplasm of abdomen 
ICD-10 CM C76.3 Malignant neoplasm of pelvis 
ICD-10 CM C76.40 Malignant neoplasm of unspecified upper limb 
ICD-10 CM C76.41 Malignant neoplasm of right upper limb 
ICD-10 CM C76.42 Malignant neoplasm of left upper limb 
ICD-10 CM C76.50 Malignant neoplasm of unspecified lower limb 
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ICD-10 CM C76.51 Malignant neoplasm of right lower limb 
ICD-10 CM C76.52 Malignant neoplasm of left lower limb 
ICD-10 CM C76.8 Malignant neoplasm of other specified ill-defined sites 
ICD-10 CM C77.0 
Secondary and unspecified malignant neoplasm of lymph nodes of head, 
face and neck 
ICD-10 CM C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes 
ICD-10 CM C77.2 
Secondary and unspecified malignant neoplasm of intra-abdominal lymph 
nodes 
ICD-10 CM C77.3 
Secondary and unspecified malignant neoplasm of axilla and upper limb 
lymph nodes 
ICD-10 CM C77.4 
Secondary and unspecified malignant neoplasm of inguinal and lower limb 
lymph nodes 
ICD-10 CM C77.5 Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes 
ICD-10 CM C77.8 
Secondary and unspecified malignant neoplasm of lymph nodes of multiple 
regions 
ICD-10 CM C77.9 Secondary and unspecified malignant neoplasm of lymph node, unspecified 
ICD-10 CM C78.00 Secondary malignant neoplasm of unspecified lung 
ICD-10 CM C78.01 Secondary malignant neoplasm of right lung 
ICD-10 CM C78.02 Secondary malignant neoplasm of left lung 
ICD-10 CM C78.1 Secondary malignant neoplasm of mediastinum 
ICD-10 CM C78.2 Secondary malignant neoplasm of pleura 
ICD-10 CM C78.30 Secondary malignant neoplasm of unspecified respiratory organ 
ICD-10 CM C78.39 Secondary malignant neoplasm of other respiratory organs 
ICD-10 CM C78.4 Secondary malignant neoplasm of small intestine 
ICD-10 CM C78.5 Secondary malignant neoplasm of large intestine and rectum 
ICD-10 CM C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum 
ICD-10 CM C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct 
ICD-10 CM C78.80 Secondary malignant neoplasm of unspecified digestive organ 
ICD-10 CM C78.89 Secondary malignant neoplasm of other digestive organs 
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ICD-10 CM C79.00 Secondary malignant neoplasm of unspecified kidney and renal pelvis 
ICD-10 CM C79.01 Secondary malignant neoplasm of right kidney and renal pelvis 
ICD-10 CM C79.02 Secondary malignant neoplasm of left kidney and renal pelvis 
ICD-10 CM C79.10 Secondary malignant neoplasm of unspecified urinary organs 
ICD-10 CM C79.11 Secondary malignant neoplasm of bladder 
ICD-10 CM C79.19 Secondary malignant neoplasm of other urinary organs 
ICD-10 CM C79.2 Secondary malignant neoplasm of skin 
ICD-10 CM C79.31 Secondary malignant neoplasm of brain 
ICD-10 CM C79.32 Secondary malignant neoplasm of cerebral meninges 
ICD-10 CM C79.40 Secondary malignant neoplasm of unspecified part of nervous system 
ICD-10 CM C79.49 Secondary malignant neoplasm of other parts of nervous system 
ICD-10 CM C79.51 Secondary malignant neoplasm of bone 
ICD-10 CM C79.52 Secondary malignant neoplasm of bone marrow 
ICD-10 CM C79.60 Secondary malignant neoplasm of unspecified ovary 
ICD-10 CM C79.61 Secondary malignant neoplasm of right ovary 
ICD-10 CM C79.62 Secondary malignant neoplasm of left ovary 
ICD-10 CM C79.70 Secondary malignant neoplasm of unspecified adrenal gland 
ICD-10 CM C79.71 Secondary malignant neoplasm of right adrenal gland 
ICD-10 CM C79.72 Secondary malignant neoplasm of left adrenal gland 
ICD-10 CM C79.81 Secondary malignant neoplasm of breast 
ICD-10 CM C79.82 Secondary malignant neoplasm of genital organs 
ICD-10 CM C79.89 Secondary malignant neoplasm of other specified sites 
ICD-10 CM C79.9 Secondary malignant neoplasm of unspecified site 
ICD-10 CM C80.0 Disseminated malignant neoplasm, unspecified 
ICD-10 CM C80.1 Malignant (primary) neoplasm, unspecified 
ICD-10 CM C80.2 Malignant neoplasm associated with transplanted organ 
ICD-10 CM C82.50 Diffuse follicle center lymphoma, unspecified site 
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ICD-10 CM C82.51 Diffuse follicle center lymphoma, lymph nodes of head, face, and neck 
ICD-10 CM C82.52 Diffuse follicle center lymphoma, intrathoracic lymph nodes 
ICD-10 CM C82.53 Diffuse follicle center lymphoma, intra-abdominal lymph nodes 
ICD-10 CM C82.54 Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb 
ICD-10 CM C82.55 
Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower 
limb 
ICD-10 CM C82.56 Diffuse follicle center lymphoma, intrapelvic lymph nodes 
ICD-10 CM C82.57 Diffuse follicle center lymphoma, spleen 
ICD-10 CM C82.58 Diffuse follicle center lymphoma, lymph nodes of multiple sites 
ICD-10 CM C82.59 Diffuse follicle center lymphoma, extranodal and solid organ sites 
ICD-10 CM C84.90 Mature T/NK-cell lymphomas, unspecified, unspecified site 
ICD-10 CM C84.91 
Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and 
neck 
ICD-10 CM C84.92 Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes 
ICD-10 CM C84.93 Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes 
ICD-10 CM C84.94 
Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper 
limb 
ICD-10 CM C84.95 
Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region 
and lower limb 
ICD-10 CM C84.96 Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes 
ICD-10 CM C84.97 Mature T/NK-cell lymphomas, unspecified, spleen 
ICD-10 CM C84.98 Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites 
ICD-10 CM C84.99 Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites 
ICD-10 CM C84.A0 Cutaneous T-cell lymphoma, unspecified, unspecified site 
ICD-10 CM C84.A1 
Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and 
neck 
ICD-10 CM C84.A2 Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes 
ICD-10 CM C84.A3 Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes 
ICD-10 CM C84.A4 
Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper 
limb 
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ICD-10 CM C84.A5 
Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and 
lower limb 
ICD-10 CM C84.A6 Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes 
ICD-10 CM C84.A7 Cutaneous T-cell lymphoma, unspecified, spleen 
ICD-10 CM C84.A8 Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites 
ICD-10 CM C84.A9 Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites 
ICD-10 CM C84.Z0 Other mature T/NK-cell lymphomas, unspecified site 
ICD-10 CM C84.Z1 Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck 
ICD-10 CM C84.Z2 Other mature T/NK-cell lymphomas, intrathoracic lymph nodes 
ICD-10 CM C84.Z3 Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes 
ICD-10 CM C84.Z4 Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb 
ICD-10 CM C84.Z5 
Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and 
lower limb 
ICD-10 CM C84.Z6 Other mature T/NK-cell lymphomas, intrapelvic lymph nodes 
ICD-10 CM C84.Z7 Other mature T/NK-cell lymphomas, spleen 
ICD-10 CM C84.Z8 Other mature T/NK-cell lymphomas, lymph nodes of multiple sites 
ICD-10 CM C84.Z9 Other mature T/NK-cell lymphomas, extranodal and solid organ sites 
ICD-10 CM C85.10 Unspecified B-cell lymphoma, unspecified site 
ICD-10 CM C85.11 Unspecified B-cell lymphoma, lymph nodes of head, face, and neck 
ICD-10 CM C85.12 Unspecified B-cell lymphoma, intrathoracic lymph nodes 
ICD-10 CM C85.13 Unspecified B-cell lymphoma, intra-abdominal lymph nodes 
ICD-10 CM C85.14 Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb 
ICD-10 CM C85.15 Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb 
ICD-10 CM C85.16 Unspecified B-cell lymphoma, intrapelvic lymph nodes 
ICD-10 CM C85.17 Unspecified B-cell lymphoma, spleen 
ICD-10 CM C85.18 Unspecified B-cell lymphoma, lymph nodes of multiple sites 
ICD-10 CM C85.19 Unspecified B-cell lymphoma, extranodal and solid organ sites 
ICD-10 CM C85.20 Mediastinal (thymic) large B-cell lymphoma, unspecified site 
 116 
ICD-10 CM C85.21 
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and 
neck 
ICD-10 CM C85.22 Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes 
ICD-10 CM C85.23 Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes 
ICD-10 CM C85.24 
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper 
limb 
ICD-10 CM C85.25 
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region 
and lower limb 
ICD-10 CM C85.26 Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes 
ICD-10 CM C85.27 Mediastinal (thymic) large B-cell lymphoma, spleen 
ICD-10 CM C85.28 Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites 
ICD-10 CM C85.29 Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites 
ICD-10 CM C85.80 Other specified types of non-Hodgkin lymphoma, unspecified site 
ICD-10 CM C85.81 
Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, 
and neck 
ICD-10 CM C85.82 Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes 
ICD-10 CM C85.83 
Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph 
nodes 
ICD-10 CM C85.84 
Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and 
upper limb 
ICD-10 CM C85.85 
Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal 
region and lower limb 
ICD-10 CM C85.86 Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes 
ICD-10 CM C85.87 Other specified types of non-Hodgkin lymphoma, spleen 
ICD-10 CM C85.88 
Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple 
sites 
ICD-10 CM C85.89 
Other specified types of non-Hodgkin lymphoma, extranodal and solid organ 
sites 
ICD-10 CM C85.90 Non-Hodgkin lymphoma, unspecified, unspecified site 
ICD-10 CM C85.91 Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck 
ICD-10 CM C85.92 Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes 
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ICD-10 CM C85.93 Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes 
ICD-10 CM C85.94 Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb 
ICD-10 CM C85.95 
Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and 
lower limb 
ICD-10 CM C85.96 Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes 
ICD-10 CM C85.97 Non-Hodgkin lymphoma, unspecified, spleen 
ICD-10 CM C85.98 Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites 
ICD-10 CM C85.99 Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites 
ICD-10 CM C86.0 Extranodal NK/T-cell lymphoma, nasal type 
ICD-10 CM C86.1 Hepatosplenic T-cell lymphoma 
ICD-10 CM C86.2 Enteropathy-type (intestinal) T-cell lymphoma 
ICD-10 CM C86.3 Subcutaneous panniculitis-like T-cell lymphoma 
ICD-10 CM C86.4 Blastic NK-cell lymphoma 
ICD-10 CM C88.2 Heavy chain disease 
ICD-10 CM C88.3 Immunoproliferative small intestinal disease 
ICD-10 CM C88.8 Other malignant immunoproliferative diseases 
ICD-10 CM C88.9 Malignant immunoproliferative disease, unspecified 
ICD-10 CM C90.20 Extramedullary plasmacytoma not having achieved remission 
ICD-10 CM C90.21 Extramedullary plasmacytoma in remission 
ICD-10 CM C90.22 Extramedullary plasmacytoma in relapse 
ICD-10 CM C90.30 Solitary plasmacytoma not having achieved remission 
ICD-10 CM C90.31 Solitary plasmacytoma in remission 
ICD-10 CM C90.32 Solitary plasmacytoma in relapse 
ICD-10 CM C94.40 Acute panmyelosis with myelofibrosis not having achieved remission 
ICD-10 CM C94.41 Acute panmyelosis with myelofibrosis, in remission 
ICD-10 CM C94.42 Acute panmyelosis with myelofibrosis, in relapse 
ICD-10 CM C94.6 Myelodysplastic disease, not classified 
ICD-10 CM C96.4 Sarcoma of dendritic cells (accessory cells) 
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ICD-10 CM C96.9 
Malignant neoplasm of lymphoid, hematopoietic and related tissue, 
unspecified 
ICD-10 CM C96.Z 
Other specified malignant neoplasms of lymphoid, hematopoietic and 
related tissue 
ICD-9 CM 172 Malignant melanoma of skin 
ICD-9 CM 176 Kaposi's sarcoma 
ICD-9 CM 200 Malignant Neoplasm of Lymphatic and Hematopoietic Tissue 
ICD-9 CM 201 Hodgkin Lymphoma 
ICD-10 CM C81 Hodgkin lymphoma 
ICD-10 CM C83 Non-follicular lymphoma 
ICD-10 CM C91 Lymphoid leukemia 
ICD-10 CM C92 Myeloid leukemia 
ICD-10 CM C93 Monocytic leukemia 
ICD-10 CM C95 Leukemia of unspecified cell type 
ICD-10 CM C46 Kaposi's sarcoma 
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Appendix F: Data Request  
• Patients with a primary diagnosis of Head & Neck Lip and Oral Cavity, Oropharynx, Larynx, and Salivary Gland Cancers (See 
Appendix D) between 2011- 2017.  
• Exclude patients under 18 years of age and above 64 years of age at first diagnosis of Head & Neck Cancer 
• Exclude non-US Commercial HMO plans 
• Exclude patients with break in payer coverage from start of diagnosis to 1 year, exclude secondary coverage plans 
• Exclude patients with concurrent, recurrent cancers 1 years during 1 year after start of diagnosis and 3 months before start 
of diagnosis, using claims 2011-2017 
Data Variables Requested Below: 
DATA TABLE VARIABLE DESCRIPTION TYPE FORMAT 
Member PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
and is compliant with HIPAA §164.514c. 
Num 19 
Member ASO A code which identifies if the financial arrangement is Administrative Services Only 
(ASO).Values: Y = ASO,  N = Not ASO 
Char $1 
Member BUS Identifies the type of business the product is intended to service. Char $5 
Member CDHP Consumer Driven Health Plan: Code that defines what a customer decides on in 
regards to the type of Health Plan.  
Char $1 
Member ELIGEFF The date this member coverage row of information is effective. Num YYMMDD10. 
Member ELIGEND The date this member coverage row of information ended (or will end). Num YYMMDD10. 
Member GDR_CD A code identifying the sex of the member M=male, F=female, U=unknown Char $1 
Member GROUP_NBR The number assigned to a healthcare entity, such as a plan, however not an 
individual, that has purchased products or services from our affiliate company.  
Char $20 
Member HEALTH_EXC
H 
Identifies which type of health exchange  Char $1 
Member PRODUCT The code commonly used by the health care industry to identify the product. Char $5 
Member STATE The two-character US Postal Service Abbreviation for the state name. Char $2 
Member YRDOB The member's year of birth, capped at 90 years. Num 5 
Member 
Detail 
PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
Num 19 
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and is compliant with HIPAA §164.514c. 
Member 
Detail 
PAT_PLANID An encrypted, system-generated number that identifies an individual within in a 
group or policy. This identifier is not derived from or related to information about the 
individual, and is compliant with HIPAA §164.514(c)(1). If an individual is eligible for 
more than one type of insurance at a time (for example, a supplemental plan), then 
this variable links the claim to the correct plan. 
Num 19 
Member 
Detail 
ASO A code which identifies if the financial arrangement is Administrative Services Only 
(ASO).Values: Y = ASO,  N = Not ASO 
Char $1 
Member 
Detail 
BUS Identifies the type of business the product is intended to service. Char $5 
Member 
Detail 
CDHP Code that defines what a customer decides on in regards to the type of Health Plan.  Char $1 
Member 
Detail 
ELIGEFF The date this member coverage row of information is effective. Num YYMMDD10. 
Member 
Detail 
ELIGEND The date this member coverage row of information ended (or will end). Num YYMMDD10. 
Member 
Detail 
GDR_CD A code identifying the sex of the member M=male, F=female, U=unknown Char $1 
Member 
Detail 
GROUP_NBR The number assigned to a healthcare entity, such as a plan, however not an 
individual, that has purchased products or services from our affiliate company.  
Char $20 
Member 
Detail 
HEALTH_EXC
H 
Identifies which type of health exchange  Char $1 
Member 
Detail 
LIS Indicates whether member qualifies for Low Income Subsidy (LIS) available under 
Medicare Part D prescription drug program. Available on Medicare only. 
Char $1 
Member 
Detail 
PRODUCT The code commonly used by the health care industry to identify the product. Char $5 
Member 
Detail 
STATE The two-character US Postal Service Abbreviation for the state name. Char $2 
Member 
Detail 
YRDOB The member's year of birth, capped at 90 years. Num 5 
Medical PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
and is compliant with HIPAA §164.514c. 
Num 19 
Medical PAT_PLANID An encrypted, system-generated number that identifies an individual within in a Num 19 
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group or policy. This identifier is not derived from or related to information about the 
individual, and is compliant with HIPAA §164.514(c)(1). If an individual is eligible for 
more than one type of insurance at a time (for example, a supplemental plan), then 
this variable links the claim to the correct plan. 
Medical ADMIT_CHAN This code identifies how the inpatient stay was initiated. Char $16 
Medical ADMIT_TYPE Identify the priority of the admission Char $1 
Medical BILL_PROV Billing Provider Num 19 
Medical CHARGE Amount the provider requested to be reimbursed for the service provided. Num 11.2 
Medical CLMID Encrypted Claim ID. A provider can bill multiple revenue codes for services rendered 
on one claim. Each revenue code will generate a claim line. Providers typically submit 
separate claim for each visit they have with a patient. 
Char $19 
Medical CLMSEQ Number assigned in the source system to the service within the claim. This field is 
used to distinguish between the detail records for a claim. Use with CLMID 
Char $5 
Medical COB The coordination of benefits code (COB) indicates if other insurance was considered 
as part of the payment determination. 
Char $5 
Medical COINS The amount (usually calculated as a percent of the provider's submitted charges) the 
member pays for a specific service as defined in their benefit plan. For example, 80% 
of the cost of an outpatient physical therapy visit.  
Num 11.2 
Medical CONF_ID Confinement Identifier.  Used to identify claims records associated with an inpatient 
hospitalization.  This data element is encrypted. 
Char $21 
Medical COPAY The fixed amount the member pays for a specific service as defined in their benefit 
plan. For example, $10 for an office visit.  
Num 11.2 
Medical DEDUCT The set amount a member pays for services until they reach a specified limit (usually 
defined on an annual basis). After the limit is reached, the member's payment for 
services changes (often insurance pays 100% of the cost of services).  
Num 11.2 
Medical DIAG1 Level 1 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG2 Level 2 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG3 Level 3  ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
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Medical DIAG4 Level 4 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG5 Level 5 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG6 Level 6 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG7 Level 7 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG8 Level 8 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG9 Level 9 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DIAG10 Level 10 ICD-X as entered on the claim (without decimal point). ICD-X-CM is an 
accepted national standard for coding diagnostic and disease information. The 
Diagnosis Codes are sequenced in order of importance for the medical services. 
Char $7 
Medical DRG The Diagnosis Related Group (DRG) Code assigned by the source system. A DRG 
classifies patients by diagnostic or surgical procedure into major diagnostic categories 
for the purpose of determining payment of hospitalization charges. Effective 
10/1/2007, the Centers for Medicare and Medicaid Services (CMS) introduced the 
MS-DRG code set and retired the CMS-DRG set. The new code set refined the DRGs 
based on the presence of complications or co-morbidities. One affect of this change is 
that the MS-DRG descriptions are completely different from previous descriptions. 
The DRG code table contains historical CMS-DRGs as well as MS-DRG codes.  
Char $5 
Medical DSTATUS Discharge status code.  Identifies the discharge status of the member's inpatient stay 
as of the last service date on the claim. 
Char $2 
Medical ENCTR Identifies if the service is fee-for-service or capitated.  Char $2 
Medical FST_DT The beginning date for the service, event, or confinement being billed by the 
provider.   
Num YYMMD
D10. 
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Medical HCCC Identifies an affliated company's categorization of health care services. Char $2 
Medical ICD_FLAG ICD Version Code – will distinguish between ICD-9 and ICD-10 codes.  Char $2 
Medical LOC_CD Identifies if the claim is a facility claim or a non-facility claim.  Char $1 
Medical LST_DT The service date for the service, event, or confinement being billed by the provider Num YYMMD
D10. 
Medical NDC The unique code that identifies a drug product as defined by the National Drug Data 
File (all drug products regulated by the FDA must use an NDC). 
Char $11 
Medical PAID_DT The date the service, event, or confinement was paid.  Num YYMMD
D10. 
Medical PAID_STATUS The payment determination of this service line. Char $2 
Medical POA Present on Admission Code provides the ability to indicate whether diagnosis codes 
on a claim were present on admission.  POA is defined as present at the time the 
order for inpatient admission occurs -- conditions that develop during outpatient 
encounter, including emergency department, observation, or outpatient surgery, are 
considered POA. Corresponds to POA 1 - 18.  
Char $50 
Medical POS Identifies the place where the service was performed. Char $5 
Medical PROC_CD CPT/HCPCS Procedure code that describes the service provided.   Char $7 
Medical PROC1 Claim Level 1 ICD-X procedure code off of the header portion of the claim.  Char $7 
Medical PROC2 Claim Level 2 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC3 Claim Level 3 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC4 Claim Level 4 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC5 Claim Level 5 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC6 Claim Level 6 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC7 Claim Level 7 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC8 Claim Level 8 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC9 Claim Level 9 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROC10 Claim Level 10 ICD-X procedure code off of the header portion of the claim. Char $7 
Medical PROCMOD Provides additional information on the PROC_CD referenced in the claim. Standard 
modifiers will now be used. 
Char $5 
Medical PROV A unique system-generated number that identified the provider. It is possible for a 
provider to have multiple IDs or an ID to point to multiple physicians, particularly in 
the case of group practice. 
Num 19 
Medical PROV_PAR Identifies if the servicing provider has a contract to provide services to affiliate 
members at agreed upon rates.  These contracts may be either with affiliate or with a 
Char $5 
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customer. 
Medical PROVCAT  Contains the four-character provider category code to indicate the type of provider 
for the provider responsible for the service.  
Char $4 
Medical SERVICE_PRO
V 
Rendering Provider on Non-Facility Claim 
Attending Provider on Facility Claim 
Num 19 
Medical STD_COST An estimate of the allowed amount for the facility charges related to the 
confinement. Associated surgeon's fees are likely to be found in the medical table. 
Num 15.2 
Medical STD_COST_Y
R 
The year when standard cost is updated in our source system Char $4 
Medical TOS_CD Type of Service Code Char $13 
Medical UNITS The revised number of units of the service based on the reasonable number of units 
for that service type. 
Num 8 
Facility 
Detail 
PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
and is compliant with HIPAA §164.514c. 
Num 19 
Facility 
Detail 
PAT_PLANID An encrypted, system-generated number that identifies an individual within in a 
group or policy. This identifier is not derived from or related to information about the 
individual, and is compliant with HIPAA §164.514(c)(1). If an individual is eligible for 
more than one type of insurance at a time (for example, a supplemental plan), then 
this variable links the claim to the correct plan. 
Num 19 
Facility 
Detail 
CHARGE_ALL
OC 
Amount the provider requested to be reimbursed for the service provided. Num 11.2 
Facility 
Detail 
CLMID Encrypted Claim ID. A provider can bill multiple revenue codes for services rendered 
on one claim. Each revenue code will generate a claim line. Providers typically submit 
separate claim for each visit they have with a patient. 
Char $19 
Facility 
Detail 
CLMSEQ Number assigned in the source system to the service within the claim. This field is 
used to distinguish between the detail records for a claim. Use with CLMID 
Char $5 
Facility 
Detail 
DETAIL_LINE_
NBR 
Sequential Number within CLMID / CLMSEQ Char $2 
Facility 
Detail 
FST_DT The beginning date for the service, event, or confinement being billed by the 
provider.   
Num YYMMD
D10. 
Facility 
Detail 
PROC_CD 
CPT/HCPCS Procedure code that describes the service provided.   
Char $7 
Facility PROCMOD Provides additional information on the PROC_CD referenced in the claim. Standard Char $5 
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Detail modifiers will now be used. 
Facility 
Detail 
RVNU_CD Identifies a specific accommodation, ancillary service or billing calculation for facility 
claims.  
Char $4 
Facility 
Detail 
STD_COST_A
LLOC 
An estimate of the allowed amount for the facility charges related to the 
confinement. Associated surgeon's fees are likely to be found in the medical table. 
Num 15.2 
Facility 
Detail 
STD_COST_Y
R 
The year when standard cost is updated in our source system Char $4 
Facility 
Detail 
UNITS The revised number of units of the service based on the reasonable number of units 
for that service type. 
Num 8 
Rx PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
and is compliant with HIPAA §164.514c. 
Num 19 
Rx PAT_PLANID An encrypted, system-generated number that identifies an individual within in a 
group or policy. This identifier is not derived from or related to information about the 
individual, and is compliant with HIPAA §164.514(c)(1). If an individual is eligible for 
more than one type of insurance at a time (for example, a supplemental plan), then 
this variable links the claim to the correct plan. 
Num 19 
Rx AHFSCLSS A code that identifies therapeutic category of drug according to the American 
Hospital Formulary Service Classification system. *From NDC table 
Char $8 
Rx AVGWHLSL The average wholesale price is the average cost to the pharmacy for a dispensed 
drug. 
Num 11.2 
Rx BRND_NM Provides the drug name on the package label and frequently is a trademark name.  
For non-branded generic products, the description will usually be the generic name. 
*From NDC table 
Char $30 
Rx CHARGE Amount the pharmacy requested to be reimbursed for the service provided.  This 
amount is what was entered into the source system and is also referred to as the 
claimed amount or billed charge amount. 
Num 11.2 
Rx CLMID Encrypted Claim ID. A provider can bill multiple revenue codes for services rendered 
on one claim. Each revenue code will generate a claim line. Providers typically submit 
s separate claim for each encounter they have with a patient. 
Char $19 
Rx COPAY The fixed amount the member pays for a specific service as defined in their benefit 
plan. For example, $10 for an office visit. 
Num 11.2 
Rx DEDUCT The deductible is a set amount a member pays for services until a specific limit is 
reached (usually on an annual basis).  After the limit is reached, the member's 
Num 11.2 
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payment for services changes (often insurance pays 100% of the cost of services). 
Rx DISPFEE Amount the pharmacy charged to fill the prescription. Num 9.2 
Rx FILL_DT Date the prescription was filled by the pharmacy. Num YYMMDD10. 
Rx FORM_IND Indicates if the drug being dispensed is on the formulary list or not. Char $1 
Rx FORM_TYP Type of formulary used to pay a claim.  For example, open, closed, etc. NONE/NULL 
for Medicare. 
Char $2 
Rx FST_FILL Indicates if this is the first time a prescription is being filled.  Char $1 
Rx GNRC_IND Indicates if the drug is multiple sourced. *From NDC table Char $1 
Rx GNRC_NM Contains the drug ingredient name for a specific drug as adopted by the United States 
Adopted Names.  The chemical name is used when the USAN name is not available. 
*From NDC table 
Char $50 
Rx MAIL_IND Indicates if the type of pharmacy utilized to fill the prescription was Mail Order.  Char $1 
Rx NDC The unique code that identifies a drug product as defined by the National Drug Data 
File (all drug products regulated by the FDA must use an NDC). 
Char $11 
Rx NPI The National Provider Identifier (NPI) was adopted as the standard unique health 
identifier for health care providers to carry out a requirement in the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) for the adoption of such a 
standard. This number is encrypted 
Char $10 
Rx PHARM An encryption of a number assigned by the National Council for Prescription Drug 
Programs (NCPDP) to uniquely identify a pharmacy.  
Char $9 
Rx QUANTITY The number of metric units of medication dispensed. Num 12.3 
Rx RFL_NBR Indicates if this is the first, second, or subsequent refill for the prescription.  Char $2 
Rx SPCLT_IND Indicated if the pharmacy is a specialty pharmacy. Char $1 
Rx SPECCLSS Description of First DataBank's low level classification of drugs. *From NDC table Char $3 
Rx STD_COST Standard price reflects the allowed payment for all provider services. Num 15.2 
Rx STD_COST_Y
R 
The year when standard cost is updated in our source system Char $4 
Rx STRENGTH Description of drug potency in units of grams, milligrams, percentage, and other 
terms.  This field includes needle sizes, length of devices, and release rates of 
transdermal patches. *From NDC table 
Char $10 
Confinemen
t 
PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies.  This identifier is not derived from information about the individual, 
and is compliant with HIPAA §164.514c. 
Num 19 
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Confinemen
t 
PAT_PLANID An encrypted, system-generated number that identifies an individual within in a 
group or policy. This identifier is not derived from or related to information about the 
individual, and is compliant with HIPAA §164.514(c)(1). If an individual is eligible for 
more than one type of insurance at a time (for example, a supplemental plan), then 
this variable links the claim to the correct plan. 
Num 19 
Confinemen
t 
ADMIT_DATE Admission Date of Confinement (YYYYMMDD) Num YYMMDD10. 
Confinemen
t 
CHARGE Amount the provider requested to be reimbursed for the service provided. Num 11.2 
Confinemen
t 
COINS The amount (usually calculated as a percent of the provider's submitted charges) the 
member pays for a specific service as defined in their benefit plan. For example, 80% 
of the cost of an outpatient physical therapy visit.  
Num 11.2 
Confinemen
t 
CONF_ID Confinement Identifier.  Used to identify claims records associated with an inpatient 
hospitalization.  This data element is encrypted. 
Char $21 
Confinemen
t 
COPAY The fixed amount the member pays for a specific service as defined in their benefit 
plan. For example, $10 for an office visit.  
Num 11.2 
Confinemen
t 
DEDUCT The set amount a member pays for services until they reach a specified limit (usually 
defined on an annual basis). After the limit is reached, the member's payment for 
services changes (often insurance pays 100% of the cost of services).  
Num 11.2 
Confinemen
t 
DIAG1 First ICD-X Diagnosis Char $7 
Confinemen
t 
DIAG2 Second ICD-X Diagnosis Char $7 
Confinemen
t 
DIAG3 Third ICD-X Diagnosis Char $7 
Confinemen
t 
DIAG4 Fourth ICD-X Diagnosis Char $7 
Confinemen
t 
DIAG5 Fifth ICD-X Diagnosis Char $7 
Confinemen
t 
DISCH_DATE Discharge Date of Confinement (YYYYMMDD) Num YYMMDD10. 
Confinemen
t 
DRG The Diagnosis Related Group (DRG) Code assigned by the source system. A DRG 
classifies patients by diagnostic or surgical procedure into major diagnostic categories 
for the purpose of determining payment of hospitalization charges. Effective 
Char $5 
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10/1/2007, the Centers for Medicare and Medicaid Services (CMS) introduced the 
MS-DRG code set and retired the CMS-DRG set. The new code set refined the DRGs 
based on the presence of complications or co-morbidities. One affect of this change is 
that the MS-DRG descriptions are completely different from previous descriptions. 
The DRG code table contains historical CMS-DRGs as well as MS-DRG codes.  
Confinemen
t 
DSTATUS Patient status code (01-99).  Identifies the discharge status of the member' s 
inpatient stay as of the last service date on the claim.(i.e., discharged to home; 
transferred to SNG, left against medical advice, expired) 
Char $2 
Confinemen
t 
ICD_FLAG ICD Version Code – will distinguish between ICD-9 and ICD-10 codes.  Char $2 
Confinemen
t 
IPSTATUS Claims occurred in runout period (usually most recent three months) so there is a 
higher than usual chance of the confinement changing in the next build. Char $1 
Confinemen
t 
LOS Length of Stay from start of first confinement record to end of last confinement 
record. 
Num 5 
Confinemen
t 
POS Client-defined code identifying the place where the service was performed. Standard 
POS is now being used. 
Char $5 
Confinemen
t 
PROC1 First ICD-X Proc Code Char $7 
Confinemen
t 
PROC2 Second ICD-X Proc Code Char $7 
Confinemen
t 
PROC3 Third ICD-X Proc Code Char $7 
Confinemen
t 
PROC4 Fourth ICD-X Proc Code Char $7 
Confinemen
t 
PROC5 Fifth ICD-X Proc Code Char $7 
Confinemen
t 
PROV A unique system-generated number to identify providers. A provider may have 
multiple provider IDs. 
Num 19 
Confinemen
t 
STD_COST An estimate of the allowed amount for the facility charges related to the 
confinement. Associated surgeon's fees are likely to be found in the medical table. 
Num 15.2 
Confinemen
t 
STD_COST_Y
R 
The year when standard cost is updated in our source system Char $4 
Confinemen
t 
TOS_CD Type of Service Code Char $13 
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Provider PROV_UNIQU
E 
A unique system-generated number that identified the provider. It is possible for a 
provider to have multiple IDs or an ID to point to multiple physicians, particularly in 
the case of group practice. 
Num 19 
Provider PROV_STATE The state associated with the provider address. Char $2 
Provider PROVCAT Contains the four-character provider category code to indicate the type of provider 
for the provider responsible for the service.  
Char $4 
Diagnosis 
Lookup 
DIAG_CD ICD-10/IDC-9 (International Classification of Disease, 10th/9th Revision, Clinical 
Modification) as entered on the claim (without decimal point). ICD-10/IDC-9-CM is 
designed for the classification of morbidity and mortality information for statistical 
purposes and for the indexing of hospital records by disease and operations, for data 
storage retrieval. ICD-10/ID-9-CM is an accepted national standard for coding 
diagnostic and disease information.  
Char $10 
Diagnosis 
Lookup 
DIAG_DESC Describes the International Classification of Disease, 10th/9th Revision, Clinical 
Modification (ICD-9-CM/ICD-10-CM) code. ICD-9-CM/ICD-10-CM is designed for the 
classification of morbidity and mortality information for statistical purposes and for 
the indexing of hospital records by disease and operations, for data storage retrieval. 
ICD-9-CM/ICD-10-CM is an accepted national standard for coding diagnostic and 
disease information.  
Char $100 
Diagnosis 
Lookup 
DIAG_FST3_C
D 
The first three characters of the International Classification of Disease, 9th Revision, 
Clinical Modification (ICD-9-CM/ICD-10-CM) code. This used for grouping ICD-9-
CM/ICD-10-CM code together. ICD-9-CM/ICD-10-CM is designed for the classification 
of morbidity and mortality information for statistical purposes and for the indexing of 
hospital records by disease and operations, for data storage retrieval. ICD-9-CM/ICD-
10-CM is an accepted national standard for coding diagnostic and disease 
information. 
Char $3 
Diagnosis 
Lookup 
DIAG_FST3_D
ESC 
Describes the first three characters of the International Classification of Disease, 9th 
Revision, Clinical Modification (IICD-9-CM/ICD-10-CM) code. This used for grouping 
ICD-9-CM/ICD-10-CM code together. ICD-9-CM/ICD-10-CM is designed for the 
classification of morbidity and mortality information for statistical purposes and for 
the indexing of hospital records by disease and operations, for data storage 
retrieval.ICD-9-CM/ICD-10-CM is an accepted national standard for coding diagnostic 
and disease information. 
Char $35 
Diagnosis 
Lookup 
DIAG_FST4_C
D 
The first four characters of the International Classification of Disease, 9th Revision, 
Clinical Modification (ICD-9-CM/ICD-10-CM) code. This used for grouping ICD-9-
CM/ICD-10-CM code together. ICD-9-CM/ICD-10-CM is designed for the classification 
Char $4 
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of morbidity and mortality information for statistical purposes and for the indexing of 
hospital records by disease and operations, for data storage retrieval. ICD-9-CM/ICD-
10-CM is an accepted national standard for coding diagnostic and disease information 
Diagnosis 
Lookup 
DIAG_FST4_D
ESC 
Describes the first four characters of the International Classification of Disease, 9th 
Revision, Clinical Modification (ICD-9-CM/ICD-10-CM) code. This used for grouping 
ICD-9-CM/ICD-10-CM code together. ICD-9-CM/ICD-10-CM is designed for the 
classification of morbidity and mortality information for statistical purposes and for 
the indexing of hospital records by disease and operations, for data storage retrieval. 
ICD-9-CM/ICD-10-CM is an accepted national standard for coding diagnostic and 
disease information 
Char $35 
Procedure 
Lookup 
CATEGORY_D
TL_CODE_DE
SC 
Describes the AHRQ (Agency for Healthcare Research and Quality) detailed grouping 
of procedure codes.  For example, Glaucoma Procedures, Repair of Retinal Tear & 
Detachment. 
Char $50 
Procedure 
Lookup 
CATEGORY_G
ENL_CODE_D
ESC 
Describes the AHRQ (Agency for Healthcare Research and Quality) high-level grouping 
of procedure codes which is primarily by organ system. 
Char $50 
Procedure 
Lookup 
PROC_CD Procedure Code describes the type of procedure performed or service provided. This 
procedure code is usually a CPT© OR HCPCS Level II Code.  
Char $10 
Procedure 
Lookup 
PROC_DESC Describes a specific procedure performed or service provided. A procedure code can 
be an ICD9, CPT©, or HCPCS Level II code.  
Char $100 
Procedure 
Lookup 
PROC_END_D
ATE 
The date that the procedure code was deleted from the Industry Standard Code 
listing.  
Num  YYMMD
D10. 
Procedure 
Lookup 
PROC_TYP_C
D 
Identifies the industry standard code set where the procedure code is defined. This 
will identify the code as a ICD9, CPT© or HCPCS Level II.  
Char $5 
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Appendix G: Treatment Modality One-Way ANOVA and Bonferroni Test Results 
Analysis of Variance     
Source               SS          df       MS             F      Prob > F 
Between groups       709327.038       6 118221.173      12.46     <0.05 
In groups 1868578.4     197 9485.16953   
TOTAL 2577905.43     203 12699.0416   
Bartlett's test for 
equal variances:   
     
chi2(6) =   6.0077        
Prob>chi2 = 0.422      
 
 C CR CRS CS R RS 
CR 0.089      
CRS 0.000         0.228     
CS 1.000       1.000       0.059    
R 1.000       1.000       0.006          1.000         
RS 1.000  1.000 0.381           1.000   1.000  
S 0.492       1.000 1.000 0.401       0.479       0.003 
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Appendix H: Bundled Group A One-Way ANOVA and Bonferroni Test Results  
Analysis of Variance     
Source               SS          df       MS             F      Prob > F 
Between groups       614221.072   2 307110.536    31.44   <0.05 
In groups 1963684.36  201 9769.57394   
TOTAL 2577905.43     203 12699.0416   
Bartlett's test for 
equal variances:   
     
chi2(6) =   
4.1613   
     
Prob>chi2 = 
0.125 
     
 Bundle 1 Bundle 2 
Bundle 2 <0.05  
Bundle 3 <0.05 <0.05 
 
  133 
Appendix I: Bundled Group B One-Way ANOVA and Bonferroni Test Results 
Analysis of Variance     
Source               SS          df       MS             F      Prob > F 
Between groups       702101.194 3 234033.731 24.95 <0.05 
In groups 1875804.24 200 9379.02121   
TOTAL 2577905.43 203 12699.0416   
Bartlett's test for 
equal variances:   
     
chi2(6) =   
5.0516 
     
Prob>chi2 = 
0.168 
     
 Bundle 1 Bundle 2 Bundle 3 
Bundle 2 <0.05   
Bundle 3 <0.05 <0.05  
Bundle 4 <0.05 <0.05 <0.05 
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Appendix J: Bundled Group A Levene’s Test of Equal Variances Results 
Group A 
W0=  1.8438633    df(2, 201)      Pr > F = 0.16087096   
W50=              1.8167144 df(2, 201)      Pr > F = 0.165218   
W100=       1.8252850 df(2, 201) Pr > F = 0.16383302   
Group B 
W0=  1.7165869 df(3, 200)      Pr > F = 0.164814   
W50=              1.7239884 df(3, 200)      Pr > F = 0.16329245   
W100=       1.7136061 df(3, 200) Pr > F = 0.16543058   
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Appendix K: Bundled Group A Monte Carlo Simulation Summary Sample  
BUNDLE A1       
Trials (Xj) Min Average (Xi) Median Max SD 
1 $64,009 $86,130 $87,025 $114,921 $10,621 
2 $63,001 $88,104 $87,025 $115,600 $9,657 
3 $67,600 $88,681 $87,616 $111,556 $10,435 
4 $60,516 $87,796 $87,915 $114,244 $11,573 
5 $56,169 $85,717 $85,264 $121,104 $11,415 
… … … … … … 
9995 $63,001 $85,449 $86,436 $108,241 $9,182 
9996 $66,564 $87,724 $86,436 $119,716 $9,682 
9997 $63,504 $87,009 $87,913 $111,556 $9,658 
9998 $64,516 $85,692 $83,521 $108,900 $8,898 
9999 $65,536 $86,199 $85,264 $110,224 $9,623 
10000 $64,009 $86,844 $85,849 $114,921 $10,779 
Overall (Xij) $63,417 $86,632 $86,251 $114,191 $10,029 
BUNDLE A2      
Trials (Xj) Min Average (Xi) Median Max SD 
1 $112,225 $146,601 $146,689 $182,329 $15,401 
2 $121,104 $147,799 $148,225 $199,809 $12,829 
3 $111,556 $145,539 $144,781 $181,476 $15,088 
4 $113,569 $148,462 $147,841 $179,776 $13,942 
5 $108,900 $146,598 $144,400 $195,364 $14,952 
… … … … … … 
9995 $113,569 $143,626 $142,507 $179,776 $12,690 
9996 $106,929 $146,782 $146,307 $179,776 $13,688 
9997 $110,889 $145,489 $147,073 $188,356 $15,964 
9998 $112,225 $146,838 $145,543 $186,624 $15,277 
9999 $113,569 $146,826 $146,307 $189,225 $16,688 
10000 $116,964 $147,122 $145,161 $178,929 $12,827 
Overall (Xij) $111,546 $146,315 $145,811 $186,912 $14,877 
BUNDLE A3      
Trials (Xj) Min Average (Xi) Median Max SD 
1 $176,400 $223,068 $223,729 $268,324 $20,374 
2 $184,041 $221,380 $219,961 $281,961 $17,410 
3 $163,216 $215,294 $214,370 $263,169 $20,289 
4 $173,889 $217,784 $219,493 $268,324 $18,192 
5 $171,396 $216,008 $216,225 $265,225 $19,499 
… … … … … … 
9995 $173,889 $218,121 $220,431 $305,809 $21,688 
9996 $183,184 $217,517 $217,160 $274,576 $20,605 
9997 $160,801 $219,333 $219,493 $262,144 $21,342 
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9998 $164,025 $213,772 $212,521 $259,081 $19,913 
9999 $178,084 $222,075 $221,842 $284,089 $19,522 
10000 $175,561 $216,853 $216,225 $266,256 $18,782 
Overall (Xij) $171,845 $219,294 $218,673 $274,228 $20,176 
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Appendix L: Bundled Group A Monte Carlo Risk Analysis for Pricing at Cost Percentiles  
 Pricing @ 50th Percentile 
of Episode Cost 
Percent of 
Patients >50th 
Percentile 
Average Financial Loss 
per Patient >50th 
Percentile  
Bundle A1  $82,885 50% $8,281 
Bundle A2 $141,012 49% $12,647 
Bundle A3 $209,539 50% $16,578 
 
 Pricing @ 75th Percentile 
Episode Cost 
Percent of 
Patients >75th 
Percentile 
Average Financial Loss 
per Patient >75th 
Percentile  
Bundle A1 $113,809 0.85% $4,087 
Bundle A2 $203,889 2.6% $6,894 
Bundle A3 $268,832 6.1% $9,486 
 
 Pricing @ 95th Percentile 
Episode Cost 
Percent of 
Patients >95th 
Percentile 
Average Financial Loss 
per Patient >95th 
Percentile  
Bundle A1 $164,311 0.0003% $4,087 
Bundle A2 $276,521 0.0004% $6,894 
Bundle A3 $418,891 0.0004% $1,466,060 
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Appendix M: Bundled Group B Monte Carlo Risk Analysis for Pricing at Cost Percentiles  
 50th Percentile 
Episode Cost 
Percent of Patients 
>50th Percentile 
Average Financial Loss per 
Patient >50th Percentile  
Bundle 1 $82,885 50% $8,281 
Bundle 2 $116,848 80% $15,871 
Bundle 3 $157,150 68.27% $16,699 
Bundle 4 $209,539 50% $16,578 
  
 75th Percentile 
Episode Cost 
Percent of Patients 
>75th Percentile 
Average Financial Loss per 
Patient >75th Percentile  
Bundle 1 $113,809 0.85% $4,087 
Bundle 2 $173,606 0.115% $4,799 
Bundle 3 $215,728 0.237% $6,277 
Bundle 4 $268,832 6.1% $9,486 
  
 95th Percentile 
Episode Cost 
Percent of Patients 
>95th Percentile 
Average Financial Loss per 
Patient >95th Percentile  
Bundle 1 $164,311 0.0003% $4,087 
Bundle 2 $247,734 0.0004% $57,384 
Bundle 3 $286,571 0.0004% $122,825 
Bundle 4 $418,891 0.0004% $1,466,060 
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Appendix N: Monte Carlo Financial Loss Summary at Cost Percentiles 
GROUP A Bundle 1 Bundle 2 Bundle 3 
Average Expected Loss 
Per Patient 
  21% 59% 20% 100% 
>50th Percentile $876 $3,631 $1,664 $6,171 
>75th Percentile $7 $106 $115 $229 
>95% Percentile $0.13 $0.82 $4.70 $5.65 
 
 
 
GROUP B Bundle 1 Bundle 2 
 
Bundle 3 Bundle 4 
Average 
Expected Loss 
Per Patient 
  21% 30% 29% 20% 100% 
>50th Percentile $870 $3,809 $3,306 $1,658 $9,642 
>75th Percentile $7 $2 $4 $116 $129 
>95% Percentile $0.00 $0.07 $0.14 $5.86 $6 
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Appendix O: UTHSC Committee for the Protection of Human Subjects Institutional 
Review Board Outcome Letter 
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Appendix P: UTHSC Committee for the Protection of Human Subjects Request for 
Changes Outcome Letter 
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Appendix Q: UTSPH Dissertation Proposal Approval Letter 
 
 
